0001062822-12-000021.txt : 20120503 0001062822-12-000021.hdr.sgml : 20120503 20120503160650 ACCESSION NUMBER: 0001062822-12-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120503 DATE AS OF CHANGE: 20120503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 12809716 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 10-Q 1 lxrx331201210-q.htm FORM 10-Q 03-31-2012 LXRX 3.31.2012 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
 (Mark One)
 
R
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2012

or

q
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from _____________ to _____________
 
Commission File Number:  000-30111
 
Lexicon Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
76-0474169
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of Principal Executive Offices and Zip Code)

(281) 863-3000
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes
þ
 
No
 
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes
þ
 
No
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer             Accelerated filer    þ     Non-accelerated filer             Smaller reporting company          
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes
 
 
No
þ
 
As of May 1, 2012, 480,656,570 shares of the registrant’s common stock, par value $0.001 per share, were outstanding.


Lexicon Pharmaceuticals, Inc.
 
Table of Contents
 
 
 
Page
Item 1.
 
 
 
 
 
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 6.
 
 
 
 
 
 
 
 
 
 

The Lexicon name and logo, OmniBank® and LexVision® are registered trademarks and Genome5000™ is a trademark of Lexicon Pharmaceuticals, Inc.
 
——————

Factors Affecting Forward Looking Statements
This quarterly report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Part II, Item 1A. - Risk Factors,” that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.


2

Part I – Financial Information
 
Item 1.                 Financial Statements
 
Lexicon Pharmaceuticals, Inc.

Consolidated Balance Sheets
(In thousands, except par value)
 
 
 
As of March 31,
 
As of December 31,
 
 
2012
 
2011
Assets
 
(unaudited)
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
29,010

 
$
186,309

Short-term investments, including restricted investments of $430
 
224,646

 
95,383

Accounts receivable, net of allowances of $35
 
186

 
350

Prepaid expenses and other current assets
 
5,143

 
3,748

Total current assets
 
258,985

 
285,790

Property and equipment, net of accumulated depreciation and amortization of $81,654 and $80,535, respectively
 
45,526

 
46,417

Goodwill
 
44,543

 
44,543

Other intangible assets
 
53,557

 
53,557

Other assets
 
181

 
205

Total assets
 
$
402,792

 
$
430,512

Liabilities and Equity
 
 
 
 
Current liabilities:
 
 
 
 
Accounts payable
 
$
5,324

 
$
6,042

Accrued liabilities
 
13,710

 
13,786

Current portion of deferred revenue
 
421

 
119

Current portion of long-term debt
 
1,478

 
1,443

Total current liabilities
 
20,933

 
21,390

Deferred revenue, net of current portion
 
13,910

 
14,212

Long-term debt
 
23,063

 
23,451

Deferred tax liabilities
 
18,745

 
18,745

Other long-term liabilities
 
57,170

 
55,146

Total liabilities
 
133,821

 
132,944

Commitments and contingencies
 

 

Equity:
 
 
 
 
Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding
 
—

 
—

Common stock, $.001 par value; 900,000 shares authorized; 480,942 and 480,389 shares issued, respectively
 
481

 
480

Additional paid-in capital
 
1,088,666

 
1,087,033

Accumulated deficit
 
(819,489
)
 
(789,621
)
Accumulated other comprehensive gain (loss)
 
(57
)
 
21

Treasury stock, at cost, 380 and 218 shares, respectively
 
(630
)
 
(345
)
Total equity
 
268,971

 
297,568

Total liabilities and equity
 
$
402,792

 
$
430,512


The accompanying notes are an integral part of these consolidated financial statements. 


3

Lexicon Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
2012
 
2011
Revenues:
 
 
 
 
Collaborative research
 
$
152

 
$
516

Subscription and license fees 
 
148

 
80

Total revenues 
 
300

 
596

Operating expenses:
 
 
 
 
Research and development, including stock-based compensation of $1,037 and $839, respectively
 
23,037

 
23,921

Increase in fair value of Symphony Icon, Inc. purchase liability
 
2,081

 
1,058

General and administrative, including stock-based compensation of $681 and $633, respectively
 
4,565

 
4,753

Total operating expenses
 
29,683

 
29,732

Loss from operations 
 
(29,383
)
 
(29,136
)
Interest income 
 
56

 
87

Interest expense 
 
(537
)
 
(607
)
Other income (expense), net
 
(4
)
 
27

Consolidated net loss
 
$
(29,868
)
 
$
(29,629
)
Consolidated net loss per common share, basic and diluted
 
$
(0.06
)
 
$
(0.09
)
Shares used in computing consolidated net loss per common share, basic and diluted  
 
480,324

 
337,527

 
 
 
 
 
Other comprehensive loss:
 
 
 
 
Unrealized gain (loss) on investments
 
(78
)
 
35

Comprehensive loss
 
$
(29,946
)
 
$
(29,594
)


The accompanying notes are an integral part of these consolidated financial statements.


4

Lexicon Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited)


 
 
Common Stock
 
Additional
 
 
 
Accumulated Other
 
 
 
 
 
 
Shares
 
Par Value
 
Paid-In Capital
 
Accumulated Deficit
 
Comprehensive Gain (Loss)
 
Treasury Stock
 
Total
Balance at December 31, 2010
 
337,566

 
$
338

 
$
920,324

 
$
(673,406
)
 
$
5

 
$
(237
)
 
$
247,024

Stock-based compensation
 
—

 
—

 
1,472

 
—

 
—

 
—

 
1,472

Issuance of common stock under Equity Incentive Plans
 
309

 
—

 
523

 
—

 
—

 
—

 
523

Repurchase of common stock
 
—

 
—

 
—

 
—

 
—

 
(108
)
 
(108
)
Net loss
 
—

 
—

 
—

 
(29,629
)
 
—

 
—

 
(29,629
)
Unrealized gain on investments
 
—

 
—

 
—

 
—

 
35

 
—

 
35

Balance at March 31, 2011
 
337,875

 
$
338

 
$
922,319

 
$
(703,035
)
 
$
40

 
$
(345
)
 
$
219,317

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2011
 
480,389

 
$
480

 
$
1,087,033

 
$
(789,621
)
 
$
21

 
$
(345
)
 
$
297,568

Stock-based compensation
 
—

 
—

 
1,718

 
—

 
—

 
—

 
1,718

Issuance of common stock under Equity Incentive Plans
 
553

 
1

 
51

 
—

 
—

 
—

 
52

Other
 
—

 
—

 
(136
)
 
—

 
—

 
—

 
(136
)
Repurchase of common stock
 
—

 
—

 
—

 
—

 
—

 
(285
)
 
(285
)
Net loss
 
—

 
—

 
—

 
(29,868
)
 
—

 
—

 
(29,868
)
Unrealized loss on investments
 
—

 
—

 
—

 
—

 
(78
)
 
—

 
(78
)
Balance at March 31, 2012
 
480,942

 
$
481

 
$
1,088,666

 
$
(819,489
)
 
$
(57
)
 
$
(630
)
 
$
268,971



The accompanying notes are an integral part of these consolidated financial statements.


5

Lexicon Pharmaceuticals, Inc.
 
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
2012
 
2011
Cash flows from operating activities:
 
 
 
 
Consolidated net loss
 
$
(29,868
)
 
$
(29,629
)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
 
 
 
 
Depreciation
 
1,125

 
1,307

Impairment of fixed assets
 
—

 
769

Increase in fair value of Symphony Icon, Inc. purchase liability
 
2,081

 
1,058

Stock-based compensation
 
1,718

 
1,472

Changes in operating assets and liabilities:
 
 
 
 
(Increase) decrease in accounts receivable
 
164

 
(87
)
Increase in prepaid expenses and other current assets
 
(1,395
)
 
(565
)
Decrease in other assets
 
24

 
315

Increase (decrease) in accounts payable and other liabilities
 
(851
)
 
3,849

Decrease in deferred revenue
 
—

 
(29
)
Net cash used in operating activities
 
(27,002
)
 
(21,540
)
Cash flows from investing activities:
 
 
 
 
Purchases of property and equipment
 
(234
)
 
(507
)
Proceeds from disposal of property and equipment
 
—

 
43

Purchases of investments
 
(151,776
)
 
(33,895
)
Maturities of investments
 
22,435

 
29,041

Net cash used in investing activities
 
(129,575
)
 
(5,318
)
Cash flows from financing activities:
 
 
 
 
Proceeds from issuance of common stock
 
52

 
160

Repurchase of common stock
 
(285
)
 
(108
)
Repayment of debt borrowings
 
(353
)
 
(284
)
Other financing activities
 
(136
)
 
—

Net cash used in financing activities
 
(722
)
 
(232
)
Net decrease in cash and cash equivalents
 
(157,299
)
 
(27,090
)
Cash and cash equivalents at beginning of period
 
186,309

 
47,208

Cash and cash equivalents at end of period
 
$
29,010

 
$
20,118

 
 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
 
Cash paid for interest
 
$
516

 
$
584

 
 
 
 
 
Supplemental disclosure of non-cash investing and financing activities:
 
 
 
 
Unrealized gain (loss) on investments
 
$
(78
)
 
$
35


The accompanying notes are an integral part of these consolidated financial statements.


6

Lexicon Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements
(Unaudited)
 
1.      Basis of Presentation
 
The accompanying unaudited consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
 
In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012.
 
The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2011, as filed with the SEC.
 
2.      Net Loss Per Share
 
Net loss per share is computed using the weighted average number of shares of common stock outstanding during the applicable period and excludes shares underlying stock options and restricted stock units because they are antidilutive.  There are no differences between basic and diluted net loss per share for all periods presented.
 
3.      Stock-Based Compensation
 
The Company recorded $1.7 million and $1.5 million of stock-based compensation expense for the three months ended March 31, 2012 and 2011, respectively.  The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions for options granted in the three months ended March 31, 2012 and 2011:
 
 
Expected Volatility
 
Risk-free Interest Rate
 
Expected Term
 
Dividend
Rate
March 31, 2012:
 
 
 
 
 
 
 
 
Employees
 
92
%
 
0.8
%
 
5

 
0%
Officers and non-employee directors
 
80
%
 
1.6
%
 
8

 
0%
March 31, 2011:
 
 
 
 
 
 
 
 
Employees
 
88
%
 
2.2
%
 
5

 
0%
Officers and non-employee directors
 
78
%
 
3.2
%
 
8

 
0%


7

The following is a summary of option activity under Lexicon’s stock-based compensation for the three months ended March 31, 2012:
 
 
 
Options
 
Weighted Average Exercise Price
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
20,476

 
$
2.84

Granted
 
3,032

 
1.80

Exercised
 
(35
)
 
1.43

Expired
 
(726
)
 
8.57

Forfeited
 
(210
)
 
1.77

Outstanding at March 31, 2012
 
22,537

 
2.53

Exercisable at March 31, 2012
 
14,582

 
$
2.94


During the three months ended March 31, 2012, Lexicon also granted its employees annual restricted stock units. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2012:
 
 
Shares
 
Weighted Average Grant Date
Fair Value
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
2,127

 
$
1.81

Granted
 
2,390

 
1.80

Vested
 
(518
)
 
1.81

Forfeited
 
(227
)
 
1.81

Nonvested at March 31, 2012
 
3,772

 
$
1.80

During 2010, Lexicon granted certain employees restricted stock units with a performance condition. The shares subject to the restricted stock units granted in 2010 vest upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by Lexicon as a basis for a New Drug Application. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. The following is a summary of performance-based restricted stock units activity under Lexicon's stock-based compensation plans for the three months ended March 31, 2012:
 
 
Shares
 
Weighted Average Grant Date
Fair Value
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
350

 
$
1.90

Forfeited
 
(5
)
 
1.90

Nonvested at March 31, 2012
 
345

 
$
1.90


4.      Recent Accounting Pronouncements
In June 2011, the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-05, “Presentation of Comprehensive Income”, which improves the comparability, consistency, and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments in this standard require that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. The standard does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, the standard does not affect the calculation or reporting of earnings per share. This pronouncement should be applied retrospectively for fiscal years beginning after December 15, 2011, with early adoption permitted. Lexicon adopted this pronouncement in 2012 and there was no material impact to its consolidated results of operations and financial condition.

8


5.      Cash and Cash Equivalents and Investments
 
The fair value of cash and cash equivalents and investments held at March 31, 2012 and December 31, 2011 are as follows: 
 
 
As of March 31, 2012
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
 
(in thousands)
Cash and cash equivalents
 
$
29,010

 
$
—

 
$
—

 
$
29,010

Securities maturing within one year:
 
 
 
 
 
 
 
 
Certificates of deposit
 
548

 
—

 
—

 
548

U.S. treasury securities
 
224,155

 
3

 
(60
)
 
224,098

Total short-term investments
 
$
224,703

 
$
3

 
$
(60
)
 
$
224,646

Total cash and cash equivalents and investments
 
$
253,713

 
$
3

 
$
(60
)
 
$
253,656

 
 
 
 
 
 
 
 
 
 
 
As of December 31, 2011
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
 
 
 
(in thousands)
 
 
Cash and cash equivalents
 
$
186,309

 
$
—

 
$
—

 
$
186,309

Securities maturing within one year:
 
 
 
 
 
 
 
 
Certificates of deposit
 
548

 
—

 
—

 
548

U.S. treasury securities
 
94,814

 
24

 
(3
)
 
94,835

Total short-term investments
 
$
95,362

 
$
24

 
$
(3
)
 
$
95,383

Total cash and cash equivalents and investments
 
$
281,671

 
$
24

 
$
(3
)
 
$
281,692


There were no realized gains or losses for the three months ended March 31, 2012 and 2011. The cost of securities sold is based on the specific identification method.


6.      Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

•
Level 1 - quoted prices in active markets for identical investments

•
Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)

•
Level 3 - significant unobservable inputs (including the Company's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels described above as of March 31, 2012 and December 31, 2011.


9

 
 
Assets and Liabilities at Fair Value as of March 31, 2012
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
(in thousands)
Assets
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
29,010

 
$
—

 
$
—

 
$
29,010

Short-term investments
 
224,646

 
—

 
—

 
224,646

Total cash and cash equivalents and investments
 
$
253,656

 
$
—

 
$
—

 
$
253,656

Liabilities
 
 
 
 
 
 
 
 
Other long-term liabilities
 
$
—

 
$
—

 
$
57,114

 
$
57,114

Total liabilities
 
$
—

 
$
—

 
$
57,114

 
$
57,114

 
 
Assets and Liabilities at Fair Value as of December 31, 2011
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
(in thousands)
Assets
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
186,309

 
$
—

 
$
—

 
$
186,309

Short-term investments
 
95,383

 
—

 
—

 
95,383

Total cash and cash equivalents and investments
 
$
281,692

 
$
—

 
$
—

 
$
281,692

Liabilities
 
 
 
 
 
 
 
 
Other long-term liabilities
 
$
—

 
$
—

 
$
55,033

 
$
55,033

Total liabilities
 
$
—

 
$
—

 
$
55,033

 
$
55,033


The Company's Level 3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the three months ended March 31, 2012 and 2011.
 
 
Other Long-term Liabilities
 
 
(in thousands)
Balance at December 31, 2011
 
$
55,033

Change in valuation of purchase consideration payable to former Symphony Icon stockholders
 
2,081

Balance at March 31, 2012
 
$
57,114

 
 
 
Balance at December 31, 2010
 
$
48,267

Change in valuation of purchase consideration payable to former Symphony Icon stockholders
 
1,058

Balance at March 31, 2011
 
$
49,325

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.

7.      Debt Obligations
 
Mortgage Loan.  In April 2004, Lexicon obtained a $34.0 million mortgage on its facilities in The Woodlands, Texas.  The mortgage loan has a ten-year term with a 20-year amortization and bears interest at a fixed rate of 8.23%.  The mortgage had a principal balance outstanding of $24.5 million as of March 31, 2012. The fair value of Lexicon’s mortgage loan approximates its carrying value.  The fair value of Lexicon’s mortgage loan is estimated using discounted cash flow analysis, based on the Company’s current incremental borrowing rate.



10

8.      Arrangements with Symphony Icon, Inc.
     
On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the “Programs”). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (“Holdings”), the Company's intellectual property rights related to the Programs. Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.

Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings 7,650,622 shares of its common stock on June 15, 2007 in exchange for $15 million and an exclusive purchase Option (the "Purchase Option") that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and agreed to make up to $80 million in additional base and contingent payments.

The base payments will be in an amount equal to $50 million less 50% of the expenses Lexicon incurs after its exercise of the Purchase Option for the development of LX1032, LX1033 and other pharmaceutical compositions modulating the same target as those drug candidates (the “LG103 Programs”), subject to certain exceptions and up to an aggregate reduction of $15 million. The base payments are payable in Lexicon's discretion at any time before July 30, 2013.

The contingent payments will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize a drug candidate from the LG103 Programs (a “Licensing Transaction”), subject to certain exceptions and up to a maximum of $30 million plus the amount of any reduction in the base payments for Lexicon's development expenses for the LG103 Programs (the “Recapture Eligible Amount”). The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.

The base payments and the contingent payments may be paid in cash, common stock, or a combination of cash and common stock, in Lexicon's discretion, provided that at least 50% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.

Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid $10.0 million in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 14% for the base payments; (2) a discount rate of 18% for the contingent payments; and (3) a probability adjusted contingency. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. During the three months ended March 31, 2012 and 2011, the fair value of the Symphony Icon purchase consideration liability increased by $2.1 million and $1.1 million, respectively.

11


9.      Commitments and Contingencies
 
Operating Lease Obligations:  A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an agreement which expires in June 2013.  The lease provides for two five-year renewal options at 95% of the fair market rent and includes escalating lease payments.  Rent expense is recognized on a straight-line basis over the original lease term.  Lexicon is the guarantor of the obligations of its subsidiary under this lease.  The maximum potential amount of future payments the Company could be required to make under this agreement is $3.3 million without taking into account the exercise of the renewal options. The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.  The Company had $0.4 million in restricted investments as collateral as of March 31, 2012 and December 31, 2011.  Additionally, Lexicon leases certain equipment under operating leases.
 
Legal Proceedings.  Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.
 
10.      Collaboration and License Agreements
 
Lexicon has derived substantially all of its revenues from drug discovery and development collaborations, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. Revenues generated from third parties under collaborative arrangements are recorded on a gross basis on the consolidated statements of comprehensive loss as Lexicon is the principal participant for these transactions for the purpose of accounting for these arrangements.


12

Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
Overview
 
We are a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. We have used gene knockout technologies and an integrated platform of advanced medical technologies to identify and validate, in vivo, more than 100 targets with promising profiles for drug discovery. For targets that we believe have high pharmaceutical value, we engage in programs for the discovery and development of potential new drugs. We have five drug programs in various stages of clinical development and have advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research.

We are working both independently and through strategic collaborations and alliances to capitalize on our technology, drug target discoveries and drug discovery and development programs. Consistent with this approach, we seek to retain exclusive rights to the benefits of certain of our small molecule drug programs by developing drug candidates from those programs internally and to collaborate with third parties with respect to the discovery, development and commercialization of small molecule and biotherapeutic drug candidates for other targets, particularly when the collaboration provides us with access to expertise and resources that we do not possess internally or are complementary to our own. We have established drug discovery and development collaborations with leading pharmaceutical and biotechnology companies which generated near-term cash while offering us the potential to retain economic participation in products developed from the collaboration. In addition, we have established collaborations and license agreements with other leading pharmaceutical and biotechnology companies, research institutes and academic institutions under which we received fees and, in some cases, are eligible to receive milestone and royalty payments, in return for granting access to some of our technologies and discoveries.

We have derived substantially all of our revenues from drug discovery and development collaborations and other collaborations and technology licenses, and will continue to do so for the foreseeable future. To date, we have generated a substantial portion of our revenues from a limited number of sources.    
    
Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our success in establishing new collaborations and technology licenses, the success rate of our discovery and development efforts leading to opportunities for new collaborations and licenses, the timing and willingness of collaborators to commercialize products that would result in milestone payments and royalties and their success in such efforts, and general and industry-specific economic conditions which may affect research and development expenditures. Future revenues from our existing collaborations and technology licenses are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaboration. As a result, we depend, in part, on securing new collaborations and license agreements. Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests. We may determine, as we have with our five most advanced clinical drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues. Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.

Since our inception, we have incurred significant losses and, as of March 31, 2012, we had an accumulated deficit of $819.5 million. Our losses have resulted principally from costs incurred in research and development, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our preclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. General and administrative expenses consist primarily of salaries and related expenses for executive and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with our drug discovery and development programs. As a result, we will need to generate significantly higher revenues to achieve profitability.
Critical Accounting Policies
 
The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes.  Actual results could differ from those estimates.  We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2011.

13

 
Recent Accounting Pronouncements
 
See Note 4, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of the new accounting standards on our consolidated financial statements.
 
Results of Operations
 
Revenues
 
Total revenues and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):
 
 
Three Months Ended March 31,
 
 
2012
 
2011
Total revenues
 
$
0.3

 
$
0.6

Dollar decrease
 
$
(0.3
)
 
 
Percentage decrease
 
(50
)%
 
 
 
•
Collaborative research – Revenue from collaborative research for the three months ended March 31, 2012 decreased 71% to $0.2 million, as compared to the corresponding period in 2011, primarily due to reduced revenues from the United States Army Medical Research Acquisition Activity and our alliance with Taconic Farms.

•
Subscription and license fees – Revenue from subscriptions and license fees for the three months ended March 31, 2012 increased 85%, as compared to the corresponding period in 2011, primarily due to an increase in technology license fees.
 
Research and Development Expenses
 
Research and development expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions): 
 
 
Three Months Ended March 31,
 
 
2012
 
2011
Total research and development expense
 
$
23.0

 
$
23.9

Dollar decrease
 
$
(0.9
)
 
 
Percentage decrease
 
(4
)%
 
 
Research and development expenses consist primarily of third-party and other services principally related to preclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs, laboratory supplies, and stock-based compensation expenses.
  
•
Third-party and other services – Third-party and other services for the three months ended March 31, 2012 increased 18% to $8.9 million, as compared to the corresponding period in 2011, primarily due to an increase in external preclinical and clinical research and development costs. Third-party and other services relate principally to our clinical trial and related development activities, such as preclinical and clinical studies and contract manufacturing.

•
 Personnel – Personnel costs for the three months ended March 31, 2012 decreased 12% to $8.0 million, as compared to the corresponding period in 2011, primarily due to reductions in our personnel in February 2011 and January 2012. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

•
Facilities and equipment – Facilities and equipment costs for the three months ended March 31, 2012 decreased 29% to $3.0 million, as compared to the corresponding period in 2011, primarily due to an impairment of buildings due to excess capacity in 2011.

•
Stock-based compensation – Stock-based compensation expense for the three months ended March 31, 2012 increased 24% to $1.0 million, as compared to the corresponding period in 2011.


14

•
Laboratory supplies – Laboratory supplies expense for the three months ended March 31, 2012 decreased 27% to $0.9 million, as compared to the corresponding period in 2011, primarily due to reductions in early-stage research activities.
 
•
Other – Other costs for the three months ended March 31, 2012 increased 21% to $1.3 million, as compared to the corresponding period in 2011.
 
Increase in Fair Value of Symphony Icon Liability

The increase in fair value of the Symphony Icon purchase liability was $2.1 million and $1.1 million for the three months ended March 31, 2012 and 2011, respectively (see Note 8, Arrangements with Symphony Icon, Inc., of the Notes to Consolidated Financial Statements, for more information).

General and Administrative Expenses
 
General and administrative expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):
 
 
Three Months Ended March 31,
 
 
2012
 
2011
Total general and administrative expense
 
$
4.6

 
$
4.8

Dollar decrease
 
$
(0.2
)
 
 
Percentage decrease
 
(4
)%
 
 
General and administrative expenses consist primarily of salaries and other personnel-related expenses, professional fees such as legal fees, facility and equipment costs, and stock-based compensation expenses.
 
•
Personnel – Personnel costs for the three months ended March 31, 2012 decreased 3% to $2.4 million, as compared to the corresponding period in 2011, principally due to reductions in our personnel in February 2011 and January 2012. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

•
Stock-based compensation – Stock-based compensation expense for the three months ended March 31, 2012 increased 8% to $0.7 million, as compared to the corresponding period in 2011.

•
Professional fees – Professional fees for the three months ended March 31, 2012 were $0.7 million, consistent with the corresponding period in 2011.

•
Facilities and equipment – Facilities and equipment costs for the three months ended March 31, 2012 decreased 11% to $0.5 million, as compared to the corresponding period in 2011.
 
•
Other – Other costs for the three months ended March 31, 2012 decreased 24% to $0.3 million, as compared to the corresponding period in 2011.
 
Interest Income and Interest Expense
 
Interest Income.  Interest income for the three months ended March 31, 2012 was $0.1 million, consistent with the corresponding period in 2011.
 
Interest Expense.  Interest expense for the three months ended March 31, 2012 decreased 12% to $0.5 million, as compared to the corresponding period in 2011.
 
Consolidated Net Loss and Consolidated Net Loss per Common Share

Consolidated Net Loss and Consolidated Net Loss per Common Share. Consolidated net loss increased to $29.9 million in the three months ended March 31, 2012 from $29.6 million in the corresponding period in 2011. Consolidated net loss per common share decreased to $0.06 in the three months ended March 31, 2012 from $0.09 in the corresponding period in 2011.
    

15

Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.

Liquidity and Capital Resources
 
We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments to us under our drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts, and financing obtained under debt and lease arrangements. We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc. From our inception through March 31, 2012, we had received net proceeds of $947.8 million from issuances of common and preferred stock. In addition, from our inception through March 31, 2012, we received $455.6 million in cash payments from drug discovery and development collaborations, target validation, database subscription and technology license agreements, sales of compound libraries and reagents, and government grants and contracts, of which $441.7 million had been recognized as revenues through March 31, 2012.
As of March 31, 2012, we had $253.7 million in cash, cash equivalents and investments. As of December 31, 2011, we had $281.7 million in cash, cash equivalents and investments. We used cash of $27.0 million in operations in the three months ended March 31, 2012. This consisted primarily of the consolidated net loss for the period of $29.9 million and a net increase in other operating assets net of liabilities of $2.1 million, partially offset by non-cash charges of $2.1 million related to the increase in fair value of the Symphony Icon purchase liability, $1.7 million related to stock-based compensation expense and $1.1 million related to depreciation expense. Investing activities used cash of $129.6 million in the three months ended March 31, 2012, primarily due to net purchases of investments of $129.3 million and purchases of property and equipment of $0.2 million. Financing activities used cash of $0.7 million primarily due to repayment of debt borrowings of $0.4 million and repurchase of common stock of $0.3 million.
Symphony Drug Development Financing Agreements. In June 2007, we entered into a series of related agreements providing for the financing of the clinical development of certain drug programs, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates. Under the financing arrangement, we licensed to Symphony Icon, Inc., a then wholly-owned subsidiary of Symphony Icon Holdings LLC, our intellectual property rights related to the programs and Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the programs. We also issued and sold to Holdings shares of our common stock in exchange for $15 million and received an exclusive option to acquire all of the equity of Symphony Icon, thereby allowing us to reacquire the programs.
Upon the recommendation of Symphony Icon's development committee, which was comprised of an equal number of representatives from us and Symphony Icon, Symphony Icon's board of directors had the right to require us to pay Symphony Icon up to $15 million for Symphony Icon's use in the development of the programs in accordance with the specified development plan and related development budget. Through July 2010, Symphony Icon's board of directors requested us to pay Symphony Icon $9.3 million under the agreement, all of which was paid prior to the exercise of the purchase option in July 2010.
In July 2010, we entered into an amended and restated purchase option agreement with Symphony Icon and Holdings and simultaneously exercised our purchase option. Pursuant to the amended terms of the purchase option, we paid Holdings $10 million and agreed to make up to $80 million in additional base and contingent payments.
The base payments will be in an amount equal to $50 million less 50% of the expenses we incur after our exercise of the purchase option for the development of LX1032, LX1033 and other pharmaceutical compositions modulating the same target as those drug candidates, which we refer to as the “LG103 programs,” subject to certain exceptions and up to an aggregate reduction of $15 million. The base payments are payable in our discretion at any time before July 30, 2013.
The contingent payments will consist of 50% of any consideration we receive pursuant to any licensing transaction under which we grant a third party rights to commercialize a drug candidate from the LG103 programs, subject to certain exceptions and up to a maximum of $30 million plus the amount of any reduction in the base payments for our development expenses for the LG103 programs, which we refer to as the “recapture eligible amount.” The contingent payments will be due if and when we receive such consideration from such a licensing transaction. In the event we receive regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 programs prior to entering into such a licensing transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a licensing transaction, we will pay Holdings the sum of $15 million and any recapture eligible amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such licensing transaction outside of the United States with respect to such

16

product. In the event we make any such payment upon United States regulatory approval, we will have no obligation to make subsequent contingent payments attributable to any such licensing transactions for the commercialization of such product outside the United States until the proceeds of such licensing transactions exceed 50% of the payment made as a result of such United States regulatory approval.

The base payments and the contingent payments may be paid in cash, common stock, or a combination of cash and common stock, in our discretion, provided that at least 50% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.
Facilities. In April 2004, we obtained a $34.0 million mortgage on our facilities in The Woodlands, Texas. The mortgage loan has a ten-year term with a 20-year amortization and bears interest at a fixed rate of 8.23%. The mortgage had a principal balance outstanding of $24.5 million as of March 31, 2012. In May 2002, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 76,000 square-foot laboratory and office space in Hopewell, New Jersey. The term of the lease extends until June 30, 2013. The lease provides for an escalating yearly base rent payment of $1.3 million in the first year, $2.1 million in years two and three, $2.2 million in years four to six, $2.3 million in years seven to nine and $2.4 million in years ten and eleven. We are the guarantor of the obligations of our subsidiary under the lease.
Our future capital requirements will be substantial and will depend on many factors, including our ability to obtain drug discovery and development collaborations and other collaborations and technology license agreements, the amount and timing of payments under such agreements, the level and timing of our research and development expenditures, market acceptance of our products, the resources we devote to developing and supporting our products and other factors. Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses. We expect to devote substantial capital resources to continue our research and development efforts, to expand our support and product development activities, and for other general corporate activities. We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from drug discovery and development collaborations, other collaborations and technology licenses and other sources will be sufficient to fund our operations for at least the next 12 months. During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements. Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.
Disclosure about Market Risk
 
We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less
at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills, money market accounts, and certificates of deposit that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.

We had approximately $253.7 million in cash and cash equivalents and short-term investments as of March 31, 2012. We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12 months.
We have operated primarily in the United States and substantially all revenues to date have been in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.
Item 3.                 Quantitative and Qualitative Disclosures About Market Risk
See “Disclosure about Market Risk” under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” for quantitative and qualitative disclosures about market risk.
 
Item 4.                 Controls and Procedures
Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report.
Subsequent to our evaluation, there were no significant changes in internal controls or other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.

17

Part II -- Other Information 

Item 1.
Legal Proceedings
 
We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.
 
Item 1A.  
Risk Factors
 
The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements. The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Need for Additional Financing and Our Financial Results
•
We will need additional capital in the future and, if it is unavailable, we will be forced to significantly curtail or cease our operations. If it is not available on reasonable terms, we will be forced to obtain funds by entering into financing agreements on unattractive terms.

•
We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.

•
Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.

Risks Related to Discovery and Development of Our Drug Candidates
•
We have not proven our ability to successfully develop and commercialize drug candidates based on our drug target discoveries.

•
Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.

Risks Related to Regulatory Approval of Our Drug Candidates
•
Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our ability to commercialize products.

•
If our potential products receive regulatory approval, we or our collaborators will remain subject to extensive and rigorous ongoing regulation.

Risks Related to Commercialization of Products
•
The commercial success of any products that we may develop will depend upon the degree of market acceptance of our products among physicians, patients, health care payors, private health insurers and the medical community.

•
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate product revenues.

•
If we are unable to obtain adequate coverage and reimbursement from third-party payors for any products that we may develop, our revenues and prospects for profitability will suffer.

•
Current and future healthcare laws and regulations may negatively affect our revenues and prospects for profitability.

•
Our competitors may develop products that make our products obsolete.

•
We may not be able to manufacture our drug candidates in commercial quantities, which would prevent us from commercializing our drug candidates.

18


Risks Related to Our Relationships with Third Parties
•
We are dependent in many ways upon our collaborations with major pharmaceutical companies. If milestones are not achieved under our collaborations or if our collaborators' efforts fail to yield pharmaceutical products on a timely basis, our opportunities to generate revenues and earn royalties will be reduced.

•
Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.

•
We rely on third parties to carry out drug development activities.

•
We lack the capability to manufacture materials for preclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.

Risks Related to Our Intellectual Property
•
If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.

•
We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our discovery and development and planned commercialization activities. We may not prevail in any such litigation or other dispute or be able to obtain required licenses.

•
We use intellectual property that we license from third parties. If we do not comply with these licenses, we could lose our rights under them.

•
We have not sought patent protection outside of the United States for some of our inventions, and some of our licensed patents only provide coverage in the United States. As a result, our international competitors could be granted foreign patent protection with respect to our discoveries.

•
We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.

Risks Related to Employees, Advisors and Facilities Operations
•
The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to expand our operations.

•
Our collaborations with outside scientists may be subject to restriction and change.

•
Because most of our operations are located at a single facility, the occurrence of a disaster could significantly disrupt our business.

Risks Related to Environmental and Product Liability
•
We use hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

•
We may be sued for product liability.

Risks Related to Our Common Stock
•
Invus, L.P., Invus C.V., which we collectively refer to as Invus, and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.

•
Invus has additional rights under our stockholders' agreement with Invus, L.P. which provides Invus with substantial influence over certain significant corporate matters.


19

•
Our stock price may be extremely volatile.

•
We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.

•
Future sales of our common stock may depress our stock price.

•
If we are unable to meet Nasdaq continued listing requirements, Nasdaq may take action to delist our common stock.

For additional discussion of the risks and uncertainties that affect our business, see “Item 1A. Risk Factors” included in our annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission.
Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about our purchases of shares of our common stock during the three months ended March 31, 2012:
Period
 
Total Number of Shares Purchased
 
Average Price Paid Per Share
 
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
 
Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs (3)
January 1-31, 2012
 
17,680

(1) 
$
1.49

(2) 
—

 
—

February 1-29, 2012
 
145,105

(1) 
$
1.78

(2) 
—

 
—

March 1-31, 2012
 
—

 
$
—

 
—

 
—


(1) 
Represents shares retained by us in satisfaction of the tax withholding obligations of certain recipients of restricted stock units granted in February 2011 under our Equity Incentive Plan with respect to the vesting of such restricted stock units.
(2) 
Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our Equity Incentive Plan.
(3) 
In the future, we may grant additional equity securities under our Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities. Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions. Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years.

Item 6.
Exhibits
 
Exhibit No.
 
Description
31.1
—
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
—
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
—
Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
—
XBRL Instance Document
101.SCH
—
XBRL Taxonomy Extension Schema Document
101.CAL
—
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
—
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
—
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
—
XBRL Taxonomy Extension Presentation Linkbase Document


20

Signatures
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
Lexicon Pharmaceuticals, Inc.
 
 
 
 
Date:
May 3, 2012
By:
/s/ Arthur T. Sands
 
 
 
Arthur T. Sands, M.D., Ph.D.
 
 
 
President and Chief Executive Officer

Date:
May 3, 2012
By:
/s/ Jeffrey L. Wade
 
 
 
Jeffrey L. Wade
 
 
 
Executive Vice President, Corporate Development and Chief Financial Officer


21


Index to Exhibits
 
Exhibit No.
 
Description
31.1
—
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
—
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
—
Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
—
XBRL Instance Document
101.SCH
—
XBRL Taxonomy Extension Schema Document
101.CAL
—
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
—
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
—
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
—
XBRL Taxonomy Extension Presentation Linkbase Document


22
 EX-31.1 2 exh311certificationofprinc.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Exh 31.1 Certification of Principal Executive Officer 3.31.2012


Exhibit 31.1

CERTIFICATIONS
I, Arthur T. Sands, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 3, 2012
 
/s/ Arthur T. Sands
 
Arthur T. Sands, M.D., Ph.D.
 
President and Chief Executive Officer



 EX-31.2 3 exh312certificationofprinc.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER Exh 31.2 Certification of Principal Financial Officer 3.31.2012


Exhibit 31.2
CERTIFICATIONS
I, Jeffrey L. Wade, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 3, 2012

/s/ Jeffrey L. Wade
Jeffrey L. Wade
Executive Vice President, Corporate Development and
Chief Financial Officer



 EX-32.1 4 exh321certificationofprinc.htm CERTIFICATION OF PRINCIPAL EXECUTIVE AND PRINCIPAL FINANCIAL OFFICERS Exh 32.1 Certification of Principal Executive and Principal Financial Officers 3.31.2012




Exhibit 32.1
CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Arthur T. Sands, M.D., Ph.D., Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (“Lexicon”), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that:
1.
Lexicon's Quarterly Report on Form 10-Q for the period ended March 31, 2012, and to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and
2.
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.
IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 3rd day of May, 2012.

By:
/s/ Arthur T. Sands
 
Arthur T. Sands, M.D., Ph.D.
 
President and Chief Executive Officer


By:
/s/ Jeffrey L. Wade
 
Jeffrey L. Wade
 
Executive Vice President, Corporate Development
and Chief Financial Officer 





 EX-101.INS 5 lxrx-20120331.xml XBRL INSTANCE DOCUMENT 0001062822 2011-01-01 2011-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-01-01 2011-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-03-31 0001062822 us-gaap:CommonStockMember 2011-01-01 2011-03-31 0001062822 us-gaap:RetainedEarningsMember 2011-01-01 2011-03-31 0001062822 us-gaap:TreasuryStockMember 2011-01-01 2011-03-31 0001062822 2012-01-01 2012-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0001062822 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0001062822 us-gaap:RetainedEarningsMember 2012-01-01 2012-03-31 0001062822 us-gaap:TreasuryStockMember 2012-01-01 2012-03-31 0001062822 2010-12-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-12-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001062822 us-gaap:CommonStockMember 2010-12-31 0001062822 us-gaap:RetainedEarningsMember 2010-12-31 0001062822 us-gaap:TreasuryStockMember 2010-12-31 0001062822 2011-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2011-03-31 0001062822 us-gaap:CommonStockMember 2011-03-31 0001062822 us-gaap:RetainedEarningsMember 2011-03-31 0001062822 us-gaap:TreasuryStockMember 2011-03-31 0001062822 2011-12-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001062822 us-gaap:CommonStockMember 2011-12-31 0001062822 us-gaap:RetainedEarningsMember 2011-12-31 0001062822 us-gaap:TreasuryStockMember 2011-12-31 0001062822 2012-03-31 0001062822 2012-05-01 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001062822 us-gaap:CommonStockMember 2012-03-31 0001062822 us-gaap:RetainedEarningsMember 2012-03-31 0001062822 us-gaap:TreasuryStockMember 2012-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares 6042000 5324000 350000 186000 13786000 13710000 81654000 80535000 21000 -57000 1088666000 1087033000 0 1472000 1718000 0 0 0 0 0 1718000 0 0 1472000 35000 35000 402792000 430512000 285790000 258985000 186309000 29010000 47208000 20118000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents and investments held at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="52%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,098</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,713</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2011</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,671</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no realized gains or losses for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">. The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> -157299000 -27090000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Lexicon has derived substantially all of its revenues from drug discovery and development collaborations, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. Revenues generated from third parties under collaborative arrangements are recorded on a gross basis on the consolidated statements of comprehensive loss as Lexicon is the principal participant for these transactions for the purpose of accounting for these arrangements. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</font><font style="font-family:inherit;font-size:10pt;">:&#160;&#160;A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an agreement which expires in June 2013.&#160;&#160;The lease provides for two five-year renewal options at 95% of the fair market rent and includes escalating lease payments.&#160;&#160;Rent expense is recognized on a straight-line basis over the original lease term.&#160;&#160;Lexicon is the guarantor of the obligations of its subsidiary under this lease.&#160;&#160;The maximum potential amount of future payments the Company could be required to make under this agreement is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.3&#160;million</font><font style="font-family:inherit;font-size:10pt;"> without taking into account the exercise of the renewal options. The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.&#160;&#160;The Company had $0.4&#160;million in restricted investments as collateral as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Additionally, Lexicon leases certain equipment under operating leases.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</font></div></div> 0.001 0.001 900000000 900000000 480942000 480389000 337566000 337875000 481000 480000 -29946000 -29594000 152000 516000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Obligations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mortgage Loan.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In April 2004, Lexicon obtained a $34.0 million mortgage on its facilities in The Woodlands, Texas.&#160;&#160;The mortgage loan has a ten-year term with a 20-year amortization and bears interest at a fixed rate of 8.23%.&#160;&#160;The mortgage had a principal balance outstanding of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$24.5&#160;million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">. The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan is estimated using discounted cash flow analysis, based on the Company&#8217;s current incremental borrowing rate.</font></div></div> 119000 421000 14212000 13910000 18745000 18745000 1307000 1125000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Stock-Based Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.7&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.5&#160;million</font><font style="font-family:inherit;font-size:10pt;"> of stock-based compensation expense for the three months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions for options granted in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="51%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2012:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2011:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of option activity under Lexicon&#8217;s stock-based compensation for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,537</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, Lexicon also granted its employees annual restricted stock units. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Weighted Average Grant Date</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at March 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2010, Lexicon granted certain employees restricted stock units with a performance condition. The shares subject to the restricted stock units granted in 2010 vest upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by Lexicon as a basis for a New Drug Application. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. The following is a summary of performance-based restricted stock units activity under Lexicon's stock-based compensation plans for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Weighted Average Grant Date</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at March 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> -0.06 -0.09 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share is computed using the weighted average number of shares of common stock outstanding during the applicable period and excludes shares underlying stock options and restricted stock units because they are antidilutive.&#160;&#160;There are no differences between basic and diluted net loss per share for all periods presented.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - quoted prices in active markets for identical investments</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - significant unobservable inputs (including the Company's own assumptions in determining the fair value of investments)</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels described above as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets and Liabilities at Fair Value as of March 31, 2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets and Liabilities at Fair Value as of December 31, 2011</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Level 3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="560px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="103px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,081</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div></div> 4753000 4565000 44543000 44543000 769000 0 -3849000 851000 87000 -164000 29000 0 315000 24000 -1395000 -565000 53557000 53557000 607000 537000 516000 584000 87000 56000 132944000 133821000 430512000 402792000 21390000 20933000 80000 148000 1443000 1478000 23451000 23063000 -232000 -722000 -129575000 -5318000 -21540000 -27002000 -29629000 -29868000 0 0 0 -29629000 0 0 -29868000 0 0 0 29683000 29732000 -29383000 -29136000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC.</font></div></div> 5143000 3748000 205000 181000 -78000 35000 0 0 0 35000 0 -78000 0 0 0 0 55146000 57170000 27000 -4000 108000 285000 33895000 151776000 234000 507000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 52000 160000 0 0 0 0 -136000 -136000 0 29041000 22435000 43000 0 45526000 46417000 353000 284000 23037000 23921000 430000 430000 -819489000 -789621000 596000 300000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June&#160;2011, the Financial Accounting Standards Board issued Accounting Standards Update No.&#160;2011-05, &#8220;Presentation of Comprehensive Income&#8221;, which improves the comparability, consistency, and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments in this standard require that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (&#8220;OCI&#8221;) to net income, in both net income and OCI. The standard does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, the standard does not affect the calculation or reporting of earnings per share. This pronouncement should be applied retrospectively for fiscal years beginning after December&#160;15, 2011, with early adoption permitted. Lexicon adopted this pronouncement in 2012 and there was no material impact to its consolidated results of operations and financial condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 1718000 1472000 224646000 95383000 553000 309000 0 0 523000 51000 0 0 523000 0 0 1000 52000 0 268971000 297568000 -345000 21000 338000 40000 -703035000 -237000 219317000 268971000 -673406000 922319000 5000 1088666000 -57000 480000 -630000 -819489000 338000 247024000 481000 -789621000 297568000 1087033000 -345000 920324000 218000 380000 630000 345000 0 0 0 0 0 -108000 0 -285000 -285000 -108000 0 0 35000 -78000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arrangements with Symphony Icon, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &#8220;Programs&#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&#8220;Holdings&#8221;), the Company's intellectual property rights related to the Programs. Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings 7,650,622 shares of its common stock on June 15, 2007 in exchange for $15 million and an exclusive purchase Option (the "Purchase Option") that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and agreed to make up to $80 million in additional base and contingent payments.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The base payments will be in an amount equal to $50 million less 50% of the expenses Lexicon incurs after its exercise of the Purchase Option for the development of LX1032, LX1033 and other pharmaceutical compositions modulating the same target as those drug candidates (the &#8220;LG103 Programs&#8221;), subject to certain exceptions and up to an aggregate reduction of $15 million. The base payments are payable in Lexicon's discretion at any time before July 30, 2013.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent payments will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize a drug candidate from the LG103 Programs (a &#8220;Licensing Transaction&#8221;), subject to certain exceptions and up to a maximum of $30 million plus the amount of any reduction in the base payments for Lexicon's development expenses for the LG103 Programs (the &#8220;Recapture Eligible Amount&#8221;). The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The base payments and the contingent payments may be paid in cash, common stock, or a combination of cash and common stock, in Lexicon's discretion, provided that at least 50% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid $10.0 million in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 14% for the base payments; (2) a discount rate of 18% for the contingent payments; and (3) a probability adjusted contingency. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2.1&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 1058000 2081000 337527000 480324000 633000 681000 1037000 839000 false --12-31 Q1 2012 2012-03-31 10-Q 0001062822 480656570 Yes Accelerated Filer LEXICON PHARMACEUTICALS, INC./DE EX-101.SCH 6 lxrx-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2122100 - Disclosure - Arrangements with Symphony Icon Inc link:presentationLink link:calculationLink link:definitionLink 1002500 - Statement - Balance Sheet Parenthetical (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Cash and Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Collaboration and License Agreements link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Debt Obligations link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Other Capital Stock Agreements link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 1004500 - Statement - Statements of Comprehensive Loss Parenthetical (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 lxrx-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 lxrx-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 lxrx-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net Loss Per Share [Abstract] Net Loss Per Share [Abstract] Earnings Per Share, Policy Earnings Per Share, Policy [Policy Text Block] Consolidated Statements of Operations [Abstract] Consolidated Statements of Operations [Abstract] Statement [Table] Statement [Table] Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Collaborative research Contracts Revenue Subscription and license fees Licenses Revenue Total revenues Revenues Operating expenses: Operating Expenses [Abstract] Research and development, including stock-based compensation of $1,037 and $839, respectively Research and Development Expense Increase in fair value of Symphony Icon, Inc. purchase liability Change in fair value of Symphony Icon Inc. purchase liability This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. General and administrative, including stock-based compensation of $681 and $633, respectively General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Gain on investments, net Gain (Loss) on Investments Interest income Investment Income, Interest Interest expense Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Consolidated net loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Consolidated net loss Net Income (Loss) Attributable to Parent Consolidated net loss per common share, basic and diluted Earnings Per Share, Basic and Diluted Shares used in computing consolidated net loss per common share, basic and diluted Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted The average number of shares issued and outstanding that are used in calculating both basic and diluted earnings per share, determined based on the timing of issuance of shares in the period. Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Arrangements with Symphony Icon Inc [Abstract] Arrangements with Symphony Icon Inc [Abstract] Arrangements with Symphony Icon Inc Arrangements with Symphony Icon Inc [Text Block] Information about a series of related agreements in 2007 providing for the financing of the clinical development of certain of its drug candidates. These agreements were amended in 2010, when Lexicon exercised is purchase option and reaquired the clinical programs. Stock-Based Compensation [Abstract] Stock-Based Compensation [Abstract] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Other Capital Stock Agreements [Abstract] Other Capital Stock Agreements [Abstract] Stockholders' Equity Note Disclosure Stockholders' Equity Note Disclosure [Text Block] Statements of Operations Parentheticals [Abstract] Statements of Operations Parentheticals [Abstract] Stock-based compensation expense associated with research and development expense Stock-based compensation expense associated with research and development expense Stock-based compensation expense included in research and development expense. Stock-based compensation expense associated with general and administrative expense Stock-based compensation expense associated with general and administrative expense Stock-based compensation expense associated with general and administrative expense. Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Collaborative Arrangement Disclosure Collaborative Arrangement Disclosure [Text Block] Consolidated Statements of Stockholders’ Equity [Abstract] Consolidated Statements of Stockholders’ Equity [Abstract] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Gain (Loss) Accumulated Other Comprehensive Income (Loss) [Member] Treasury Stock Treasury Stock [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Balance, shares Common Stock, Shares, Issued Balance, value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Issuance of common stock under Equity Incentive Plans, shares Stock Issued During Period, Shares, New Issues Issuance of common stock under Equity Incentive Plans, value Stock Issued During Period, Value, New Issues Other Proceeds from (Payments for) Other Financing Activities Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Net loss Unrealized gain (loss) on investments Balance, shares Balance, value DEI [Abstract] DEI [Abstract] Document Information [Table] Document Information [Table] Document Information, Document [Axis] Document Information, Document [Axis] Document [Domain] Document [Domain] Document Information [Line Items] Document Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Measurements [Abstract] Fair Value Measurements [Abstract] Fair Value, Measurement Inputs, Disclosure Fair Value, Measurement Inputs, Disclosure [Table Text Block] Balance Sheet Parentheticals [Abstract] Balance Sheet Parentheticals [Abstract] Common Stock [Member] Restricted investments Restricted Investments Allowances for accounts receivable Allowance for Doubtful Accounts Receivable, Current Accumulated depreciation and amortization, property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred stock, par value per share Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value per share Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Treasury stock, shares Treasury Stock, Shares Commitments and Contingencies [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure Commitments and Contingencies Disclosure [Text Block] Debt Obligations [Abstract] Debt Obligations [Abstract] Debt Disclosure Debt Disclosure [Text Block] Consolidated Balance Sheets [Abstract] Consolidated Balance Sheets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments, including restricted investments of $430 Short-term Investments Accounts receivable, net of allowances of $35 Accounts Receivable, Net, Current Prepaid expenses and other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net of accumulated depreciation and amortization of $81,654 and $80,535, respectively Property, Plant and Equipment, Net Goodwill Goodwill Other intangible assets Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Total assets Assets Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Current portion of deferred revenue Deferred Revenue, Current Current portion of long-term debt Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred revenue, net of current portion Deferred Revenue, Noncurrent Long-term debt Long-term Debt, Excluding Current Maturities Deferred tax liabilities Deferred Tax Liabilities, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Equity: Equity [Abstract] Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, $.001 par value; 900,000 shares authorized; 480,942 and 480,389 shares issued, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive gain (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost, 380 and 218 shares, respectively Treasury Stock, Value Total equity Stockholders' Equity Attributable to Parent Total liabilities and equity Liabilities and Equity Basis of Presentation [Abstract] Basis of Presentation [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Cash and Cash Equivalents and Investments [Abstract] Cash and Cash Equivalents and Investments [Abstract] Cash and Cash Equivalents Disclosure Cash and Cash Equivalents Disclosure [Text Block] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Consolidated net loss Adjustments to reconcile consolidated net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation, Depletion and Amortization Impairment of fixed assets Impairment of Long-Lived Assets Held-for-use Increase in fair value of Symphony Icon, Inc. purchase liability Stock-based compensation Share-based Compensation (Gain) loss on disposal of property and equipment Gain (Loss) on Sale of Property Plant Equipment Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] (Increase) decrease in accounts receivable Increase (Decrease) in Accounts Receivable Increase in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Decrease in other assets Increase (Decrease) in Other Operating Assets Increase (decrease) in accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Decrease in deferred revenue Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Purchases of investments Payments to Acquire Investments Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Repurchase of common stock Payments for Repurchase of Common Stock Proceeds from debt borrowings Proceeds from Issuance of Long-term Debt Repayment of debt borrowings Repayments of Long-term Debt Other financing activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Net Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments EX-101.PRE 10 lxrx-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Loss Per Share
 3 Months Ended
Mar. 31, 2012
Net Loss Per Share [Abstract]  
Earnings Per Share, Policy
Net Loss Per Share
 
Net loss per share is computed using the weighted average number of shares of common stock outstanding during the applicable period and excludes shares underlying stock options and restricted stock units because they are antidilutive.  There are no differences between basic and diluted net loss per share for all periods presented.
 
EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V.&4Y8S$Q-%\X9#DT7S0T86-?838S-5\S.#1D M-35D,38W,C$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E8G1?3V)L:6=A=&EO;G,\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K6UP:&]N>5])8V\\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;&QA8F]R871I;VY?86YD M7TQI8V5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O M=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D M/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D M('=I=&@@36EC'1087)T7S8X93EC,3$T7SAD M.31?-#1A8U]A-C,U7S,X-&0U-60Q-C'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,CQS<&%N/CPO M'0^43$\2!# M=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'!E;G-E6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA"!L:6%B M:6QI=&EEF5D.R!N;R!S:&%R97,@ M:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S MF5D.R`T.#`L.30R(&%N9"`T.#`L,S@Y M('-H87)E3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S2!S M=&]C:RP@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V.&4Y M8S$Q-%\X9#DT7S0T86-?838S-5\S.#1D-35D,38W,C$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-CAE.6,Q,31?.&0Y-%\T-&%C7V$V,S5?,S@T M9#4U9#$V-S(Q+U=O'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N M;&5S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V.&4Y M8S$Q-%\X9#DT7S0T86-?838S-5\S.#1D-35D,38W,C$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-CAE.6,Q,31?.&0Y-%\T-&%C7V$V,S5?,S@T M9#4U9#$V-S(Q+U=O'0O:'1M;#L@8VAA'!E;G-E(&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V.&4Y8S$Q-%\X9#DT7S0T86-?838S-5\S M.#1D-35D,38W,C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-CAE M.6,Q,31?.&0Y-%\T-&%C7V$V,S5?,S@T9#4U9#$V-S(Q+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!);F-E;G1I=F4@ M4&QA;G,L('-H87)E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D(&=A:6X@*&QO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&]T:&5R(&QI86)I;&ET M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-3$I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S0I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@;V8@9&5B="!B;W)R;W=I;F=S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-3,I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M86QI9VXZ;&5F=#MP861D:6YG+6QE9G0Z M,S!P>#MT97AT+6EN9&5N=#HM,S!P>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FIU6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CQD:78@'0M86QI9VXZ M;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M&EC;VXF(S@R,C$[(&]R('1H92`F(S@R,C`[0V]M<&%N M>28C.#(R,3LI(&AA=F4@8F5E;B!P2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9F]R(&-O;7!L M971E(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9F]N=#X\+V1I=CX\9&EV('-T M>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N M=#HT.'!X.V9O;G0M2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!H879E(&)E96X@:6YC;'5D M960N($]P97)A=&EN9R!R97-U;'1S(&9O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SYT:')E93PO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/BUM;VYT:"!P97)I;V0@96YD960@/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`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`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UEF4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY. M970@3&]S6QE/3-$;&EN M92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z-#AP M>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@ M07=A'0M:6YD96YT.BTS,'!X.V9O M;G0M'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT M.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&AE($-O;7!A;GD@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXD,2XW)B,Q-C`[;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.R<^)#$N-28C,38P.VUI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE3I4 M:6UE3II;FAE3I4:6UE3II;FAE2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!U=&EL:7IE9"!T M:&4@0FQA8VLM4V-H;VQE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&UO;G1H3II;FAE3II;FAE6QE/3-$<&%D9&EN9RUL M969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A M9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG M;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R M:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY%>'!E8W1E9"!6 M;VQA=&EL:71Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I M9VAT.F)O;&0[/E)I6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/D5X<&5C=&5D(%1E M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$9F]N="US M:7IE.CEP=#MT97AT+6%L:6=N.F-E;G1EF4Z.7!T.SX\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF M;VYT+7=E:6=H=#IB;VQD.W1E>'0M86QI9VXZ8V5N=&5R.SY$:79I9&5N9#PO M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$9F]N="US:7IE.CEP=#MT97AT+6%L M:6=N.F-E;G1EF4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD M.W1E>'0M86QI9VXZ8V5N=&5R.SY2871E/"]F;VYT/CPO9&EV/CPO=&0^/"]T M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M6QE M/3-$;W9E6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@#L@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@'0M86QI9VXZ6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,"4\+V9O M;G0^/"]D:78^/"]T9#X\+W1R/CQT#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^3V9F:6-E#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZF4Z,3!P=#L^-S@\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS M1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,"4\+V9O;G0^ M/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/&1I=B!S='EL M93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X M.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC M;VQO'0M9&5C;W)A=&EO;CIN;VYE.SYT:')E93PO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!M;VYT:',@96YD960@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T M>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M17AP:7)E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@ M'0M86QI M9VXZ6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*##MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^1F]R9F5I=&5D/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R<@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`R,#$R/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^.CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQD:78@'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H M=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG M/3-$,"!C96QL'0M86QI9VXZ;&5F=#LG/CQT6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[ M/E-H87)E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$=&5X M="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^3W5T#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BPQ M,C<\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O M='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^1W)A;G1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#L@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BPS.3`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`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,RPW M-S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@"!S;VQI9"`C M,#`P,#`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`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`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`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`C,#`P,#`P M.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,S0U/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M:6YD96YT.BTS,'!X M.V9O;G0M'0M M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@2G5N928C,38P M.S(P,3$L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A M2!E;&EM:6YA=&EN9R!T:&4@;W!T:6]N('1O('!R97-E;G0@8V]M<&]N M96YT2X@5&AE(&%M96YD;65N=',@:6X@=&AI&5S+"!P'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UEF4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY# M87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(&%N9"!);G9E6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L M:6=N.FIU6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CQD:78@'0M86QI M9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HT.'!X.V9O;G0M6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`R M,#$R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z-W!T.SXF(S$V,#L\ M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N M="US:7IE.C$P<'0[/CQD:78@'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z M,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL'0M86QI9VXZ;&5F=#LG/CQT#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ8V5N M=&5R.V9O;G0MF5D($-O#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@ MF4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF M;VYT+7=E:6=H=#IB;VQD.SY%F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG M+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M'0M86QI9VXZ6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X M,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD M+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M,CDL,#$P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^4V5C=7)I=&EE6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`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`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`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`P,#`[8F%C:V=R M;W5N9"UC;VQO#MP861D:6YG+6)O M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R M;W5N9"UC;VQO#MP861D:6YG+6)O M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB86-K M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[ M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC M;VQO#MP861D:6YG+6)O='1O;3HR M<'@[8F]R9&5R+71O<#HQ<'@@#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[ M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^,C(T+#8T-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^5&]T86P@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT6QE/3-$;W9E#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE M/3-$)W9E"!D M;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.R<@'0M86QI9VXZ6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C4S+#6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[)R!R M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN M9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ M#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@'0M86QI9VXZ8V5N=&5R.V9O;G0MF4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI M9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E M:6=H=#IB;VQD.SXH:6X@=&AO=7-A;F1S*3PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1'9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@'0M86QI9VXZ8V5N=&5R M.V9O;G0M#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.R<@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z M,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A M9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M.R<@'0M M86QI9VXZ6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.34L,S8R/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O M;G0M#MP861D:6YG+6)O='1O M;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O M<#HQ<'@@6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X M.W!A9&1I;F#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.V)A8VMGF4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`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`@("`\+W1R/@T*("`@("`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`M('%U M;W1E9"!P6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[<&%D M9&EN9RUL969T.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@ M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0[)SX\='(^/'1D('-T>6QE/3-$=VED M=&@Z-#AP>#L@6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C(V.SPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1'9E6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MT97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUL969T.C0X<'@[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQT M86)L92!C96QL<&%D9&EN9STS1#`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`E.V)O#MP M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X] M,T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ8V5N M=&5R.V9O;G0M6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB M;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC M96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY, M979E;"`Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X] M,T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`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`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C4S M+#8U-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X M,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X M,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M)W9E"!D;W5B M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C4S M+#8U-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E M:6=H=#IB;VQD.SY,:6%B:6QI=&EE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@ MF4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE M/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG M+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT M;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X M,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X="UA M;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9EF4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@ M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^-36QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S M('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG M(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG M;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD M.SY,979E;"`R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`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`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I M9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.34L M,S@S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P M,#`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`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D M('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN M9RUT;W`Z,G!X.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P M,#`[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A M9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P M=#L^/&9O;G0@3II;FAE#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M.R<@'0M M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.V)O6QE/3-$=&5X="UA;&EG;CIL969T M.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P M>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MB;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!D;W5B;&4@ M(S`P,#`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`R,#$R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^ M/&9O;G0@3II;FAE3II;FAE'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C0X<'@[ M9F]N="US:7IE.C$P<'0[/CQD:78@'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT M;W`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`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M6QE/3-$=&5X="UA;&EG;CIR:6=H M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^)B,Q-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PP M-3@\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q,3PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E6QE M/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.V)A8VMG"!S M;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$)W9E'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-#DL,S(U/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$)W9E"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F M;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^5&AE($-O;7!A;GD@86QS;R!H87,@87-S971S('1H870@=6YD97(@ M8V5R=&%I;B!C;VYD:71I;VYS(&%R92!S=6)J96-T('1O(&UE87-U2`S,"P@,C`Q,"!A;F0@:6YT M86YG:6)L92!A6UP:&]N>2!)8V]N(&]N($IU;'D@,S`L(#(P,3`N($9O6QE/3-$;&EN92UH96EG M:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C=P=#L^/&9O;G0@ M3II;FAE'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0M:6YD96YT.BTS,'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIUF4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD M:78@'0M86QI9VXZ;&5F=#MT M97AT+6EN9&5N=#HT.'!X.V9O;G0M6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q M-C`[26X@07!R:6P@,C`P-"P@3&5X:6-O;B!O8G1A:6YE9"!A("0S-"XP(&UI M;&QI;VX@;6]R=&=A9V4@;VX@:71S(&9A8VEL:71I97,@:6X@5&AE(%=O;V1L M86YD65A6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,C0N-28C,38P.VUI;&QI;VX\+V9O;G0^ M/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SY-87)C:"8C,38P.S,Q+"`R,#$R/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+B`@5&AE(&9A:7(@=F%L=64@;V8@3&5X:6-O;B8C.#(Q-SMS(&UO6EN9R!V86QU92XF(S$V,#LF M(S$V,#M4:&4@9F%I28C.#(Q-SMS(&-U M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UP:&]N>2!)8V]N($EN8SQB'0M:6YD96YT M.BTS,'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O M;G0M2!O M=&AE2UO=VYE9"!S M=6)S:61I87)Y(&]F(%-Y;7!H;VYY($EC;VX@2&]L9&EN9W,@3$Q#("@F(S@R M,C`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`S,"P@,C`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`S M(%!R;V=R86US("AA("8C.#(R,#M,:6-E;G-I;F<@5')A;G-A8W1I;VXF(S@R M,C$[*2P@2!P M2!C;VYT:6YG96YT('!A M>6UE;G0@9G)O;2!S=6-H(&$@3&EC96YS:6YG(%1R86YS86-T:6]N+"!,97AI M8V]N('=I;&P@<&%Y($AO;&1I;F=S('1H92!S=6T@;V8@)#$U(&UI;&QI;VX@ M86YD(&%N>2!296-A<'1U&-E960@-3`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`Q,CPO9F]N=#X\ M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P M<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SXR,#$Q/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@9F%I2!I;F-R96%S960@8GD@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.R<^)#(N,28C,38P.VUI M;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE'1087)T M7S8X93EC,3$T7SAD.31?-#1A8U]A-C,U7S,X-&0U-60Q-C'0O:F%V87-C3X-"B`@("`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`R,#$R M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CQD:78@'0M M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M&EC;VX@:7,@9G)O;2!T:6UE('1O('1I M;64@<&%R='D@=&\@8VQA:6US(&%N9"!L96=A;"!P2X\+V9O;G0^/"]D:78^/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`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htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation
 3 Months Ended
Mar. 31, 2012
Basis of Presentation [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure
Basis of Presentation
 
The accompanying unaudited consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
 
In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012.
 
The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2011, as filed with the SEC.
XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2012
Dec. 31, 2011
Current assets:    
Cash and cash equivalents $ 29,010 $ 186,309
Short-term investments, including restricted investments of $430 224,646 95,383
Accounts receivable, net of allowances of $35 186 350
Prepaid expenses and other current assets 5,143 3,748
Total current assets 258,985 285,790
Property and equipment, net of accumulated depreciation and amortization of $81,654 and $80,535, respectively 45,526 46,417
Goodwill 44,543 44,543
Other intangible assets 53,557 53,557
Other assets 181 205
Total assets 402,792 430,512
Current liabilities:    
Accounts payable 5,324 6,042
Accrued liabilities 13,710 13,786
Current portion of deferred revenue 421 119
Current portion of long-term debt 1,478 1,443
Total current liabilities 20,933 21,390
Deferred revenue, net of current portion 13,910 14,212
Long-term debt 23,063 23,451
Deferred tax liabilities 18,745 18,745
Other long-term liabilities 57,170 55,146
Total liabilities 133,821 132,944
Commitments and contingencies      
Equity:    
Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $.001 par value; 900,000 shares authorized; 480,942 and 480,389 shares issued, respectively 481 480
Additional paid-in capital 1,088,666 1,087,033
Accumulated deficit (819,489) (789,621)
Accumulated other comprehensive gain (loss) (57) 21
Treasury stock, at cost, 380 and 218 shares, respectively (630) (345)
Total equity 268,971 297,568
Total liabilities and equity $ 402,792 $ 430,512
XML 16 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)
In Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Treasury Stock
Balance, value at Dec. 31, 2010 $ 247,024 $ 338 $ 920,324 $ (673,406) $ 5 $ (237)
Balance, shares at Dec. 31, 2010   337,566        
Stock-based compensation 1,472 0 1,472 0 0 0
Issuance of common stock under Equity Incentive Plans, shares   309        
Issuance of common stock under Equity Incentive Plans, value 523 0 523 0 0 0
Other 0          
Repurchase of common stock (108) 0 0 0 0 (108)
Net loss (29,629) 0 0 (29,629) 0 0
Unrealized gain (loss) on investments 35 0 0 0 35 0
Balance, value at Mar. 31, 2011 219,317 338 922,319 (703,035) 40 (345)
Balance, shares at Mar. 31, 2011   337,875        
Balance, value at Dec. 31, 2011 297,568 480 1,087,033 (789,621) 21 (345)
Balance, shares at Dec. 31, 2011   480,389        
Stock-based compensation 1,718 0 1,718 0 0 0
Issuance of common stock under Equity Incentive Plans, shares   553        
Issuance of common stock under Equity Incentive Plans, value 52 1 51 0 0 0
Other (136) 0 (136) 0 0 0
Repurchase of common stock (285) 0 0 0 0 (285)
Net loss (29,868) 0 0 (29,868) 0 0
Unrealized gain (loss) on investments (78) 0 0 0 (78) 0
Balance, value at Mar. 31, 2012 $ 268,971 $ 481 $ 1,088,666 $ (819,489) $ (57) $ (630)
Balance, shares at Mar. 31, 2012   480,942        
ZIP 17 0001062822-12-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001062822-12-000021-xbrl.zip M4$L#!!0````(`."`HT`XN_0O8EP``,`"TR,#$R,#,S,2YX M;6Q55`D``V/EHD]CY:)/=7@+``$$)0X```0Y`0``[%UI<^/(D?WN"/^'6GK' M,1LA2H4;8+?:@7.VO3TS[5:WU]\<$%`DRXV#"X`Z_.LW"P0IBH>N!DE02L=8 M3>*HRLQZ^3*S"D2]_\M-FI`K5I0\S\Y[TBGM$99%>34F_\LN`Y[`;66_+ZZ^N2P2 M/A!_"721E8.8\?/>N*HF@[,S<)N)N.P2,/3 M*$^%0#)5[L29EOU1&$X6=PS#\K)NO#FQ00/1?[RB-#`H MZU-?V)#4#0[&!1N>]X3=^G/KG-Z4<:\Y7=U.V'FOY.DD`3G/9@W-4!#E6<5N M*L+C\YXG#/4W:=;1X@J`$Z]NFV.+HSP6QX><%:06AMW39(X?]^/_]#Y0T(?J MLBG+[\]6;YYW=;:AKZ:G"2MX'J_V#S8I*@\P_F$^NE2:MW)W;N4FEL5+MR@` MB+N.XZ4;YD>7NIX?:NSUB`G_V4#OGQ<5M"H\TO^_*6CFYNDDS^!K:=_P9$#&+< M3!(>\6HF(XEY*B07I-4H.'C0#+T/\\N>;(?W9QN[OA/Y;)/,;QUE<ACQHL4PY;IAP[?K!,0>1\A*;IW]2C*%-F:TR5 ML`;M@T'NK#$_TY(UL.)X'15'9P&#Q<-ABX>N`@/K@#<.`$SI]Y[2=Q4*F)V_ M.A``@8GV&P<`)MJ'3+0[!05, MM%\A"(YN1EO:9=F!,]JO,='N$F`PT>Y0HMTA8&"B_<8!@(GV81/M#D$!$^U7 M!X)C><)]R1KR[LH.L,:%=X3VT):>16K9'EAXO+K"8[<.A(7'T18>G0(&%AYO M'`!8>!RR\.@4%+#P.'H03#,^0T`Y#@M6K@Q?6FO+/C0:U)?,&YN?6^Y`M+:Q M]6D9;VFZ>5G4X-N%]]*6/[/B0HBVTD/,KP`KJV84-_XV35D15GFQ"I4GB[5L MZ,TM+G7GL2Q/>?9PAX^9>+7']4;G9Y?T7K?>4B*<3P'>G\/;\#)A[K0H`(JD M0<@7\4*I^8(/B5G$TS`ISWM]I5<;/0BCJF^;CNP8KF%(LJMXLBY+KJ'9OFT' MKJG9JMTCHMNZJ7KX=:K*X,[OSQZ6X45RBGIYFYPZ]5U?HJ9E>:9DVKZC._9< M3LLTY%4Y-4567RSG%Q8Q?B4N^XU5+[&J[TF>+_NVI.JR:GJ^Y MV=7,P'=4755510ZH:2KN'!&N+MZSMR:NM(:))XH[+XX]!F5QQ$-1!L'GA(D/ M=A;;:5Y4_-_U\<]%#C&FNOV<0/"!P]&>,A9+JV0?6`6HYI4!7`*>FF-#.&3QU+4]>, M0;7:__=HC&W3)I_RL@2W_7WX-;QYEL[4"/3`4S0+?%&Q-9]JSH(]`LM8\T99 MVJ;P4T1K5Z\'69&:3N#+NNI)U("80KW`F>GEJ-0UUEBQKQDM*K9Y"N-Y"CBR M3@TE<%U%\37+5SQ=:6B2NHJT!D8(L::NKQ#E9CE>)NR#R8@'/&[ZU)152Z&! M#92I-M;V+=U5-@AK4$5YB;#_FI:5<)'R:[[ECCH;%>\TC<6@P8C5OO:%@7.5 MO&(7K+CB$?M<)^@0]/)15K?R]S"9LGM:[_I-+5M##G4E0X5\B5J^(5F`3%M9 M8#E-C6`.LY0!>.)]NNI>B0)5BJ,K>[9U`7[?[# ML]+;3*\I4N`8CN4I@>KY:@#,'2SF+JCYADV_RU^/;:T!9=.Q30XEJZ:`;5-=3$SZ5G.VMS'6TMZ6OOYT=8PH"F^!:6-Y`/VK<"0#->> M1V!'L:RWZP+M_-QG:[:O6[XGJ[9JRGK@Z2;PD#&WNV*J;SCC;/NWN%M'P(7J MTS&5@$(6:CH4WK7:M4DR:_%/BA!7GCY]+(:3I/U98.7+`;HON3K M.I"O;$JZ+,IV4YU-N;JN)=O>QO66)3,\1[`V=7JHF)9D!_31=$V"$*\'KFRI M7J.3;%"ZED^UJ%-9LJI\EK!V$%!?HHY+@8T=V?"!#^9(=%5_+157J6Q8*UBL M>WV2)`]!0:.!F%LV72<(=`=$">R&E3Q9-JFY)HE"->FIDKQH+=`U),DW=4,/ M+,NP3,GT%C.PFF2M85,V-<.B&P1Z8*Q>@B]54D!P%T0S=-G19$U3%_1MR^[: MS+"LF9:I/54N-RS'=A:+?P3Q785)S7F5&Q;%+03U=>)\S(ZF[3J*9%F:8U!5 MUS3-74P.J[(7:!L6*!5JW9/W24*UH<=#=H<@:4+A:JBZ:BNRX@")VW,\^'*P M%C9EBZZL!.Y-#?K`<,BF024WD'Q?516?6K[I+;(NWY;7TEX1>LS#J/'0=*_K M.*HJ^9:JNHX-'.NIOCVG"XV:Z]X)S>U(#8^749*+9T6^@O1.`AG8YMG7.Q?6 M7=7([^,I3 M5I+?V#7YDJ=A]JX^5_)_LX%$)]6[WI]'U;N5VQ/(ROMCQD?C:@"<^=,[(5L_ M3/@H&R1L6+V;A+'8VZXOO@P4.KF97<$S\;C7H%\?V=:/.+Y)3IZ-(;>H5N^K MOU[/9+G,DWC6D#`I";.8U!^6C%L?_)A=L2;=$3V>B3;FW9^!GL]46>1.?'C; MED:S^\)T\NY/DD[?M2GA\BBH9GN#4-_W=V,@K\ M;A3(F"4Q"2NRINPS!8GR)"\&?Z+U_V;J@L/G19VK#C+(N&>R_AH6T?C.QHIT M0H17_6CW==NUE2,!*69)B+-+(<_$"C1HO0?@)'W:.@ M5082WY<;S?("8L*"MJI\(AJ^N6NX$DDRB5B2--><]VBO_EY.PFC^_?GL>LWC M:@P?0:?+O(A9T8>!3\))R0;S#VOD>B=4L?@$+I8+4<3NHE`1%#!6LR^+B\^J M^.YCL;&)6ICSGB;_=*^%I:8WM79WH[3G^ZPCD1/U0_UVU]\V;V[(Z(H5%8_" MI&&0R[RJ\O1^@B8#TRU3W_+WV?7W#A4U98HCCXJYQ,=++!8!!;/B$.G2?7-W MS$(Y"#*$*#L8\QBBU.'MNUFO?6$V\JV/MY(:4><)C,D]X-H:P?:!IS:NUEABW=O:L>51.?3LL6D6$SA'XN_6 MT>@*'O]S;^9[%)A/I<6G6ZN&;:OFDJT3*M'#VZPK\!'W718D2EA8G/?$ZG7O M;&$(9#-D,V2S#K/9#':F+,G[PUWG,824AI36(3@BI2&E(:4AI2&EO55*PYJS M73;#E8%W%RR:%O4K!DD:5O`Q&Y%K7HUY1L"<$#^('\0/X@?Q\R;PL\O5;O/8$TU7:#\$_2M6/VD?LTE>\M:>R\6) MARZQG?\86\1^12U6BO@ MN@+^@]1I3ROI5?78"[BON=BBLASG1=6O6)$NOYL6YYC>U-//3W_Q!3X:_9B- M=V#*W<0+@[96<;S!O%T7,LB2R)+(DMUC2>1'Y$?D1^1'Y,>=S]']N#6? M-;MW%%!M;>H/^1/Y$_FS>_PIJG!=U0]OT:-`WD$F@_?/D+N?\GWR#F5M`1/# MS`'"3%7$D/8WP=`5-.QZJ@"I!JD&J>9`LYA=P0&2#)(, MDLRKG0K$Y_F0A)"$D(0V%E6ZMK_YM*Z@X8W,C*WR3[./N2R>Q.PV%Z&MNOS. MI$[;"G&%N$)<(:Z.Q5:(*\15-]XC>-"E6]Q._CBF$.[$W<66E<>TH:Q=OX32 M8Q%++UE!%.F$R%22T$7113OBHKA)]+-].LW!4&+K8:/FB$VNXC-3_`=7VF&X.P"./VRXFE8`2J#D!?D[V$R M99B=8W9^)`Z]GSDL1-#Q(L@X[%N9]L'A/_.,5.-\6H997.*C0$A#.(&^M^UV MMOWJ";UP/Z$.'\AKU4K'\$">9.HG"K7V9INNH$'+/7$ ME-2=@ZLKWK7K4([>A=ZU=)^,GH6>A9ZUB[>SM[<'1*O;,';%'7&G1?2[7>6+ MBH91;9>E[CU0J.JQ5[2S+?K*<5Y4_8H5*>[']TH>L#Z*/38[]?3U<6SB:FDG MBB[OS6Y'`:-=ES=(8$A@2&#=FW9!\D+R0O)"\CK*F:V=;#MX%+C#%Y$AM2&U M=8W:1&%I[H_>C@)&!YEA[-"D_JIM[TL@)C_K*W@&7%@-^JUOW3.;G8RVO4JO M/KB#"Z\>2=?G9GM*[@9]D*3>49`,X6,U9F1-J6?VV>"W`7:M6:^O],#VY[T@C*J^*U-%5A2JFQ[\W](LQ7$TV[?MP+95R0MZ M9)KQ65/3,NY]Z$N:(5L6(.LQG38+UZ):T@-J:9JI!K9%;=DS?=V05GY\\)6/=R9$5?7>6KC[3D M=?77M6WKEFP+G"'H\A./6`;PL$<05QY?ZSLDA3RMIGE(PI7<69+G(["OI()\ M8C<<0$O&80G.5P#"(0>>7I95"&0>)LDM@3\B#O"JA*3CBF53D604>4KB8CHB M,3B!*!QOZ\&+X8(DGXAA$TGNW="6)Z0*BQ&K"#@>CV?#??^*1>:RW`@T>D)X M!J$G96)1F$%#818FMR6O7Z$GKI^,X1L$R9%(V`EDVRRJZI,CEH&L85)!SB16 MC\GW#'PTGU8D!9"=D)$0/*O[&8%7-ZO,PH4+\%8A,HO&F6CYEB0S6,)!89VH MX).9T%5>6P8T"D58G#>13D01`'==%J%X?P2P37E*OLSM)R0KZAUW:TM68U[$ M9!(6=9B%&UFQ;)PK1L([VH$N(`4L1`H0S\)P".*+[:5!`&&565P&->HG+>I> M8#BKYF:PBQ"O8&/01S0M\D8"HS]'`C116[7@6<0G8-%:+O$1[-2,$?@GV"@K MP4SWAFXR+28YG(1.PB@"$U2`[J6;EM4X7<^,'HFU3^?A50)/4SY[;D!$@+R6 MBH%V8.QEPOY81R%UB;`=7]%-7_(L4U=D7W<5B9HSPG946;*\E;A#;DH^R'@" M-5PQ93UR]G(Y[@<.:E/)E`-%M53)\JGN:ZHQEP/"27MR/#^FV;H=F*876+(, M<8VZFJ(L8IILN,&!8QI=BVET]S%M8=Z:#>X9>#?!S'R9$F:+H6Q?86OV55P^ MX!7T%\U:^GTB"%6PS:%>2*S-%PSFT,$+F?];#5K&M[P=)J225ZQ.CVJ+L%&H"0>0OT.86R^5*$;*@[1"8".4,:?F?+7=\-^/^S=ZV_C1M) M_OL!]S\TC,QE%I`=OA_9G0#4ZS#`)#.7&60_+BBJ;7%#D0H?]FC_^JMNDA;U MMB22;LH58!#)(IO5Q:I?5U575<.7MB(&/ZAWZFJ.,&(`O]<3^&#'?3!#*W7_ M9*+BP_LH+0+.'/J=QIZ?6PKL^X9(WA$>@RA9R"6GRCP8#_[!'T&`?"^E:[F! M[!)N/8'$\"`9%S20X@E3SA3^RHT@&,PO#9JC+[^D9.9.R0_2G;;%-K*?'#>I MD,.^P=,QNG7B1,`UI_,)C;?F4E/,:R>\@R'!R&!N4.\9Z@M\]VC,99#)9>ZK MY.HJX&[P`O^)_H`VO0ECCQ*F;VW@]$7,F;7`I.[:V"U,I#A M_V?>T9)#3N#Z\]SB"SAMBQ5M`#&PR+HQ0SP_]\_"*)ZSC.EEVP5CEY8:X#?(?!!UF' MK\O#,KW+73 MV`CTKDW#&IM]15>-H>XHBFTH?6(.1[MB6)6N2H>JJ5+X&P](&%?H3_IR;7VRI^&\G^9O4G$_VH?"Z91NR M;@QDQ]`MV1@.1V/=+-DN:<:P:;(_)DFVF^1_%??\ZVL9ZF%1[G3)#!=81)GF M??>3YZLJ(__*U]6]4Y8MV;'EL3V6)1E\^H&M.DX^Y1%,:FCLF+)F2;:F')YR M/I/SI@N"U=AT#=4QS9$SUBS;[$NRH0U'!3XX(WV@J+NGJUIV<].5&IRNJ>N* M8]NF(IN6H:$>2S9(VOL2/!J3=,VAGU- M,LOICLS!+OV%Z5JF?M%T.9Z>A#/ZP`9,EQD^ZOI@;!N6).5T6@-I.+(W][LT M2]Y'(7_XB:0=0F[#48:P=(XT11XZEF8H@_&X#$4",&SM,()VG$;:*C3],?2B M.?V-II_OO[G?3]L'M0:VH=M]VU%'8]6Q!H;BZ'T-EGUM),NFMKUA:-O:EE#O M(^5\F@]MQ"<8:*[5CF)FFZO/G2#Y$VI),S=GV'EB+I0UE3;1/,',VV`&N?=WU-4W][ M$7+&QX,1VNO9X7UE+_G7*$X?W`=*/D5NV)R'_#$DSB+V`P**KJU")=&$A4A@ MC7?)#ZIV)Y$R6#8OR2K\T'O7\X,\R0B\6!9P^V<430/P@L$;!3US=X>7>5BV M'"J`&?)M;)>D-,PCW;S/(8M%PA\5*?^;R^[P_[/*.)C`7]ESV39QDK)HN`L> M\'<@FVW1,M_8NE/4=\*G(NLI#]@=?)LZ3]YZR(WGIZ7A&X7GN`E\5\ M8\=G:4_,NF:R&L5Q],1&9T)_:H!GS\*XN7K>4WCPM%A:!P45)QF?UFAL*CK8 MPV#:24--,F2CS`/3E>%HR_*0U_VRW22<1>8A`TD=Z^9`'_4-&US&$3/CY'YI M(TLC2]VRD17Y4C)_BT+O#(8J1E^UQB/#D"VP,U5EK`S+W7N)N?Q;#`52E4.T MKN@XE]R#C'5430]_>? MTRI;,]+E.[,I&_V4[?DC.G3"=)IR.5@M"M>$W+[U*IKPG&)4YJ'RHJ3U>J+6 M62%.ZD5-$ZHMV:+']IT7U&-YO,'R:,Y-EOIYJ1M[L_W`!1'XZLVB`.;$'*FB MW"B:TH"__\);8JY,NN5P\8JE-%^/*O+#T[_IM)?'"OAM41#D_E".S'1ZZS[2 MF+EE;I)D\\4J\;E,HRL&*??AL0"O:WHB2@'>SXVG#%7&6#-T-NT<]KWZD#QI M9:T$7&;7/`_,:X*)1X.@N.;##?B0[#O+?"V_GXY13_XTG<%'F&-1A,U3ZA8) M_;G\L#7Y%5'5AHRKVFMEYPD^+^CIR(GY<*/+[XZ6=:\7EQI1%GZO:+U]GE5OG^B$8`OJ4_CS\H/6UAIE;'?] M;8"7[2AY+4C>[W[RY^T]WH+_7"?CA.EV76.CZZMLVO].2/%!O>NZ MWDEW%BH>*AXJ7MN*IS?.'E$TB-V'QVU=NV+5YKHTL,:]&,-KV)/HO*?WF7?[ MC/,^7J"MM[1P_*U7W&B><<_L3;8>^\OO*Y,H6M MAMZOKD.'B&O]E(Y54WZ?'?.79/.Y&R_ST^OSX_S8F0)^NB0@CS3>>;K:WC,D MRK,CMMAQ(K78MU_,#OCF>1)HGHB=YVASY9XUV'Q+[?BM"[OQ&V;;/=G5KC2/ M/_<^O94'=J^')3:K[X+9BDV;]S=M_KPX?NXV2MM9TJ:BM&U*VS^+$[2(4YR@ M-?I.8\]/*/D2^]X5-SO&A:)3JMM.MU"A5/,]/ZPNRA(WG"9_0Z%J?SWHM%"U MF18N9J2Q_O2)+$U2T$86Y7)3,J0>G4]H_%Q#>86!6^&4]PUN)2E23S-KZY^! M^TFH7>V9#L)+VP^MB54GH.;.TA!HKM;IK9V%_YN?JXW.B;@(+`RVJ#U)K2T9 M310%:-I808UH-@9T@G/>1%>\^II(7HM"8/SA0+EZ$9NO;;T5B&_"P*(U$'IE0T!3T>U&M_OEAL#"C]'M1K?[)8NZJ6#O[5H7 M;U27*_;)K3O=1)\C4KSGU9FV6!#KU8ACB+687KAW/4'LOQ3<,12T'FMKM&?:2)G>+P`T3;'4GD!0VT>H.N\MM1HPN[BYG8'>Y MFN]KAZ.=W_/!ED$"NI?86VY_2Z&O,S?&PRZ;$+9NM)9;EY&V1&_[.7SDK=9S MO)B<#-WT<-LY4>WP[%G MGLC*^TH)MZ^ZR=23%++?/> M``(+@RU*3[6Q0QAJA%`A(&R9)YA"8/AA/V__H`G6YK_^*GR=08;WNMS\,<_; M8M(/402;+)OZF7DC3BA%J;QLE>2D07P7!CR:>:#20F_!E,RH21CE=9`+!``[]E/ M9B1Q[VFZA#&F!$0:!O9X33<\%68X=SV:<8T@BSB:9C#3J9]X#.UAG"@F4_I( M@V@!7R;+59DZJP^?N(F?5W"[O()V&&7H,?6BAQ`D`8@"VC@3X&H_FI+[.)KG;'936OZP/0P;94I3&L]! MGCF+@%LPYPFO'0:&1)Z7Q45?!,""AQD?*_7G^:!N/C->:%P=BRE?P.E]+@$=@J5L)@>A:KUI:[30G4F?W#G'(OI15;>-YCGKNJX MKR2DA+PEU<(-[#>P@5U?M:OPK_Y2H.F>QXM9_6\1@X5!E_=ZW6S`G/XWKBS7 MG-./C2' MI6Y_`R;U@\C[\Y?__B]"_E$./G+C$`0M^4+C\C[?<\+IT`\RGJD/4X0[?Z?W M'VZ&S'#Z/W@=4^KY3+^\F7=%NRC+[NZ)JJCP?C MT5C2<_+[VEB5G$/DVS61_P466V_Y_*IV<_^98G-D&1(0JO7UOJP/)&,\=`J* M1ZKLC&Y^V5"4JM`?R03>I6='\Z#7P%_=S'*^Y7^I23GYUZWD@-]H2CY%24*` MH81S]*">OG!NV\=2MK;RGL+]1LMY&&<#QMD%<);7W+#J"5;BP/4L2_SBH,JG M,NO++;*^PHSO!D?W9:D.?(+[YE%8E%1$E?WCZ>K$RTHA1U%!PDMCOGM!-F4% M/_E@O``C6+*;BM$6>3$*NWA/]<:$>FZ6\'*1)6$S<7-/'_Z M!HRA_-(P(E/__AZ^AAYE0Z5/E(:\R,;CSYP6R!-N,XR7T01!,1WX!>ACJ0W3 MN]IDX#6,PZT%ZPBJK4,@RZKC276_4I>M<6S!^AB"5"6K=>^E@&@[NM*7AKJA MCA1%40U%EP8Y(`XLW7`&;P\05SF+I,+?PQG"B(HOKXIB]63,$F.5?P`I"7ET M0;>SA/A(OAD/(/']3";L<8,I-$LIJ M"%D%8DS+XC=>UG='B)/_RNX+?'?B!W[JT[P0+Y[FD:_*$_V\TA'4B/OU+D.J MB1OP$KQD1OE(@%0>_/`0Q;R.;[+DMP2LP)#7W_%"R[S\#4B+/)^/P@L#V87% MS,L"QV(R[">@8D7*5C$>?T#^^*D/Y*?!$F81\,&+JDYWSHHK^5*2O8P*N/'Y MD7DA7E[=N6+K!N/J.UVU4<$[RRVIK6J,["-I5P0ZKRGC'#BQ[*BI6B-PLD]Q M+[?>],;LUT,>6K5.[WP,M!3%N#PH`S,]R9-NU;[XQ!%%)K?DKRQBRKL`6XUR MS.3UM93,W?A/IJ/,Y+0^)'+:[$VO_=#YLNQM7\=`)BZ)SX\S8VKRMXK\`!F',?1A%6+ M\U8.;+`>H:EW]^(L`L0#Q`/$@Y;P0`4\J")!%A[$@G3E4OT(7L\3:V.29/,B MK'/QP8:%JTKBE;]7@QG?HIB?WDSRUG,)<'-G)>.`:>W^H16TYH M#J"+.'KTI[D#7A6O>26$PGOSK$*491!@MU<)`X$?SN93#+'IE^]R[L$*9CX\ M)RO:)*7PEH%(+_8G;+Q)],B<6D;7EE#L>V='8EXBM&GAK&Q[0F4-T]:NB%F8Q-;.P`JV"D'UFOSPE8YFM65#C125PC%">($L4E2LQDV0N2@ M75F.WHI<_14:U[P\A?2PK&T5_C>P0UK9/_M4,=C!/*_LG>9F]7D9Y*CBJ.+8 MFJIMM2XVEU#>4-Y:E+?:RHI0WE#>7B!O*LH;RELK\O:--;Z_,I-7.!%$_M3E MU390MWG(Q4<];'^I;&*//:!_I7YCVYP2B%"A_@HEE1BWY%&Q:H+?4<4NR?) MV'D$H0:A!J&F6:@I*S1DI7EU$T4"$&\0;Q!O$&\0;Q!O$&^N&V_0E<)3+4YC MX==9%*>WK/#VG/X;XO%*.$B^WJ[]BJ+U#,VH2U9$T8BF[1?4B2O6B08,?M0+ MU`O4"]0+U(LKU`NTH5K/59"Z[K+QE/T\4V%7R@+_8P.^',;=FCJRI];`7">. M^:DO:G?Q:5.=/UQ*T=6>H=>VA.`!4XB2B))"R"JBI-`.*"(E(B4BI1"RBDB) M2(E(B4B)2(E(B9ZWF)+W*C'AJTG6X5^WNP6M.AO6)86XIF`9*25E-`R$OA./7 MR-+I0DI$>\DX5Y-S\RK9B5V0I::M340Q1#%$,40Q1#%$,40Q1+'ZG6P$,`0P M!#`$,`2P+@-8)93X4^K"]'=>7_E'32,XKD;K`FPS*YY'IA33#P:!,4U'VZD&_X=7H=7?M_!TF_^G";D M-_I$?H_F[A9*/OG3=`8?84Z%%,`;#MQ%0G\N/_Q]\ZVNB*J&9%>28>Y,O'Q! M5)<3\^%&L]X=%;IU\2]NE-N^3^H*H3A!G&"3#WS;-7`";0=?F4F](O?8`=SK M1LZV&=.L>7U8UMHXO3L_6M1WE24-Y2W5N2-Y].AR8LFKQ`J>M2Q/8=9@FG<>S\DZ2S*$O!.D[^AZEWJ MY:,>MK]4MK,4"LMYB2]RHQX:M)U>%?M[L%X3EH6$8JUIJ+\H/R@_*# M\H/R@_(C(G^P#<)^;GY.X3<21(Q^E@_>P#&[`G%2++G$XIU&Q:H+Q3M8+(BQ M4\0;Q!O$&\0;Q!O$FVO#&UWO26IMN>["OWR$&H0:A!J$F@Y`30U[JU=25M-` MR`OA^#6R=+J0$H&'@0OAL^*)X(ABB&*(8HABKRY+B&*(8HAB'4&QFIUL!#`$ M,`0P!#`$L"X#6"64^%/JPO1W7E_Y7)E7X(?T=I87.\F1L^P"/YR::4W+M^3![=(*,DNN=_^;J<+V91N"0?O?]G[\J: MVSB2]/M&[']`Z,D3(6KK/NRQ(^K-/\+A96;X:))Z?SR9@"]/-E7`/RL7E95;` MV)35XVM.I)>M/?M#-LFF0[CZ(L^!75E15.^O>925Y6PXKJ[[/)Y?;!W,,TOBCR_[\NJ)PTNX7YR#MKMI7'KOE= M:;%H]2'I\^I[I[/B,INL.1HX7=,^N)Y\PWPR65[S\POTHOH,9G/8?-["HO?C M2YA.O^>?!^]FEUG'FX6Y_'$\K4%FB_FL^:)VG:MO/H]'\XL?A<(W;@X,YB2[ M*O,?FS\ZMN`&^.KR6FOE^=8:^AT6Z"HP<+\`[MSI0:S[,LVMA]ZH#[T1(WKH MK6R_&[_OEM%'5#WQQ"+0G1MLUD."KM-_'%[N'E?T"]]2NQ^)O=7'3L=RW6+R M:]MB>F#]4`=)L48)W6_[EI'/Q$14NGG*2VF70E\T' M/A_FEQ]`\2T#D:Y+_UP#^OCUW:,O`WRN`7VN`7W>7^=P%KHV>Y1"T](K?H*WF85<)[<&N>^]F]?`IE"-_T_G_/.T\>T;65+S%F#\_0;T+P MOA/'>%-!-DMXQZX\>!RQ^!/FU2/+0SY>7CV[A@_F$/S]!O0O".:('NWTZU5D]/FAK\!VA9&F23FP]9.:Y[=\J\>=MX.IPL1OG@XVPV^CR>3#HM.'6GT#\7XW*) M`!QQ-\LGV3";PL]N5EPM6S62OTX0PE53R+H+#O__UV)R/:"H3KLL#V:?@YL_ M3@*^!'/'N].K^Y_[:A#K[J"6P)<]+`*\5S!$LU&96-IT<`%7X0%PT7@*;\TF M5?O5QVF-8%RF/K`)S-T$>WP."*H^K,L9C`O\.,I3*2\(VR@]YP-\!X,\+O+1 M47I.-J:D/$P,Y?TFY/+OO_['HCS[F&57/T8@\'\30W^[X?3KZ=5B7OIQ.9S, MTG?O@0@[@3CLEW__M\'@K\VM_YE/(8J;F.G(C(!KXW*>1.E3'I:=:C#&B?QW M^?G/+WQRJ/X'--@H'XXO8=;\_.*,OAB,1S^_B-EP?F8TB<2'("F.0F'"HF;< M!&.B)R%$B%(6,(C5HQ;EZ,4O3'(*ZO&&CCO`W`\YZ4&.O6P\)[4$"WS-)H.1,;9 M!G>7K]T13!^_G`_4$$U"="AH80R1+1AK-#\4S.MJKB;Q?7.>RO)_!1:.3*5& M_I9/1J!:_MQ3)C%F3BA"A...:V(]4Z)&JH5GU&XBE4*OX=P)T3&(Z&.WB90C MC:B%::61\,XZ6A-A4)"L,_;WQ+_L;O7+SM;74S.L>FW+MW6>)TGY<%@L\M%* MP\1>H^*HH$8($!]M#1'4,AB?FB##D/:;!)U1Q3;&Y2"0)R&T=^0(Z(GH)*(B M<":T%$@M)TJ(D714HN+X*Y+Y+A_FXT]U]^(>HRPW!$%:);73F$G!6!"4$]1H!.DMVB2`W#5[-L#<%WNO\3"<$L>#PHY3 M%3&CP31S@C*A^K39?7%7'5]OKJK$]?1CK0?W8CR)2C,4M<;&*(9`#[/&\H4` MBGD3/,7\#LYO@W04,OK&@'!M,=6>AD#`I4!6XMB0@8**'?FY2_P/H>)MD8-Q M&C5#N/250*-5#SN`JJ`0P\;RZ'4DE`3!HVJ,/6/,=:,;?Y4RU3$K9YO^ZG'H;*+'^M??\WGXDF)9$("#O$IP<[") MT2(9+)@5BMKA`ZHX[W@%'+[<-"UW0SH"$7U^.AA$H$!#(,&95Y[;H%Q#A`@A MG(B(O,C+^2%!6V144X&PP%9%9R-W4;::P'=#'X$Z:%??O1^PWLFL):@F(C5U M&"0<0C.K&QN-N.S$&)P>`.PMB/SO:1>4?8)%9[S`,C@?I04P@,$8I'CE7E-8:QMG`(($KNBIS:U>B^P3_!3G5E(>_0T M%^\7C5FOB53`)66(`G@^BD;8?'1==WAS2+=C.!!IKRYB""LE&7%&.(4HT5HW MN0QF0E?Z-L=X%Z2W115WZ1A0AY)Q+3"6%FL&+DF\<4*4[3C@&."S];&^-5KH MP]3',.YQU(Y**0AB`1,FFI#.P@0)G5F!*54$[XT)#-(?*]4$X9^+M*_2/LSS MVE*:AM\$QQEUH$ILD[L05G=S/6"',+D-Z%8\]T3?ZSQ3"Q$6)XPI&[@@,A#9 MF!='2&>.,P0:]$CHW0(\@^E\+VY3ZY0BBL`,\N"9Z0AL;W02@O'O.)K@DJ'; MX"X![`VP-Q343`O'`)KAH#J-@=BV59J(=L2!($WIG@"'R0"5A\1Y$12E1(); M2HC&H#D-"XVM"3)VP@VUR;NU5^^'JX]K&B(&YTA$FJ7$&J/"M&((X5PGAL-, M[0%L-OWX/B\N??YA?HC,"685T9R"H582V$0M<6VZ##1G%]Q&WBU"JPQ'^/IL.#V`C@$-*Z^"-B@1B1$5N<@Q1 MX(X)))1M9*^V@S@(:&\P*Y"#(68&*VT5A^$FK.$F=:QC#@E%XO8!OPTH>$0N M*R_>%K-/XU$^LM=_EOGH]32.I]DT;?)EAO/QI_U3H98+S9TGDE)"J?&(&1#^*)U`L5T:8C!6W9P"J![)=R%I"[2CD=0K11."T$A# MK-IJ'ZJZ:1)0I>J4!-WDC0XCR+$(0L==H(&!HO).VM#D?;!#HCN',&=H%XJV M(#L:17U2!VXI0E$K31R&*R4(6FO"1`Q=J2,0*>TTCW:AJ(Y9?IV5^PU##,9S M*C`Q$.%))%V:"(UG#3Y,%[06&XGIM9?O@ZN/F5;)2,"&*0B"D0A*P>@WN*B. M6YBIE>@(_&&X@%]_7U[Y]S^:35UK/SN5G\RF:8]7\V59X7!QN9BD&HPJ M]>96-W^MW_1;U4)SN_^C4AX=(0:AET0>/"&+FE#,$=;Q+H[$_SWIA*\O9],J M_+B#'DVHX=@)PH,6#%,93!-:LJ27'P<]9E17"&63E#]Y/779U7B>3>Z@#5P6 MZ2)606F%'!"#E6E45R!=W^5A9/)=GJJ@\E'(BBFHCO(.HHCP@3J+HE0>7%N8 M?XU[ZPGXCB=5!/L3M[L@!J:\YX::M!S/-68B^D8K*]===7L807Q?5%5`U[M0 M1,&1MS@2S4QDQ',O<9N0,\'WK<5]18KV%#\>4'18.46!]?Y#>`$5(.<>@"'&0PB)K=!-!(M#Q'1H?AK9]1!%)`50(JY002`=DL6MK MB@SF':_T@;3\_:TS#ES#(*5`*>G(F-80EAI?FN[2ZVYTMF[=!UL`!">$IINZ3!5*?`"/2U6H^@.^_?%UZ?8\DET)E'(>VJ"HR:5#B+'%&DB*D"\S<.DMS'PSA$^T#MW6&@2 M02-:*P2+@@)#&R8J9SJ>!F#$5.R)L?B83_;)3VKI;EWK'Y M^K;:_#LK@]=Z6>CFQO)GU3='JF*O/G8V3K6IP#Q5::]R^QB%S_]80&!_?OT0 MS4:/ZIB3M2,[%M-L`<8['ZT?L''>R/9@_1B/7_,OXU0S__8B*RZS8;ZH.E#* MEP.83J\&/S3G,!+TT_+*]AO\TZ`Y<^/FHF7[PLI%?QE<9)_RP8<\GPZN4CU' M41VI4H$N1E6#7%75_[&N5IYIC>!J492+K"W<'Q2+=&_ZI<@_)EO9="U4IZ^D9HCEH3!P1?BR M/*4D>>'CLDS/7.7$'\&M$OAJ8"I:`.?D^F5ZX/5@-!M,9_.VCP+H:MZU"?1\ M-IO#I?#J(@/N)7EN=@L9F-8>!+38\A:I)#[[Z?#$#^W0V^YS:VE*GW'@T!KG. MRU>#JK)H^=+!O,BF)7C&=:/BM#WK:WD`VV1\"2CFM5,P7/7/CR<5)V5QZBT\ M7Q35L1TKQOTE3.9S^&KI?VQE];K]3T_(X?)&LR>&;#A=6/Z4[IHN*G-R-2OF MJ=D1$%P.,#K[[T>I(HYS.M?+=,S=^7BRV@0*?EB_C'2[$H\=#&Z$FC=ER8=4 M8#@BF*5$*R^D#UQ`/'RSIJ"[=4D<;]2(=-^_-[[>*K48J`G!"P91>*KCC$V1 MJ4'6T4Y&ALJ-"IL]\!U8'Z*PY(%9I)"76FLCA6=-]*UE[*RZ$L1O0WA;S<5N M('O7_KQDU@?*"`I,8D7:A50;4@5OI])&X8-`;LD#_CDM^;XO=?1"*+***,C M:!;/G69"M863`=F.97_::ORT90(18>.]H"10&JR).#9EZ#90;#H5U<]\/J:D M[A@QWI3%S.,1-=N[05R,&`>_NVHY/&6%#>7%IGA05MTPP,T]U-J[C$ M$AT.&'Z;[D'&5*22(^E%4J1ID#3&$-\A\M$=A'?BN1>J'O;%RCR M08*OZ"!"0@R"(Q^:"DQ);==C80>C?IM=5PGC."O>Y;53HME50\$8&4Q]&T&QMQJ;OB MHOA1X+^?F6%547'3^+[GCB81$VL8)5Y:4"N!`16-&^`U[E2G4:KT=NC;H-P# M=.\6%5%'ZV!*&FRX%M9;9QINPW\=JXHYEE(<"_7;(LV/^?7;23:=F^DH&;&K MRTVM>!<-44A#&;/."2L89L@W6_DY9<,6B:&LGX!;81V-G%XY4I$S'2SFBD@I MH_>Z+0FD/'1VF.`;VYD<3$ZQW#BGFB1OL^)-47D7HVI?3C#'?URD)=@[#"Q9 M\R.L05)Z!0K&@!/!82Y[K"(CSE&0I'5*FC>`/_$*X15Z=L)U%%HVI&R5%NDL MQC(B(,$:$JC`F"]I(59L[@QZ.EJJ"TJSF%_,BN1.[;=3@.6(2.&ID,%1@M)V M.3417D2Y%H:7U7N2=*%U#Z(?SKV@]_EJ/*4G9:3.T,BY!C_-JQHZ&+7U_3I/ M!OUU62[VA,VH8#8"U\&1<%I@'W1LQ$;'(+?`O@-P#>)@L/T;H(!L""[!)A!/ MP:5T6#?S%6-%3P?VS6)>SK/I:%ESLC-B$`BL$7:((DDE#UKQI4!;Q<1:\\^. MB%>0W`]VGU08216*S*4M*+&'X`K,5RL5@;B3P:[4S'X"G+;YQ*`JF`#)I=R3 M9DT&`A&!^V+!+:_>'UN_\\*\(()(:PD"+6P\$NV>QQ[U)5YVP#8;YOFHC,7L M,DEQJD$ZW*DU&KP][KF@PB@L0(,IU::(Y):]F,B&XKH#S'VQ]_DC##M!M>>$ MXN#`*5?:V+8S!,F./U+M%78<\"N^?!50[;BSP\ER4!!/\2@M#D9KS01F+O5C M8^6\DP&S3FAU"Q=V(.NA>;+7THI7B%$4HM&6$`M,D=IA,'-<.`LZX^EP9<\\ MFG52@8*2#`5#4-0I'F\8HRGJ6W/ZQAAS_Q4BHPCQUB?++;W347AP49>\"O_/ MWK7W.'(C]Z_2"%5RMUD\5B5;&*9/W*'04(?VN\.NLH1RGGI(J8"NP1\S9X M=,\BB%$T"!RT!QA6'33#+\&EPUXG-28$9XA6U)8$%DC,?4XSSX2@>Y"L7]/( MCJ*):,U2,0%21:XY*2MC/:SL7A$PD<]C&'\9S>J_C5:XPWX/L;^?SV9UOEW] MT]6Y.UV"Q-)J`?])JX-P'AR;#BB1V#VYMD30@U/V0`H??XA'X\4L)! MJ`^>.LQBARZ--S`'0V1BYW;&HP_QIZO'V5^BDGH'/IV0WA$K#:>RQ3,$(UP. M\1?YT7$=(>OQQG-LJBH;B"R],I6IH@9?3)/N$F^`=Q^H9:>.9?]CNX"W7PRY M08L@"`2)B@&L0^#1=D=MQ,2!\1-2LH'U.TC*5Q!]="]&4\&"T:QRQ!A8C'0+ MWFJ5+8?1C%""ZC.)_GM]UYB_7/VCQ;@[#3X)X3&K2$70:()=CT%I%:GX<&M^ MIZK/(2+.)/5X!:((R[GR+N2[8%Z%LCWFKE@8(@'N("`_E-1EC?EKP/JJ_E3/ MYHGYYYR3`5W6:C!_UG@-;BUPN;M!*+09"##C9`?E^B@M7T/VT1O4@0?F/`&3 M!];0:TJ)['#VX[``".-V!^KW-+)7BREFY1U:CKZD<:%TGEG$#_,6DKCR7V7$5=!*^X MPP$&UVFP!6;5#I&YTP>23-3H1/]:?79=^#TO=+7P3GFDS]!^,&P(A1(RRLIQ' M;[F.-G1.'/A!ZLEQ0W9S57-47QQ+!2D;03,_H8GLVWD;*Z/=8H/*V[E,E M4=,2*W.\SM+7Z#90+BZ*S]?3\356KES,/^5LU00\,5KDJT?W%T6#>E#? MCN$?F-N:4G\1\0.^P3[Z)-BFJ_IFV3R? M%Z,"[]HU5<>FM^OY>KE#\[Y!)C258O5Y7BP1 MG`5EYW*=5JQE/5XG<((-,)'BMU2"MNGTIEY=SR<76]@7-_`)*9Q,EW>ST7V# M6Y!G,8]U@3@'X]EHN9Q>3?%WF.]CT[`)O?*3_WX+6P:F];9>-4]>X$C`?%UO M?)?D"][*$])Q?S('_B(>0X/TDJ2YN;_72`R2W;`YGP9N2@VT6'Q<(-P5/(6] M-3)27UUA#5Z4V]S]:O1[O;Q`F4Z(MYD%RS5H$OS2/)XSX?LIG=[NR!M\D;4/ MNP4AZA^%WB^R5%\99 M-RX&8G84Z6P369V(W##,\,M\/9N@8*1*N34JP`H8B-@6,->S#'ER!6,!4C%] M?0G/?IS>WB8;<;6"QH<9YE3F#/.+G!,.;R%@SJ29P#NLN;M:(41*AUV`OZ59 M&!"8RA13ENT69N(7GT?(B.)FA%A#"#$$QB[75YYF/[H'4FAQ.]">Y/N!+=A! MS_]Q6Z[YPS`G_U7`73Q.W=_'=9IV'#(4KQ(6B@FN5F`ELDB>=K6,EQ`>5+*B MWE<<8L5V>\9X)>@P]UKOP(SOI^$L.H^&LYX$;45IG&)$6J=DV47AOAI>@:-" MLS/H!#W&_81S`T1)#+-,6=S5#Z4&%SQTFUW6N\'.(V,0DJD=.HMZS[=)Q M9;S5*D@EHU=2<]65OJ[X9B#97;#:V29[V*@>A1-/F6GB1>6%,II $UB("- MW6YAU'[?[1Q.[%-Q(MU->4Q&G'2T'Y4U+)+2&E$*RA@O^S"3Q&-(KP\:SF-P MX"5.JPFFZEI@BA'<$$.4*CLDTLCT,=#I9^/+<^60.UYYQZ(B7CFOB()_=&LD MK!`:J?DT"L6D!/OOU3> M1\ME``>D0D0'+517(\J;H_?S7K%0G&(_:2DUK3116BDE*:?:=V>3,@Q%X87$ MX$@Y8NZ",L8P%2O!J,7"*,T,RE(-ZW&^E&X_I3]0$>HH.*BE+1D)-("1LUW- M!&N/%;AXQ>/_^D6PTLQ1;0,#$ZAW@^7"VF"J[A.(&*V M$E;:_OJQW;K5:3"_7J]'EK/YUCIG.,(+%?#9+Z;A[*BHWHWI*?\!:&S"CCT@. MKI'"RND=9B-1PP-G+N07N'+.J%\I)Q\A+HM!1^($WK<&JPQAO.ANSY21#RJP ML"]IQ:OE+CF9NR>D.;A2(QB8$EC[0S&M0[>PJ3C$1>#\2ZK[:MGX$GZ3)IR4 M,6!-)X>G]V79%GOU)DHW8.].G<=_:.Z>&F$*:V/P54F\XBX2*ER?;96E/FA; M0;3N@`G<^,X7+(=EO"`LYO3-&EL#VT3_=!C>;,+ M[',=$7CPJ;FJHF0J-"55T+#`92UD* M:KIC*?A^6"Q0OMDE_/1(^^&QH*BJX#V#T(104'<)L6&[^>TL'YYTIAH.;Y.- M3URGF)6E9PR3X[73C):^9:158$(']]_?*_[_B).G>E*(6J:`>T:B@RH@BNY< M=$?9T)/:D[CQAOCYE*=;O/*5Q4*JI<1-'Q5TD%V9%EL.6/F&-WO(T3P:QXRF M*E`J7.1<>=;FT01>BF'"K]"$B;?*B2<]%L-S?F*=IU;Z,E(=>M_&LFJ8JV;> M;,1X^L)[HIWCVG-G*#B*)8>P43,BVS1TP:,9.C%[LKO>%C\/L\*XD(XJN0$; M+SCQK3\'ZR<=VJD''2F]9DX\2R`"0E2!8Q)UZ2BON,14^E;`&#A\>P(13?B> M2QYOA:U/>MLG:,N5\HCUX53E064[I*Q2JL&Y[%L^W3MC&^(L`;7&L`A1'.&. M.&\D$Z)J#TLJ*P>1LH4GGV%=WA*+?*WW)&MFP8SYZ$3EI*@@L#3=[2^(%%5@%C/(_W`Z>0WD[\3/EZN_I7R[9[T29I.$A8WF1 MT9]IMZR$P,KI4DD?:)".M9PH(<@:5KQY?DX\V_UP\%NULMZ'DI>VB@8L2'?G M)0SQ(]\")TYTXZWV`:&)P(1**EB4UKA6&)B-QVY*OEH6G)!9)$IPC-`O,MPZ M6-!=V5TBKN@0?>=%1G_DBH'!];D*7!MBC-6.N^[LPPS!SM[OUE-XM3/X"->M MN`FF])0Y4FI9DA*\F'9F@6V#/&P"Z445\9745G2:O27))7L%2]Q&$BMX$S295A M''1>42%\9^C`OW]<'Z:OE=47R3H7JI-5Q#H:P`.#X,TP!EK=Y:Z06`VACK9U M^PND?!W=1T$=*9Z#0R2A:,54I2I:=:=E/)(!TO9NP<@'$3[[??'[=VZQ0&B! M]/5_3E?7O]S?W%W/;^^_!W)!-AX*R!1;P M0Q*D$KU*_278G>4T`ZK4(:)C^\6L] MOKZ=S^8?[XL?IN,$5NG:MXN[]0*+(B2HF(S;@R3@&H7#G.7G)_CKCOZ,\$'$ M^IG/9O<)#&I2+->72YB=E#0H0BW//O1=I@U5W&*%I]X)68"LSAJ@K6TB43H6 M"!H%OURM,[K.07G:ZNQUFI)S8')>C<'(\%VC(E?+^KDIIM?+[D61`8UVK,IE MO?IP(GOQ$9?*$DN%&,9*VK96HYQVGS(>&?% M?,>LH0S5OS=076BCWM%>X+";4?I]MDZP86V)P.*GC`.5#,`W/V]_^\V?,A37 MQ]&G>HMX_)R4`,D>9<FKL\3U-PIU>CVWJ^7@(- M]>_U8CQ-1NJZWFVZ'VH[I':T_6A^WC"!JQ8)#YNK%S?+;O"[[;8#OAM--^A[ M1\GV9./(DE3=C/ZW+M9W^/&=Z1]"++QN8[.XQ![PO0R+]S%9Z`91^2E,C#Y/ M1_4_AH'!=31QO&4QB!^(^V6=9@7^W"#8%VH13`W.F^SG;58OEX4D?^A4+4,O M+SNYF&)IVV4#!X=6HY73`Q+5^3,[JTSV12X:1R0)Q]&5B>)D-$P%3P`1!!=U:@7Q&=%<31%,LP;VU5M&B?]389Y"8?98IJPVXXRH MBI/;Z`7.3OIVTL`,=LJQJ,?U%)%9-]W/WN%,T9QQ,%?EO*BV]'6RK04?-K3\V9F@`+ MP.^P<-TDX>>](;D#3Z!9=I*U:?C6*TN#E+FM'V@L-I1BPV1TAJBU)[LCW%'S MO]?CT=UJ#8SE-LD+PMZ4Q8[#./$C[;K M?90GA-C9M%YOJ-(.^S.AJ:4#-/1^2IHH>*_W5=+*T`CDP$>]+PX*!AC>_L)* MZS3MK%J;H[O(P@P#`S?/%00E;M&ZS='>D!HT?5;]IVVD[>^@]^^2/S.#%YC M#'`[+^:7,"FC%BXZ.9<8?8.O4C<5;'8Y=QH3EB=(;\NO(;,0*W76`F6G8C?= MRP=Z1>,)[V]X5BV[;D:3!',]:A2U:^F++/RG(_#TGO.HW2S9(WDWHXP#CJH+ M-FT\6EY?;`71%XC4/,*O+A,<>I8Q?*X)AC8?/>`.[N)6PQ_@+?@C&\[(EBAE M?.C.E&RZCJQ;UCJ:-T-^I`G!EN<9$OWV8!?9^4]"FKR.8ZW^4T@?6T@[(.T, MVMR@N^=@[7@HEI9`W"W(\=1P,S.9H%816WPGY0?6N1(9D3[*/^K'!@^0HP@OU$N*WM"ET MF0SV[#ZY:*C,ETVQAO=(PZ3#R$>C/@*-@K@75J3LT.5O09>Q)QQ9LTMHNJ!*$ZO((!.J.IWZ]4&\#\"R\]A25U\:L/0WH]$GR:7<$Y+ M*8;]X/\4O&GD0_'O-0QG";Y-$PDTF_3?%=_2/V$XLDDC\H:*/W3BN659_UQ\ MR_:_8?ZPL48/YOC/B<7?\C]M,[.I?U!O3.CX_D/QRX;OT%=T6.T5B6U5Z'8P MMZ5B-NTZS#44<%]]DA3GMJNAD4H"U,UGZ&^[KP/]]"TWH4Y+*>IYVL&1]7TY@6%IB-E_"=&7LM-3,P+@=LCU?.#<=SV?SQ7?_DJKWD&SI)LB&Q)_O MT)AF,[6Z!E5^<*?'#!ZL2+>K:Q#VM'WYW./X&]8CZP\E..,#&7Y:UMZ MZ$#P4L.C4'WQ.`K4:DLRD<\]J^_8!]I/:F/8W]Z:AVO'SIA/^5Z41F(C$$I'[S22@3N MVN3A,N@]M]PID?F>SKG4/?+8CIVX\]7A>DG5'Z\E&?%X)849B=9I+KVV ME%D>9>EERX;2N0'D#&TK"C\JR<_!A>-Y)YR4,&`3`A.EDTI8TVJ%HD/\(L/M M4S%A4D^_+J<3;?P.%`>C#N/MXUXQ[1/&(FC,OA?&F#"%U;55)P47YYB_O MWU/VGM/<^:%>>CJJ^7A]TSV2H;TC?'?@.G/O&4D"5@H\AV@E]9RRRK!$B/)5 M-"I\\Y?_:&@XV,,A(I#.AY#@P-NR)7'>*Q-*[H`Q))$@N"O!LT&7A;)]1'0] M#$G(]#UL,JQ@)8FE\%PY5WF8&`]X=U\[.UE2,2O]W?_5]C5 M]B8(`^&_0OB\6=K20LUF0E_(2)QNNB7;UQGGS(PLCD5__NX*1E"C7TA:2I^' M]7FE[#1MW\V)**)``JU4*-D36V$9"ETP=FHW;YRXJ5GL`<^L*EQ1`/MC* M`@;T.XPH74:-F1",2I5`BXN<:R>Y\:C*@`W3<3@`':619"EK&OXLR@F)PUJ[ MVAT8_U7^",8FSG*\7GIJVV8E:HLE4LY3OQ4=),X[)+CM M9Q)U"%]@=,*^5K+)_AQ(G":Z*KR)E1K\;*)__ M=AB=13GFDB]7X`R!4"UP>NJ*"B>"@M,&YC>/I8JID%QY"DY993,0H6PVFZ\P M7`!NH:^Y3:@#=(7D/U!+`P04````"`#@@*-`K"<_2I0,``"%HP``%0`<`&QX`L``00E#@``!#D!``#M M75MSXCH2?M^J_0]LSC.#+V#CJ9D]EM#/.\^G'3N?AX>'#/.#QAY2/ M.I9AV)U'J:TEQ*?VNEA;?-4VK;9M?IAGX5D+>Y-D->I?E?PX%U^\*/]@%Z5- MS_,ZQ:^/1;.HK"!6:W;^^'9]5W2Q'2593A(*9XA!J_6)IS'<`FN)OS]O!R\J MB&$^'1,^(1]H.NF($IUSSDDR`H%N]CNB>K>83,=ILAC0-!DD%%41><KQ8Y>F=1=L.&'#)LH*#C;B6WBLC0Z()DX_,D%'\N_S.+[DDLS(?? M#))[R/+"F+M4W*<.*3JG<4R"E!=@8#/7$84D@_,1!ZBG<-T*Y&@[F41+$`1( M:9*CFT(O%T$-/7>*RM$PR=(X"H4[??Y,9#\3,@LC_':WHG5KD*WO'3X22YO= M,$'`JSA].$SO>C4IU3^=3#F,D8K1/5RGF81^[*Q197_N\I3^.4[C$`=XX1CR M1>,.U:A21H^^0I#?!'$T*CS$SN=T2W$IFJS"'7S^+_'QSQ>#A*580C2T_FVG M>GO4(4/G*Q+Q?Y-X!M^`9#->SR=7"LG0ZCODX@D8`K_#7V"7/EN*R]#D!D,+ M?D&F44[B@M#U1ZX:HC(TO`4J^$)I.BO&G"%/$_R7UE.RGK0,/2M]W>&!8<-J MY?0,C8NQ'X1"`6R]5K!8+56J%^I-9W%1[AH+K8H*'21-%Y:MPCR')!1>NG&[ MAX3M4IO?$9!+;&O_R%IFX_M%R5);KAGW2FUSOQ#VL>FB86PZ3NF+IW/57+$" MP$@6%//U6=8>$3+%>;MI=B#.L_4WXCDVVX:Y6DOX9?6U?YYE\(0TV@-B?/!3 MZK\LX#/BAD&?.6VKU^^U31.,=D"-7ML-^I9)#9=2\%YV(!;K(2E?0Z>X!Q4"@BHK-^X6!Y5?$,X7^-`6$5V%T6O) M^]"SW3YUNZ=-AH,LF>K!2P=7[L8ISW\`GY0,7B74*"N.V!E]FQB-W%PY$ZP3 M8X(D>'08?C43R,2\`"D;Q("3JQH#0H68#Y;KF818\HE@GQ@1),.D@Q#%++9N M7+!9V&#1C&B9'QT,.&W-`T?HCBNL/JZB`]A:#,+%`SW.KU\(PLWP$*' M-0=)3I)1A*/.LJ_(N\LYC6=B"[^&I>N(8\\I,XFC(/S7Z>X;L4`13IH'^^]I M0O<9[Y_*^XS9'M@NR.=`[U0X(`L8'4:_CD@0Q5$>@5C!V]RUJ[#_+E$?(.SV MO+#_]I:ZGJE>KX/8%]IWS)Z"$$;/RH9<8Z4R@=),\]T3F/QK37"WRA3T[@6V@H4.[6-!HW!0)D*Z'4`M"I0+"(X[IF,JF`UJ'P2:30=D MP:/3!?P@\V?]W\L3;!,5=+>]T#W9C2[9#D$B4-J6/ON;K/L.)HGREPFEX*5G#WSEQ@J-=QV-*RGM M&Z8-/;",4UTV:FJJC=UO&1!I.2>93B9I4LONKXOZX%B4L:X"KZ_GX9=L=`GX M:%DE#,-(@"/2$J)PD*R2=JK6",LE?+!-$GKAR1YUDVQ_>3#IH,$MY"1*(+PD M/!'7$YQ3.IL(2T"(06U$HZI0<+>PSY#\/5"Q+ZYGAB"9'$H0T[2IL%9TF>/W M/.ULD-!T4B2??8?\AN$LJ'JK89^:?+!HR*BK8-%!SZ1"MGM1#I\..OW@11;M MHE;$L5G89R$P([05Q!S.$RG:I\,**1`],_RGSJM,-9GI:_O<9*`IC:T\;V4( M/$IQ"*<"7?@*R[]5L?$>U?C,"$S;#ANMIJM!0QS0QRX,>7H?(?9?%C\S0/UO MIB"2+9/1.PI-E=DVV=$(-#V[$1BMT&AYMP=,8U@E;Y]/4IY'_WV1KEZZ([%; MW#=ZS&#>,F'E%%!!I[3]13L;NE9V-#$(U5@5A-I\W(1\8U_,19W?@R2Q^MZ;MBK>S^& M,T['.!"OU_S+MCH.KAM+MMQPF-ML/L7KOK>FZ[Y_2L;IEC1"$B4B#KM)[G`Z M(.[C>98)^9@&6<&5>A6@7Q6+A5T%W-&T$J*)/,K@U)/%^'(2.4@VL^JKPIT: MXC[TB$T\HN!PG_NNB*0(S./0:,@!@[=P?7[I-[8A95L2YI_$7&3,GX'H=]K_(!]B+:*UF1+^^`RU1PRGSG MG&H.I:8MD#)XEM>D-=Q<*ZE$8-SSO)Z"$SAZ5L./O;DF!U,MYW?)HMA5_Y&> M4T2*P];;EZJ.]=:NQ&==TG6P\TJWY8[@J1I;_/4Q8)60ZCD8GE*`,+M"!$M6 M3^HRJWXMB(,1&%9XLE>GZ6*64DB/XK/J7;Y:)88][8=FJ.(25OM]^Z5F(![# M$WTC^8Q'^:*XACV.@18O.+EA-5FT?VT^.CAVO"X'4]W.;)!E,_%.A^*%+NO\H9JNJU369W8( M+C@*;FPYZJ&YQN:M<%2R@-09.%VE_!:FJP,3M=FS4]AG/>):W;[:NSZ.$$1) MYX\**/5D?DU7JB^/;:TOM*B@S381[*'#PKZI(!WCN!&W;+)(!%#W`/6,Y\5. MT7[QSYXU^*@FCYIMS`.X&(;DYSLM21'C80:(GF4 MG+*:;Y75E%OVE),AD%V^+6Z&9EMMB&$GO@!+^2IY\P>90W8YSSE!CJ&%^6*` M'2NND$%)[#?J-QHD.7"<-U?O-*IJU3?Z'NV&1K])@H4:K!\W&6ME&964]IGI M]3RJXJ)+/=.F-V/WUW%_698YN6J^(F"SVF/LPT&Y?;-$9%AYU7KX*M8>97)45_ M7$;MDSTM(<7*S4'18>1'W[4Z!EMKI%^7]9E(&NFK.(.L:7U+MNN6`9&>X3D# M;$?L,7Q%?L9IL;V]4KIRS*Z0\YDG>NN<_D!^F/4VAG&Y6/T_E5/_2""'$>\L M8_,W2!"56!PW#B=1$F6YP.@>=KN/'9(^4,>S+/=D7Y`@UX'(1TMOSF:]\R.E MY;%OW;[EPLG>DO]65Q!DH:TG1V"MX1*E6@MVY2(^([3KN2IN1]+C6=XJGR0" MKH=22_5V#U6O2OH0@DUQ-%:ZF:9RJO-V&=04:"WS9+$;B+U/7TX8=_.H6E!L M)CJ>J^+XOYYMM;?**NFP:SHE^=>\V.W0WFC8'CER`H0D9-2$?4>^ETL2-LI" MF*,.]S+QD3M`'_D4B"Q?HW"`T7;(8_,"Y5VG/-8:'JZ+.`-S$\31:!D>J&LG MI3/139&_A5%)OA@D&(@L6;+^35GCCXM\WXHKI>'%(HCTUI#5@L]#X,7M7LK: M6=Z5OGP50T&=\Q$'Q7T3]P&A$9!C-N3XS,T2JKC9RJ-00R)>0S6&/*+B M!17//BC4!^'>>DM>67.?.N*G`$7PP_\`4$L#!!0````(`."`HT!\[#-3VR$` M`%IL`0`5`!P`;'AR>"TR,#$R,#,S,5]D968N>&UL550)``-CY:)/8^6B3W5X M"P`!!"4.```$.0$``-Q=6W,;NY%^WZK]#U[G64>X7TZ=LRE<$U4YL9J^N9K MU/NFJD?->%)_^?WM'Y].U"=S=O;VS__]G__QVW^=G/Q#?WSW MQC:CQ555S]^8MBKGU?C-M\G\\LW_5N=^,@W=9B;-[^US;3Z6%V\B3__ M^'CV9(!I=7-]6;97Y2^CYNHTMCC5Y31V_G195?,/91OT<5G-)Z-R^N0?849Q M8K]>MM7%[V^G-^U-@`PB@&\!^]-VH\R_7U>_OYU-KJZG`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`##OAM(>"48B]T9(\H*6@MT>PDJ?IZ[GV>T;HYV/"X:[F M>R;`'FV]F9:S^QWHKO;^>9_"$NLMPD`#I;S'%@-%'B)D(5V2XO%QV?P=0#"[5$5CZ="T]=^CZ@N=G4/SA&O9] MZCN_GC]6LWD[&'G"M4?7*]H76`13#H1700!]60^:6$%G,E`$^ MS9H/%J?UN&';!QPYU*RFT^9;//+P36N;Q?G\8C%5HU&S"-/]6(VJR=>XI)E% MVSXZC%VA_JW&*2#`G#C!K#%1=B:UL$L<.$6:8ITIL,M/BR%ARD*7T6AQM9C& MI`-;7;?!-;T]K:^NI]52'?58737M?/+OY>\_M$UPH^;?/TS+VV/^?RTFUU<; MF-335Q0<:T\T,@(8*BB`2L*E3;4:*VI`&LFV]R3W0++]()B#?Q_"6%5X.,;+ MQ?-#V;YOE\"-_Z><+JH/5?OILFS7'2-V&Z!`0!OF+%#AF;,"$P_]K:'V"`DC M6!)WR!%P9Q!\\C-C.;:>"R5Y5%2 M%U9R:BU-8@(].B;LB,N^&'`VFRVVUOYMIX()B&5PT8PEW!H&%09+CCOFD8"( M)VF>':GFDS#9E];?+^8Q2SGF@V^I^D<]"^X%A=03`IABEB@>O/:EK,HJI"Q, MTC\_4OVG`Y/Y,#'!)^C0N^"$!(^;<,8@ULH)'$1=RNP,HL*G)96((R!#_^!D M)L06KL":7H456GB*##9.0X^Y97JYWGFD%`$HC0#RN`BP(RA[4?Q&#^"5'H75 M%C&C`E)($6^I040L96,224D33Z#`,6H\"9$Q0[H[&(PW_=OHTY7K'-.QM;TL=20HV MA#`\/M`QJXC5+/R/0P\A#3\QI6#C;OAAI6!+C@GC%$HCHEB"2$OOI<$`Y#K) MV38%N[,2UJ=@;R?]X:=@[Y2HQ:@QA@0+9"4W6G,H$;D'0TLJ,E%AET/[SOKL ME*BU'2#'EY[C`%+2.6TM@LQA'YXP[U/?>TC)F,U"8'R7,J+.9_.V'*W- MKUC5/LH5%CI+K2:,&(81(]I;X"'FB"F33=O)VR"I85T?<&1YG,O9I:K'\4=, MT/A:3I=7Q>:F;-OOD_K+I7]!,9,\N$"$,,4\Q0):%E'4WEGKP('1 M8$?=/7_:!T`HBUMWV;3SSU5[U2U1>MA"'BC1%0R9X!+ ML^R#9;3UJ^J=XFY`E$,K;!3%:4DJ@Z6G]?P$ M[X!$GM2D5Q)K@Z%9FY?T>KH^HY-#]7YIF_&WRXVAJA9[OFQ0PK"@&*N(=$X&V0G('7`A6%:?`X,2=M)R) MZJDZ340@A_[.ZGE9?YD$K^#6R@26N9O1=!$3X#KHMDOW`GFMJ*6::FX]P%P* M8Z+47G(N+$RSW3F3S%/U/@`ZF5VPOS?U:!LO[$?[PNG@27KKK)="`@RP-3BN M=E))PJA+"[5R)I2G:KT/./(Y8AL]L,)K:6"($BCE6`"`(:;+F1MD0M3@T@H. MY

\:[JR@X%LUIX`QW4!#E!H0(H\!GR6'$CP)>M M@%@W;?>AHE=V1';")9/&VT4U?@G!>J6O[E,`BS4#U$$GH%4>44=IE(\A+R%* MO*,^6$@UC-Y[@2:'ZNW=U92/U=>J7G1XV%=W*!`'F'#/D0*::>5E]#*#9-P3 M31PZL,O!`RB]%URR+.I-_27NSMOJO,-V]XK6A;:6`4L0ID9:3H`0T$29#`J6 M#.&T!WRP.&L`7>\.RGZ\MZV\M@)#QI!VPL.1\N#^7-X^, MT5;/^&M=BT!CA062R]1<*)U2.O):,"ZD]>(([N/M^JSW!$VVK=)M*?!ZIP)1 MJY%4V$.#=+QQR#T+$DJ$+0F(IJWM6:_I[;1KV@V-YZJD+5U<%*`R&6I[ZHU;,P!?]:T$$$(3JR20$KM@L61 M4D5I!$3V9E^L23E[I46@, MJ">&8,Z,%P@*C2-(2F-C+`-IJ^Y@BVY/&NX'C!R*_EC-`R[5V)5M'5]#_:1T MY\5D-%FW`&_N7`!&F=&*66PALIACJV64V#@80X<#2S'J2?V]XY+I3/-^DLN0 M[\F;9,_J47.U?)_LWZOY^XO/YQ,\8Q`YD.UL\!'(_U@XT,*Z!! M:5LJ@Z4O]:3VG7'(,"."T=<0X@K3#1C#L?N6J%@%)*E';> M.5C:4D^:W1F'S/MCJAYOI>=-70L9=Q$LYX'-D&$-G-!Q-]!XYB2P,'%__!@2 M2WN&YA$1!BQK]N2M\>7LTD^;;T=>WDS$2SP$XO#0$2O#$T>(">$3@)2&2%EN MO&(VL%1;EC<#$F,9C(X"AA*ID5>*WTF#@=*)1PY;/T[;EC?KK(3UY`Q##X"P6$1889C*>_!()KGJG&T2ZF;SOKL5MYL*T"R^$R]%K626B%C M!83$&P6QH4RP![0PA$=0]"9-7YVK6Z4A]/,Q(3\#TLJ;92=`?L7'Z_O!D?K0 M-E\GP5G2W_^8Q;=OO0]&LXPG;FHTGWR]]1(W'VYM/UC!D)$4&BY!0%E[X.UR M]QC"6!]9)U[%SIFBD.HZ#(Y5)O;\V/993XP?[0KEG`GD]\P`894E<8\HRF$\ MUS(LLH>E\R$5]9(3R3#E.6'YO\5=K9?/S<CR;("R(]9?V[Z,R=#?%T! M/<5&&J"@I5`@C!"+1ITR%-P\30^L%D!&\AT`VGFR+3>_W&UMQN7F[H7%+J:< M<^)OU73LFS9`MH96G?H71A!$@=,<6TZ=4>&)CO&HLLP2"GU:Q?#A M"HX=$J^&`'@]L:8W[4VD"P+XCBSQ-X6Y+.LOU5GMPW269RGO+SY]O[J^;.KO M9P&B@,V'13NZ+&?5_0[MJ@WNU*$*9S7"T`'*O-;8*Z0]!TB@F`WO.JB'0*+>D4T!U?^$J"-T+RO/Y730/3\\>UG`="N&O>Q>>`.% MT,8#20!T\>:8A5%J$_!UGN8Z\NS(K2'4N9$Q.Z.V'ZY\:*L0-(SO;Q*ZF[A< M5R$8?524:ROV=!FPH"38:&B%)L%;5%13A./E5`D1U%*;M%L#@P5Y>^'3`#CN M:=6+\_UAM;=GU*H!"H.,4S98=V-"`&L)P='44VR5I-")-(LT6(RW%P;U@-M^ MUZ^[V^L: MUR..^V'8LR(96Y'I6=\",V##%W/M&330F_AZU2`O5O#^DI MT63-8`6BA$*$?0AUL;0"$A@O+5*F.`L!L3FPLY/A$TWZPRK+9>SR^]U^B!K] M:S%IJU6VDC`AZ98-TWOW3Z(%)4>E'Q\^O= M0V&8YTI_,ZJJ\5Z1TL6M^CT>D?S,/RI'OQH`ND#$1><^&D)5!;1S4*"&A@B<:2IM4H M&BR(STBGP3#<(XO\I"[K44_QV)K!"HU0DJ..2MK)O(1S!P$$EI'9>".0\#=%#?/5@ M@%:RQ*IHF2U.+PI=LX#U`5U.7]DW[*R=23R;R!UB#4*6OK';GV%Y7,MY:\ORN'-!)$`2*>XX$YQR&=;EL-8S MR&3`4_&TU/S<458^T[(#=CG8$GA]1_+.''FM2T'#&LZH09(QK(4-RWM\B0>S MAA+@G$BKBI\[:AJ"&3TAEMMZ/#)_R]/^%=!T-"4=1BH8P128$!:&($(RXH`4 MPB``A',6:9W&GMQ!TM!VI7\@#RM2ZB5"*B`56FIM&=%6*2\8TB0\5HY3A?W_ MMW=ES6WD1O@?);B/JKS@3+:RNW$Y3J7R-,65QC)3-+E%4HZ=7Y_&4)1%B2*' M&`PX/%JQ:491&P["&%*4W3_=,\%^ZV?XR6Z25 M\*Y=SU>WSZ,"3LC1)1_3$(X5ULP8PIT/E#&;/#!><*4]\2'/YUFSN'2NC3TB M2M>3%0/2OUY_`T$_6[*XS_S&:]#SL;#,I.0D(02.S!`=-/7!,#&QX)S1I6,8 M/%6RM^Y__WU7"VJVV%<_^VGY<;7^W.40];BGZ_D)C1>*A%1.7WC$A=16(]@^ MO22,<(]LWA%4LX=K=D&O40"J$\BW;=?M9IN*-\-!>3)L[V!DPP@:^ZI)]3EN8O&*\%2FD,OVZP/0*?6Z9"H3DUMX-OO[H;E[1%5R,\W MJ;C<_;KML3\,_>C474O3X!0S3&$?HPF.1!^0"-08FWF]4K.UW)`SI2)R->3L M'TO0CQ;S_[:WW_,,^SFMS\Q,:?86(8FT%,X&ACRE.M$*ZQ(IE9F.-]J.4X^U MJS%A?"(RM2JT/BT/GE[_;5=JM8@@99T6A$H6K#*!&T0X\29Z&\['P$X]J[&(S1TK@]-9J+LW5GKU2IM3<33E=JO8SZV8]=J14LWT@!28$8 M#\XY"8CLP3#1UU5JO0R0*J9?T?J<'`4.N!@1%$9$IDZ(`:OLXN0:Q/.-;SH8V*C$8>)14. MC%G*+4$1J*$H:H.]R;O/J5EE-??8'XA$%7,>=(?T:IOS"9?/AS8D:I0\&NE& M,A!%K`H>J.%*&OBB)Y:FDL^,%\WH!N%0@ZL_SV]238(>3'TVLI%@*1)AM!-( M:@^F(U8)%`%+0#B@;UKQ3,5X.@R&FAMPCXVWH4AB@K16BH+5+XQUN'M[0$9' M9B=69J\8$S/IK\&]QRS9AVHA?<[15^$8M`\R`I@9]PJ8S0H(/D MA7O4S";-/5!+05)GP6Y:>$[R]7D0S,6J2R=[>/&3J_C$O`8C$QQW)A`A+:R/ M*`D%.A5A2,/1DU=`>K0SMP"_7JSQF/>(2XN!0H4% M[''&TCQWV6A+OQS_*P%68V/X<[L$5!:I1LOM9V!&0F0[_]*>WQK.S&Q2GA@! M\U.:B+6R-MF-2?R-=R;U29W6N5]^8(GAI$IT16=\\#)/KZL9+)G+Y!)P MU(EPVK_=3AKWD3HG0YV.3VELL((*CH.13C&=&I@SH,ZFZEN>VKPBFS5C'W.9 M70B1FA%MY[6R9R,;1[0B6&D4<>0D$F%CTC*L"TCIJ/*BD$:+H"_*W2%`5#F, M4]['KZOEZO!D.<_CTQ,;M;OT98@R3ZD(!H4DOHZE!'N3>437C%C-/J)+XE)G M6>]5B902E*[RY\M[>.\'76.UW-CVXRI5>4GC/LR^MIOP%;14X,E\.5M_Z^!* ML5C)";!:+#J2>YP$HSVU`7W(TV"Q5)1+R@#:"/LH=LAA0@3/J]Q3,^@Q?[N9 M"JCU!!>H>%A;%FS=C_/S0O=B1@.;+W/:8;"2HJ(*]N=4!,P1%5HQQI3. M39]X"\$599')\@5TS]WL\D!3N/%]TH!`%I,4FNUV/?_M?IL"!#^L?FZ_SN&< M>=?%+M^T,/!FMMBD"^MV_5`2HY]<5'EN0R15W!#*,-C@,CH.5AA@9Y(6IY7( M;"$Y90_C%'&M9A$=A,KO-M+OT?]_62U`7[I[TNVIO4EUZU).]7J^@3]Y^'%Y MM\MO!;3^]A&.V'.VU`B/;'"(J;H]_//44"7U6$I9E82DEH-(1&5)%SNZ1.4Z[>6W].;7[W3 M._(0^O$DH;X$9.7WU!>`*S!^3_E.ETJ:X6K9%:;IN>S]P_CU_)*R($H_CA1,=]^?`/.O=NC.%JFHU$_+AV:29SE]5X$DBK+_>;F_O/](EV7ON85.+_T^WY&$URD-'*! M%?64^!#\=T-&,3&Q9D^%MX&14*HA)1]2\=G[];=^A_Z1T8VBT>A@F?4V.FN, M3$$6#S012O.J^XX6PUR6\\/QJ&K2N\5LL_>8]#7GG\]IC&(2*TV=-,%;(2A" M]!&KH&HU"+RJ*3\0E"JZ_)-7/&N]O1S<>*6H"=IBCXR5T6/UW0-"HU5OP(#/ MY])S[;X4/#\"XZ=KLU^3WURP][R/76E@&DSA'^/,@!],K%?8KD>;=:=]`?A*5=G)A0Y@&- ME)A$$CF`IZ2.CLC@#"BZFG9E$2=6-:BHX_\*^-6Y-?KW_4,RYH?5*Q<>W>+Y M;;9I;Y-B#=MVEW7QO@4<-O-M^_=V_65^T^XBRMZW-ZN['8O/]8\8^]&-YM$* M.!Z\8"$:I04Q1GE!B8G$^\P.Q37#!'.E=6+(5MM!=_O[TP#'W;[_:_N?[D^G M+:(^']`$J17H'6#>8T:EC-99"Y0SJ5-.*\V[&ZL90SAH!RR-SQ4EHQ/D`8)Q M.+\Q#`>),5=!*R%XY!&G%<$H`=,39;8DJ)GJ75@N!L%30RRNU\0O6M`\NP*2 M3$MA4`2<'8Z:(NL8RZS>4S-O/%=4Q@6J^G5J)^+F!@[,=3I$-]M?VNVGU2D+ MK<_TAGM"M0N1*DH`9(,QH;!4.'SK?]9C9W+I>'P/#_1*G+LGJLL5Y@H%-[J@P+H(81!FSC MRGNE,Y62FAG@N4(V$43'RY;QJYO[!)59WH;EMKN.>&Q.MO_;X;M,(>4,YHUX:@H.. M3AI\]GYI))I>2XHY-3PU_/0H>N28-9$[2QA0]D"+TIGE%PJEQI1CQ*HX$B.G MR0P0@\=%=]RWVF-6DZ[]O+$%I`!X/17 M!BYE^:MNM9>#FL"))!+L6>&MIM(9,&;W[PQ:Z@0#H8MRX@AW!P'S-I@Z&1_I M1'@Y-@]W*L[[]JZK]+O<_CK[_-IQ?&QH@R-.$9H23$38L[QWS&!X?X*%$#[J MO![4Q3V@HQS*!?`8BY^N3?U5%C^!5OKUK^VQZNFOCFVP9X)+%Q%3@5)"E7"H MHT`CIIG,6Z'%'9$C)B=O<**P_&-+#M"X(0@0\3PCAM`NO.`X(\4XCF MG8_%G5>CL'`($..MQCC?W,P6_VIGZPB_.6=L/AO=(%#28#M!7$=N??`(B=A1 M026Q0>7MK<4=3*.NR&&0C,W8W7[1G[5/QC=&*NVONU^O#Z3N]$'ZVO`&5#:+.1)>8LT\C5[R'1W*4!557L12 M<:_0*,PMA,EHQLKN]=ZWOZ=PO^5=03XW^ZWF^ULF5Q_I]?NB8E-Q$YP8X2, M2LI(%+/I+@5T"00:O_"9UX-OZ3ZI(#SC^4B?5A$\\`4GA^^[6=J#/K5=0=># M'P:X3:]759!(0R-31AOKF(U:4)-L3BM2`P[#SM:V')FJ"ZL*LL"(T%3&&+!@ M'FF$Z)X:YW6M?O&75A7LS833504OHWYD=^FUJPHBC!RH?4981IU-`:/2[\'` ML&E-R6$ZE)^]J@I>!DB5`.NBM>0",=P+G`KN1&&"D$+A1[2$P]-SJ!;B5^^B M4&FX)GQCB]+E'9,+/Z&)A@LJ M?`P(@4VDN'3<=GAX#$>UR%,W:B:XCBU.90$\;?S]Z8]I:,I1A!_^!U!+`P04 M````"`#@@*-`ZGB3\0E$``"3.`,`%0`<`&QX`L``00E#@``!#D!``#<76MOW#B6_;[`_@=N>K#3 M`]BQ).K9VST#DI)V`V0Z01X[`P2+@JRB;:&K)+>D2IS]]4M*JJ==5:1$EM3; M#3AE6]8]]Y`\O+Q\_?RWI^4"?*5EE17Y+Z_,U\8K0/.TF&?Y_2^O/G^\1A_) MFS>O_O;7?_V7G__M^OJ?^,-;$!;I:DGS&I"2)C6=@V]9_0#^06_C;,'^K+J^ MYD^SC[_]Q+_<)A4%3U7V4Y4^T&7RMDB3NC'V4->//]W^E!]EKSYI]_?_NQ\?,ZRZLZR5/ZBK$!0,M'62SH!WH'^+^? M/[PY"B^XX4_$_R>EEDQ_U@G9?TVN:4+AJ-YVT-)[UY^Q:(L]][`*0HX M1:;+*?KAS(OK[X_TEU=5MGQ<,'YNACC0`W']'*TV>`T-O_9!>8K7PQ>J!OR) MM5>J%O+S5ZH&W5:V*)_KJ,.'KU4-7BUFO96CJ).%XLKQ[)7'02_X8V_9I^Y) M_OH3,MQ8[\1UY\WTJ:;YG,Y;\=Q[-\CFO[QBGV:+I_)IQIM:456L%GQ\2$J* M;JNZ3-)ZYE@X<`W'=#%!G@,]TW/"./(-;"+/LZQHUKQK1O/KSQ_7IIL?*7CW M*QG7G[-:TJI8E6G;,S%0O"=N:*-MWG7^ M31\^/GU[<'336*1[#8H[R1J,:1FPC3Q^..7V(4M%JH:EUMD%CZJ* ME2DHRCDM67RW_JND3,_0VSUQDQ8LAGFLK_++/W^B0D09O[]-@N]*(A=PR0V]%QDNIYG0&;6 M=#R/!,2T9_6FYSS:'%39DFD9]9$._42S6,/;-HLKT$(4E!9EG)X6YS'HE-/I MXTR"+]V_'"9H<(HK3@>Q@7>75+<-QHX-AM4T;^BBKM8_X=ID7AMF-R[Z09"V M%X1*->$C:Y9R=PH]]5)0R1K5)$5>,3-S'JZQ`5U->:]8O;M[]TC+IG.L-D(: M8F1;$8+0]HD7H\C%,3(LQPJ#"-IQ;(F$1@K-Z6N%NR#!%B4H[L`69\\`2B7? M$C'52+SW"[/4\2\6>8F3FNE9!2WL?HIN5W0&8E@P"36 M=H*0Q!%"@8=(8P7%8>"X4D&;Y*LUQV@;-.!+@T=4M/H2)1:):>1(3O(EZ-$2 M6^T3<2*4ZLG81"*GON@+)=6FKS9\3&F>E%F!GK)JAI`50Y\)D&$[$2%,C"*T M-H9B0GI)A)2%2RG%%5C#8GTM`]9;,N3XDU0.;=3U%!`)UO0JR2XQ(H+2B\BI MZ4H_)X[)RP!*Q%6FL_$YKQYIFMUE=!X6RR3+9XX1.4S`D,N&>(;EF<3"WMH@ M,7U#2FEZ6]&M-AVP*[`##7QIP4DK3G\N!57G(C1**D]/!O6HSS&"3BG08%*G MHD+#'3E4(D74R,<\;[.D`5/:W^E@#U(&4\/DI(A MSYB89&@E2WKNK84".BP7%HQ#*DX(1F_6)B(8_?$7BJJ/I&"\S=APJ*(;,UY$ M?,M%`7$-+P@-.S!]KDLNBVIDY"IE!PS,M(PA\ M']K(=A$F9O-^%M,$L8U97+%9IRP<79]]J91`'%DG?:+.-TNK61S1HNDY]#C/ MC-R00RDI_88:(XTO!,85PN1,I+7+XSXRCI!T7+A]=ZM$\OOHZ;'1D\V`Q;8" MZ!`[#FT+&]!'EN=9S*#G(S1"0SZ6]$<(FR``=HAD\U`#"!03!V:;YR=@[18:O_^3#X(JG1QYIRC,E"]DM!`.+ M1#3>N51IR`9!.P6Q@VPM=1,D*_\[6:SHN[N/WY>/#T7^_0VCXDV>OF>U\H$U\+=9TN?,EXEELF`YK8QG<%65KJ:J*-&MV MM+1!$.^BV[/YX35H2Z_B_M:.3O^*"^F)Y(CK/VG. MJMJ"A3UHOF3MD8_O^#AA$_E8$%O$BST4FX&/,5\7QR,?%!*$2&3*C+F&VM(< M8'3PFK:>[`$4'G>YOMF.NEP(!XVZ!A>+V+CKDB4B%UOL%L8^MI'&7F>H.C'Z M4D7R1,9?RMPI]-3%H4GO6>A!+XQ-BZ_[Q2XVPACSW%;@P3"(3=N4F=V2?_M% MIKF*9ZGNH9GN\ZSUS'`K)6QH9GOL=+9,&EN8N(GHR@`'SJ6M):F0UPX6L15+ MRD_+F7D!MB*"/(^?)X&AX3B^P4PAQXU,TE<[ M9%B35`]-A/75CQ8.^)$#^LM8(K+E1$1&>C`X-2'IX\(Q*>E-A_A(+,ER_OYW M;/SWE59UDPR861C%KFLC`ODF;-,SV(9F&P+ MZ0KDM)8=,/5C3W"8I)TXR<$1YZP5$]!D6#>@+CTH>HF84T.A041.1%\&.G$X M[%%`B;#&;$VT>O8F9RV6_62&(^Q"US$CY!'?#B(36S:SAZ%KA"'$@8S,]#:B M?0*IQ<&3.0R6I,#TITY,8R["FIS,;"%U`0R?#VA175AGCI%S0FH&\SD1M1GN M1Z&XHDEK3OO^=1Z'6(%OF7Y@Q&;L6+'EXICG<3")##^(?6NV>S:S0+.1>[M0 M:SEQY+2XRM!S:4HU;(FJBP::>HI*Q\\X:=P#(DX*2#_*)J,;/>$_DXLA-(BG M4NH'6OY:Y,7^@&MMU6_W/-D&M$,(W0@9$=I&I4D240WZ[Q0S!PES?J3%3.^/7$3T[NBI.USGY(G6D5/=9DPEK,\*;\W MQT8PU'SE"B-QT>!>!V16%,((FYX/'0_:#&G,HC.3&,2T+-=!,JGD,7%J3DGO MG6[+9!(L>([ZMG$'U-P3Z1ALQ#(5C>?^&,4I&QONI,G;68:M:[M'%7>%VSW? MN'<%]AQLS]*Y`OL^CC=^U59<)R/8\2O)1/J<25#Q++*>`*8^O1V#TO6JF.;T M+JMG+/2W^8GYIA7'/O39Z,"TN3F?=:TA]+W9L\NM!!5.WE2/`?ZQ*[?.*Q7K M79@6--R9-N9@079)M.6EZZ;XQ MO"$U/$?J1:X9.V#KA%*IXGDBVJ7,G3/7C`VC26SW<&.H^ES1^9N<%,O'%<]X M=C0!6W3M9$7$\<( M0P8:\>QIX+N6\%;CT9%JUM;6/["JVOU]Z=K%_?U]&D1W&NR*;&L>':0^P>]* MG_O&]\1NO`.;JVWW8M-/Q683[(&//*)M>HW6S>XVW+;O0")]QQ3KAL0>Z]'! MRM21OANR*4B^TC*YIR!?+6]981=WK0I4(*NJ5;>+N5C55"X?@*Z#$*XUG[#]Z)K+N$7PADIE6SIK#'>3ID%%-L_'U6K7#`)7V@>95][9+U MG_.2)HOL?^G\OXH%;\?;5;X?:;HJLSJC%2JSBOTJ9-_F]^^;-L9/W,&U*NG,/'&R!V#H).B]!ZR9H_;QJXC'6LS%? MQUCUHZ'(SJT7&K.63&3`/SX/+ZU1&K]@)&Z4>`9U8S(.G=C%-K$"[/NVC6-L MV=PD#DQB!J;4%31#[&A/G>X*4X^IF$$L:PH*DM^LE(3^?TCJQ\.3E7:'%_K^6[L1&&$##,, M##>R>';6\BV;!)YGDW.K+)3:TM<`=Q&V1[0].YE/Z*AFC3Q+)(C&X+M?GD<5 M[V)I%4%>CF5'5-,ZA22'Q(]'&OH2CA0T"!5V9E(<*VN-]'# M>;_NY$U^5Y3+]I#!Y+98U2`!%1O^T>:HT)(NF@G&Y+ZD7?ED.6`V/7YZZ=>L MR9:L#TV]R_(D3[N$?W,4+(/`,ZB'AY^FM*R;@SGN0,;>."]7]R#E4Q)\-K-Z M#<"G!UK17:/?:,F^9Y^[-$G6J99,X]1;0^5+;9W3DGTEGTI$UPDP<_JQ'RZB^R< MU+GIH6,1*W@7.E)#H[.=*IA;@JJI,J50GW%DLRAAEF5+HIJ5?)3 MGKNYR0,$.QJ)OV^?>=\>+HZ^)>5\*Y2NY3JFC=D7C%%DA<3Q/SPE`M9 MKD]37;YLR-*NRA(9N&C).BLNFQ.9ZK%JP42RVZ.Y7TRC,TL9?*8U`1[+%^\]QQS\KL:%^7T,(##3ZP M!=@SC%9"K40L?6F*^P74"J@6"ZL%Z#@66ZMD<@H!ME)_"DU53C+4;LP]%`O& M6Q7]OLKJ[[\6-=U*[E8VG3B(0MN*/,/UB@4YO!$.*F^'"82*&IP MK-!=A>5RHNN+QM[=;4\::9?OWJ#.1KM[`=O.64/[2'NG3U6R+I5,'8G]OJE5=:4@FFD5)^AXWE4# MR5,($O4X5NBNG\/GB+H#3=#FDDD^=W7ZCF`W8D-NZ&/B6$$@2X>9+-^5UAYKN7N'9+"DHCUQ[+GF4\H6+M?IARY4(=,:)XHW/;ZRW9AQ[F"';Y/5!&Q/(,!S#\!V/.+B!%YHD#%RD(P88BFEJ4<#]T6MX-7<=@PM7 M;21PR7+5'`O\<8M43SQPR:+5%!'(%_$EXP+YRYK'*L(_6&R@S.V>T8%:VL7B M@P\TY?/N:5JL^!'-]^_+(F@2J^TFQ$LK%%%:,DV/JJ9C1*2BC:I<* M?150=JH\?:#SU8*^N_N5?CL*(I^3![X8J7J3[SZ3Y6GVN*#5=J;*(EX8\3,- M,4&F:_+CGD.#[X#S"'%"1^I^I@M#TSW^Z;SA\QG,GQ/MF(=.G4\\S[+WX-HM MV>GY"Y>RX!S^=`M89FDS)GB^HHSUBL0,26S;<1PY,?+SXMA_%$;'=&$88>PC#.(SX#N\HHBXF$FUI<>W;0ER[Z1`/% M[5G[NTO*GJ^UW=GNZ]@!A+'/]#LP#".&?FA`S\0F"U]1<&Y!NBZS.AORSGT$ M^PLM=_'^^P^^97K_L5ZWWC>65%\>4D'EJ.72-[K453ZBX:8L:=><9E:++VQJK/>FN/3=$7>Q,)/637S@P!Z&$>^%1@!\6$`D=4895%P!&VA ME:]J+&E?R]*!NUJWOBT^UA`90E&15$2L8+[U8IS*KB,90*>FG5$GF#J5SU3" M\$3B147./-OUI(XB\2L`]VV%Q3+)\AD;FT>!A=W0CTW?8U\-'ZV-A2:.I"[^ MZV5!LTX=MB;PI<4EJTX]Z1-3)?W,R:E1#]+T7-?W$B\GM&<8CQ/1G(%.'%[( MIX`2F3/R^:TS/";[.^67.LW\,`AP8"/;MI`71@X)K(V8!9[KS;[2\K:0.!M? M\OTR;607BL1(I;VBC&.2/PU?EBW19)I.FF1'VEM^P)<6SN738@=\G$Q^]>5N M(O(QP('G)]8/HD)8-M!\GO'T0+)XGV3\VJOVQ(S.J&%;9N19.#1-)XI]U[") MLS9J1(;0^]0;/%)"LM`/L5$YG)4R@G.(8O9AL6QY.D2`W#$Y$E1^].L]$B+5$B3T5=R@MC(F*H MP;'#:$P3=<*2^:FD2;4JO^^-66&,@@C;.,0QP0BQ86JP-F5!Z,N(8Y_W:Y;! M-:1>&:A>?(EIFFZJY-1KGZ6QY.D%3DX(T1`&)R(Y@UPHU%6HOE/\9)%4ZT4& MS=P<\FW/]`-(/!2%V'4A(V63-X]\H4,MAEO1O:*4X]DLM1DXF2]/H>1$OE;V M_H^\8-UR(1)5=V^5U4I7*P]18HNU)QD/5S,AK MGT]_0,Y5TEQP(X=5>5I;6K.[?R3^;#3`1F"M.PQ:Y MF-8OL32%NK5 M>L(Y1!99ZAP4O+0:\4I+9*H2EY812L)U:B#'AI6U']/Y<_I!%?W<(=^)W.AN M2YAFGCKBXJ[8!U%LHRB.PRC63?$RD&(7RC]'8F(#QWUU7,U M!H`>L-_K?Y]7Z^X+GD_-F2T!]K%\QJMJ[_J)<_9@_UATY`/]8/ MS==%=Y7_:O5P4E*KF)N:&T8J*T7)D)3",(RD1<;PL`716SO;\_S[7'O+X#UG MM[ZGGFNMM_:SSYUO^]#:]\NKC7#%82/;`0 M"BF(P0@2S+E56BEGG?`25I+CH+V%F4SV_%IJO6BG.&VQ\V%3E5AU-<_GA7O& M=Q])NJS&W?)V_\D']Z]7D66>7##&O\MEG1M686!(A00B M)6<26`VPAK;$0&E"*A@BDKEM]RR7G5^!NI<=KY\"WI)LF!;N/"W:45?\=>=L M\:59_FV[3WSO<''P>&!5#.1Y01_[NC,C4PFN&>O:O7F\]PVJ^T)L):9"M!;5F65%OB)%4[(UH)2XVL`GNSA%T[ M9*A%]65Q[A1SY\G`H^D%A0O#)H[62,9'I/--C@+_ZH']PTKDT[Y'*V1IUP$\0@XOJ(O+G'G M4OCR\3MEXBBV$\H3'?X8SH6(\KM)O.^>X_>QGDW,]O;?+[XTR^_=0]"=.#KI M#A6V!FBBI*5:(6)99ZNT6I2"^U3[DPST7-W?^54<.;8];=5WO*?QNZR%@Z$+ MU,4H:A(+4:=MVHJ*((VZI94:5F&L)W%^W%BJ+ MO0Y^B;CL4-H3V$8F!I"_K/3`)E)%DAK&A"K&V=8P"6Q&I`>AGI\8_E'!Q^8B MO\T6]?VZ_N[4Q2#ELAW("07`2$P)-CM[7$*2D(CX&[G)/*=UK^C\2\Q``F!& MI1_]<,PQZ?%"V$_>L8?BGW2$SV!%K:','!IVHF7,9I(Z.P@R!@SMK2^JA-U\9[59N-3<7"J:+T*D)@X M8M>EI7=889(2RBF#CIPB<$8_DF"-0#?2_&\R/37!.J&=,BVG\_O%8_WS/^I? M$V@(HUQ;0$2%,<*":=`9*@$I"?>>FL1=?1BEV'I5=&X5SJ]@K0BFYBL6?0*+ M4HL`5MGTXA6$BX(1"VPTBA$=P!O)2$,1-+/YY/[)A.)*&PP!KR!BMD224]-= M7TE4(1M&F*XL MN1$5C'A^UX5E$'1ANA)'+8.NG&-Q1E:2T8U`5=)C:#(^2^&KHAN+'^NG]DNW MQ=?V)$*G859HS-SLBLJ2:,%UJ:'N["D"I20T<'$TSLA`:Z3;P;+WKMBX%[Y4 M&HG2>\6T?XIQ"Z?!`/.MGYY$0@.QIMRA/-VXPF'R2_;AUV.EMVO39_[YIO=B>ZK_;]!;B`PA@E M+02T@J"$3)2`Q;9Y2.18T#?C^%XQG4" M2>'JUQWD(H$3&I01VQ@ZB&2*I,G^3`7V'3ME]'[QY`3/S%8/\Z;]V:?ZYUJY MR/^OW61O5:6ADSP@1=6V/>>`"T4LYQ5D0>(`C>>DG!'"^)W,4"N\A\;%V0V[VL*X?[P_' M`$R4RPVDYM`(J*&MD&$5:8T9S*0&?I_SI5GH>6@V>Z\ MQF*Z];-8[AT-5*;,W/T4ZW;(PY1L[V<'>^=IL7.U./AZM]NY,[#,!9&\('_] MW)&1R&)/P35#/-2A,OK@YLO/\ZD3;5,_.568;3I5UD_SNFN^OWB4W]L]27_O M?OYAV3S5R_6O]ISQM?M=V['_J=7Y"17!7/&UCZ'Y5[P((U>;!;J:G;(_Q/@8J^M$M/([A MKMA'T=TR^>)N[B)Q?VICN>O^E^KZ7>U'\C/=A4MO@Z%O]%A>%(/'_?H=[0YMBSX(/L\[#VT_8;8`Y3 M[@/A[28SYZ-3A&+CY79?A_-SL_EL\-/J?>A=4-S,^$>BI[FC>G,D?0_0(K5P MLRE./J^_-B^G> MPR3E"R<;HWB]0DU4NNUV6NG!TW*6]6B$8]2S>*CN:ABB9"2U&M[FB<3 M$)?(,&T(-YI!B4&GEQ6S2$#DU6(A@YD;J=:L\RZ#8OG2C%>K'D#F4:K[*PP' M4ZFK!_UFP#IB=0J-Q$.9HN`DJ=+QAP;<"@JI)00PR0R1W`C8F95&(FF"]MJF MVKJ1/C7!7RIE@QNO5'UQS2-7J=\IY=6LRY\MY:8\8O6*"L=#PN(QQ6P?.SLM MY80HB@EG#&(E*X&=QIU5D&KC%KITK<0US&"Z6IM)13K6010:QK4! M%(7%>_!\6G8?#/XZ,C@QH-(<`XB4@@I`(637.9Q9A=PP94%K6S'7[WG0[%QZ M.6P"W^%1W/S>W7TC"WMG[VF]>&L/K"XGD%Q0EA2`(U&5I!":?,]3R!?`K7+- M-I\1R,6C;A9M:[QZ\3"KC[[G0Q8C9U(P*!@1!I%2*"YUQ2F5%%TK0F:STV^. MN_6NVT?XPK_(CX"SD`WX"GAHPG&?`5\DG?KQKP>"$PJ4G=X8/O_-&D_3TV,6 M,6SAKHPDD^LKNA/3QMX@^N5_IOZ\?O]Y/OO: MO<8/$FY4*9'&7.**2XDDI)P!5#+M)K16\&O3HJ1K]S=$6X^*(Y24L MZ5;ZG%T-%.++U`E,PTJ3PW)-K8XE<;8MTIUA<3Y&E4NA&-(?#)&T_3R MG(6V>5BMG)5M+XE#.V3&.%:&&D48T0PC1I0UP$+,$9,ZJ`@59Z'O6M/V=*1I MY]R_AK93B(/FEP;USRM,PC?^[-O2Q$A*IG8%I\!<2(#20(XD_4D,XG57@`Q( M_`O?T]6WMD#D_M.V$_@QG7+I>_9HNOW8[""<7,95XE)X1)9BD6T+!6 MUY2MC*E`6+T[B\6^I<=YUU5:']H_U`<_0^O:>?!ZEK,')QN89^Z@=G\X;7^/;\UR_:E>?C_N=0@A M%[0BH+05*(T`1%6JM54)R"!70,&4[(GN['JBGF%R0K"2$(U&HM!B:C,]4 M>..^5YT"W]7K7;-`H@4C)2N104!J6EEF6\UC"*F*V[!^2DF&>M8C^;:=Z5VQ MJ->MWDP/G4];]<$TO)E>`F#/2>!0;`/G@J?ZE3K/;M:T]`*F2S/#''1'HE-Y M8GG;/2X7(&_=>K_^5B]?3%`GRFJJ`>'(,""ML9#JMN;%:,DJ#:J@N6'$Y7O6 MJ`_+^FDZ>RSJGT_U8E5OMM\TK9O%PXOR5*`^Q8#T4Z6>&89I4>=,\:HZ-;#^ MO`5R0742Z(U$:U(B:+(]2BD5[@DV%AO&F749%\*$6JY!:T1)K"7%<+)NUM-Y M1&7[ZI6#U&3OA/=P^-3^DS3A""054<[."BFIC'W+VK5OS=J;UDCD(=+Y2S7J M0`0![8'.]+MU><[$20Z64'!6458R!$J%2&NS!,"R"@:V+4LPU'L" MY-NDO)M&"7C'*.E^]QPO=O3?/XYVP^GT`W5=-0 M$ELQX515E+P"555!R2G0..S+6^^+]BQH.S\"M<:?B9^N]((C3$.ND^A%*79F M+ZA",)R1*$"XWTWB4Q$XLN\7:_<$S#[/ZTT&Y42D^KE=?=G;1E9):JBBBAL+ M,"^%UJUM6W(N#`QJ>YC%8,^*L"D2S/:>QDV,\J#U$X_!J88)R\&]?>G%>5C\ M=>]CL7/R;P-KCP^X"[J4E?M(-"MO3$V/#VI\K?B=0[&=*U:*66A-96PI2H`! M-AJW^YA*61)&JZ!%]C@+@ZA9:E$XA%AP7;@G6"FEX8-+MZL.'WSP*Q!'8!R) MYB0&<;Y,'(TDL%(\L:K4D)&24HZ%(P`Q[:ZND38(5&5XB?CJ)0>I#2?4A*\S M"2D&9\414P6^2?'W:M77&\M(1GJHUR?KO(%!>X_EWV;3S[/Y;#VKWVQW%I"U MQB"Q2@F!C#"RL@8R(:DVF*"0-"'!3,^YPFZ[_OS@8>AG#BD,_?1@('QA&G'D MU`B^>CB/Z(*@9.`Z$I')$4F3_:&+W)+W8?KK^.1>9I2P&E90$50)"B5`3OH@ M1PQ7DI@R9C->H(FAMN$];=R*W&D7RLTS&>D?66!RLJ.U]>C6N^I>@O'83Q=) M5F`';!BM-A.Y7R#"\ZI_%]W"$.,.&6(PD44]*6;2'86>.6*%(A%=94)\K$0!.MIW9# MS&8SS./N=*CEQM/@/CMQ*/UT:`"*82*TG0K!3H-YH+\))("C\[/T"I/#$+/\D[/]`+K.GM*K3^'TL[OT_7S\DK*V$]IYRV>2S6= M!)@CD9JD$%Y7<9)Q)-22)Q@RAE0E;'N8,H$(6J2<)8&!%8)#';)&%''Y0=:+ M=M\2Q,^I8L#%%HZS,DLO&-^\2AQ4'?:&-Q8A28C@:C4X$$;L#.EH/;O4G&&- M#"`60^1$JS*VU:U205A"$+07-]Y*SWF+>34IVG]G\/`RH4F;+(50C9HO]00T M=ITV.T[JDF4E_@DPAV)\J1&<6$V M%0WE']U=77/;.);]*WS8JDVJW%,`08)`S1,^>UV5;;N2S-,^J!2+[FA'$;V2 MG(GGUP]`ZH.690D@`8JS5=UMM=.M>^X!<7B!>W'A'0E]G?YJA5]MNU(S1%): M0)IFD"K&N-4Z@@M"I29>]VGV-C947+29_NJQUNK/J5\X-`B=':,B@^UU2NOJ MT=%[;#D$2;V)'HEBA?/GG9`I$%%^AQ!.6TQSR5/*D(8BY?;BU$)C8Y&F2&8( M*N%]$J&;F MG#J[$(*<+AO5$T4I49D0!9.IO0%=(&)%CV99)BB"K.,.]<7O'61K.LB6]&6* MO/>B@[+3>1/Z>GO/;IO.SBR-1!LZ07]_F]G3_1`7C4X4$R+#.2Q@7J2(D4QI MG2,,.32Z@YC7=DX?.[%SXT>763ZXW=,;GDXWY1B*23\E"7/9 M1Z(]05QQO\#3DQYG;;*M;38OA\ML6%$4B&0Z*S3+%2VP^6P44&)-B.;`1XX\ MOSJR`C5H?$]:^=+C)B\1F?%3E`;(],$YD9(560:,*88AQHA"KP-17;X_LC;L(25KB^DF M^8^_`)@\35?)3POOKTE^`P!(UM^G*]L-^'GSO5K-_UG._IHLJ]UOY^NU+=BO M6P4_;]8;\\&(MW=SO0[&\1K037);LSAX&[TWU)R1HCY$ MCD2/>KGPIE=>7SJ\UE'5LF6'F*\O,LDHH)0K$P=1RJP=4J3*?$"^BR>O+Q]@ MQ50M6X+T6I$H`.]I4D;`#R-5&W#RIQG"Y,/"(#XS48<9!,<0[8K\ M>X9N+>J;^J!76),&;/+!POW8-%^N'FW%X_#].GP8/1?Q11J;D6AI-/?>=OR( M2*.SRGY=E=/U\^JEM3*&2B,EA,("8FZ"4@60;7ED0E>S2A:IF"S+/RUL-RGM M8,!IMM)FMK:QN%!C,5J M)PW&QM8W]X2K`W$I7JXT$5[%'RO6K=6OA>+0PWZR9K.0&*4Y4I M!5+.4,9QH;15-4D(I)2FRJ?LLK^\> M[\T#:-YL]:V<^P(NCI$&&&BN$%`B*R0HJ%:9IC*'6+-+E3V]OS_>G*I1V>V/ M-BZG,L/`#,XJL_;>_6_C8/(5I`$8/=(KZZM5H=1$^HT&7?+^A/8$(^S*FA/. MCRKPD^1[Y'7UYW2YO?575,MUM9C/&L/+61O'W:.>+Z?+A_ET\<7\IJQKS>5\ M_;"HS,JP_%K^VG!#S-\G`'&6IR2C`DL&&52("ZUR0#!B:8J\.A\-#B[R)GS; MGYODE4=U!/%JBIHIN_E3.!*)7>P!&$KA>S__C\\W7'0BWP%A,U]_M(2?SPX;?/Z>+[;&GV^7/ M0Y@>Q[$J]A/J>\;A)(93 MHIP"+E2*,J'3E!:2(,H,`,(`TX`IZE4%$\YJY-#[_5G9.9X.R+A;H'P=LD.] MA<81UCIS>"9>#3\.(PE$(SAV?,8B$G6.H>,^IK6GSG:!Z]VCA:,7U3\.(BTT MD2K7"$,!"TREA(QJB0!$0J9(%TYQ8S!K$:=K"V-[#6K6IO4$KG%V#1C#L>T3 M+5Z%]8ZA8C#V'<-$5V[>C1&#DSN*`#&\5U74)](S-/RCW%A;]ZOJYWQ6SOC+ MW]:E"4WOGLK5U#8*8;9TK4EO[9#@5-`KGFOX=W.3;2_+!(D[F MRX_)'G1R0'V]+B3^S)Z)*B,.TTC"RY@>5H,]\_[B>RC5GC"EA%%SC04@DLG, MUFM;(T(7G*::>>JJQS?'ELQV*&.O`;%'28:?C@="SL^T#L2-9Q)U`?]V?G2F MP..@^_\^;W>_OE:?2^O@?%&^,OVU\IVF4.=(4`$8E#DD*4I3;&.D'*=F;QJYY7MG/AVAMK_Q'Y^L*_YF.EJ981W(DB6YD#Q M`LDB5X*997-A&PQ+++,<:N(C;V$L1M:W`TB[8?\X_V6[>-88/=4N$+]NJ]5O9K4RL.8Y47=&],)2/Q+5"^Q4%?-I]

3Y[O'+RX^G[]7RY=908X+0>_,$?Y\:U=@>#WJ9*,E3!!7( ML>8<:99R78"4I/:N/5U`-?E9KKY5ET0PFGF?2=M&ZCYWEP_VI'AI-Q$>#?"F MYZB=QSOLB05_8U>E?TF>M@[L#R2ZGYU[+[_I3]J[F+XXX#(4AQ5IK?I_.EW:"Z6WZ9+DI[HL_NJ6]>[LT#MK&%;T\VI)EH@@'. M!;%_82PI25FN908U%%P6J?9KHQ3(J-.$ZM-:Z8,%^K%)/U3+9#9?/U7KZ<*& M"4];R/N^!#5D3YD*1;Z;;`W)>B<9^[WN[-?L_]OFY`9EU5%?6A]]Y.VRP19-C];6_;;)LC[_?J<`(@TH4I"!H"6 MA3V$DST\5,_+ MS?IS^5#.?]IN:!,M("%<:$`S`)6]#5U":UM@JI7.][TYO_91S@YV.\257_VE M\\,.Z\=D5AYVHZ9;O+8>9@NXMW!VX;ZK9,;B.Z18[C`FGQTX'D@CW_+FI8X] M:!^M+O;QZ:(B]B:LAQ;>KTI[J8S<7BNF?MEE?LF63?/D)FDPR3,3R$))>*8+ MP'*>IZA04%.80DZY\+J0,!*$V&G+UB;]4X,W*1N@372Y;0_?7&S?,:,9:7"Z MRN?@XQ)$4+>HDRW<>G":!O+LPJ`,I*XNM'KI;=!Q&JT"A_7RHB9'(+7/4M\: M/93H-=9%*A235$LA-*8RRY`MR\N19#2'BHB>R_PN)J,7QQU4N!'<0$+;C=_. M2_G8U(99QM<$M\J;QR&?I\CS6[SW87^T\MC/J\N+]OZD!5BPWT]?;'1L*_@> M'E;/Y:S59':"95HP@;)4BQR#-,4H+PR:#!=%"HC409?PO9`,LZ@_3.M9>UKO M%_5/C0NMZ+6U0QILG=]OR/JN_.,/4Y2]@/O6T&R!)Y].F\K!"2UAX;O(NG/Y<]R^5Q.$`;2/'`%U[9Q@Q:T(,08SAD6.4$@ MC%S[&AU&F=MA[&R+,%DU$'L+KS?/734V"K?N+I[D]57, MIM_KZ:/':9[E,$6:YP6BDL`,*FR1L`++'`JO\W$1S,]"CZ/K@SZR_R(88IG&+;1`/W40W')G.XGL_?=FVA6`/__<\ M7Y6ORE?9JUL'J MZD/2[B:S0_/=25YW(&USG2W,?7']35-=?[._'_`:)?;N+)Z1T@A#,1()C>%9 M%?TY]I7,5?50EK.U-NZ?*/E_!4%IK)$BK,A%KD1.;-6J@5`4B`&"H5>/PI!V M(T>H.ZA-?!K\5%+0$7"4SRN1[ZF?KW@_/IXT#@5U)_*8]0PU?4P-&US.#\CZ1I1> M?':,(8,3&2QJO'4A5[--R_V MVI5JL2@?[,'W]=UC&XI0*"?0+-6Y%E+0(B?U>26&$5(,%;Q/R!?"?N30;PMQ MWEO/8E#?+=8;FO6^,=]-LD/I0<"!S#BB.0B00>]B=N@,^JD$4+3\SV720^=] M@O(=/=\SVB1/D.2.\UB,1$-C>-8YF>-)7E_%W%XL?3*=I%"14JH02"5@69YC M+&R!)\>0YY2D.D`&O8_Y@3/HCSNHX3/HO0:AEY(.Q7]01=V#'G,&_0RS_B(; M8IC&+;9!/'03W7!D=MHCN%VOGXW]\NY15#]^5,NZ6>2$J`P!!1FA7&E"4J5S M;0P+D.524@RZ[@ATLS9HZF>^A6A7G@\UR&1M4?;8#.C(L?_2/SZ]?1;ZMRUF M&WS)E_/,1E_4GR3,<0G?C^R1Z%]`A\XLST-0Y9VFT=7J<[GK,OW:,M,`2H@( MX:K@YC')%4#6LM"(*R$].V\&,!@]97,`UE?7`K#KE[J)36N_!,YCM4I>DWM- M:;M(F4,Z)P#?8Q&W@!Z]D]H)1E;/X,W>CO"U7/V0Y;?-)*,@I2DK5(%)D1?4 M+.&QEAAB:B)'5GA=-17`W+"5.P91\JU:K:I_F)BZ3PJG*[E]PK9HO(:*V^H; M6N04O/4@RUG>C)INI?7(7DY1AG.14HP1 M)Y(@7DAC3XH\`TJ1W"]FZVQFB$BM06:G6S\UZ\ZEFX;%);&3G7SH!,;=A.9;IUN?FHZ;)U*25PQ0G!@SC%<"#D&(YFAT=P[$TB$IS%"NG$" M<\(IYQ)G7#*F"4YY9A1%%3E#F@$4H$"CB]FA"S3\)G-TTD.G%8/R'3V=.-H< M8I#0#7;]PS4"FH+6.L/Y0&^IW*&)=]- M.Z_&NY]ZBAW%]8<6TINDP9J<:*(UL'[Z4'E&0:.,R$@T-(YOU0"/=!`=94;> M5ZL7H^3UI:@32870$/.,V0M/,<909RREBB*I6(;UY*D&_64S76WZR*BO79]Y M?`S1?TH?JV8RW23?RC_GRZ4-A^Q1W-K$*&;S$9/>T[CK2(QZ_G9VRFGB]J,L M\(S-M8`FP(*<0_-W"BG6Q,H%0T6:(YAO9ZQ:.FY(A['J/U]W`,/,UM*V8/Y_ M/4]=1^#?:IXZ.]5IGOI1YGZ?]_/3TZ*T.TK3A46@%]4_;I>/U>I'?;GOOHA2 M8I(JR"'&$N2XH)P"LT"219JEN03<[X+O0#8CI\3;,&TOBX=%M7Y>-:4_NSIR MLU[9X_8M'`]&O=O2Y!JL^ZU*7A%>*Z3%F+1`7J\BW)&],\H8FO^1:&-PMXXO M'8]"FT?G[ M(^M=/>/JR[)L.=Y\"\Z[`[DG7V[B%9,J/Y':(4DLE)O$@!F\D?@K*LXH3E?2 M1J(LG>&_:0G>AP:O%8\5IS^,=^;CX1C@NPLVRQ M&VELT+<.2]MQ.GG0[^#"]2*\OJ1?6!0/,IXC4>[A_#VQE!Z0:.=WP]^6JW*Z MF/^SG/T^G2\_5>OUW?)51PV2<0`*0`LLN,J`1(A:LR9P!83DT$?Z^]J*K.P' M>,F?!E_RP8S`^F-2+7OT#.I-KYLL#\FLG^JV2/V])O73CM3KM?VYP-89N0S% M\TC4,)@[59S'\8V6M1^43^:3^>7N5^8?WZ;KTOSF7U!+`P04````"`#@@*-` MTT076,(H``"OOP$`%0`<`&QX`L``00E#@``!#D!``#D75M3XTB6?M^(^0]LS3--WB\=W3.1UUDB MZ(:HJMZ9-X6P!6C;2(QL*)A?OYGB4A08ZV)995P5%8$QF:ESOOS.R9.WHU_^ M?GLYV[O)JGE>%K]^@#^!#WM9,2FG>7'^ZX<_/NVK3^;P\,/?__:7__KEO_?W M_Z4_'NW9;[^[%T^/CG:3K/]F[G M^<_SR45VF1Z5DW11/^=BL;CZ^>#@RY5K.?RNK\``&`#YYJO5DB_K;_ M6&P_?K4/T3Z&/]W.IQ_V@C;%O$7[#R5_OHU??%/^"ZY+0RGE0?W7IZ+S?%G! MT"P\^-=O1Y]J%??S8KY(BTGV(6"PM_=+57U[-`A`'O235Z2RJ^>DBRQ8G:16>>)$M M\DDZ^^:7)H&[M3*,W/-\?GQV4F7S\(":CLU"OEEE"(E,.K]0Q33^R^\,UA<9/-%W5G-HG8I8U!9"YGL_2TK&HPPF..\DE6S#-U7F59.X';-C", MM)>7^3T($:2R6`0W%;Q1@'Y6?NDG=[N6-BI_>7E591>!BOE-=E3.!]"CL<5-ZO-I M44[^O"AGTS#`1\>PN%M;H19-#J&1S4X7QZ>S_+SV$(UV^D;Q021Y"'>"_;M@ M_HN[P^*L#"7B@Q[_UBA>AS:&D-FG>?6_Z>PZ^RU+Y]=5.Y^\LM(04OV>+:(% MG&35I_"7K$F>-XH/(+J0;&^JV&!Y3]T/+.^K)H>1MP<9 M%J]%;-'S5\\FQD>AU$/9V.9`ZQWWC\UN%UDQ#6%F_=CPX%DY:?#&\9NDX2'J M=+ZHTLE3_#6+"H?&RDG2I7K"!?/46:<`M!(PAP3Q"@E$C.2<&/ZM,K.X%E96 MCR`.ILWG@)(.3?W94YVG^@EV#DNJC-$>:P,1\LH$?3`4&#B(99,^SVFAJLE> M684IPZ\?X(>]\)>SK*H>1IT5JW4U1Q:O[#FM)J_(]6W%AQ('5W5PL#^YR&=/ MLY.SJKS<9/>6FP<[J/=D?00MO/Z>DL6Z+>\H*)9HYI@9777FA`@**>UMIP$;YE9$?L<9GFQ0JZ+"V?,*",1X`3*`'17@I/Y;U>A$%@ M=F"\'[A_R^%1'8,M<4NC+.IUBM^RR].L6L&45V43BXW4R"$M`7;:`(*QO]/G'(2B*])9!3(<)/(,RCU]54 M]V4(VCZ&##WXXDC7[]R5;!D)T5(=B9NG\<>^PK5-Y62>QQ'J+,-!`*>^QQ4"11_VH MD*XG8_`6,V8@Q[(FE*-$)<]$;/0JKPLGE&J#'7?":`,IEQ`R]V1.7.Y07#)` MK[Z,3=:%X:W&BAK0EZ#;'$T/0-#O@_X8W#UY[+4Z##Q)J^.J!FY: M'PE\>0AO"3/;-9`@H`US%JA@KU9@XJ&_'R`\0L*(QDVY=QB'K<^[C6`[/JMJ M*>?J>G%15OE_OAX8;F33RXJ)4%XIPRC'F&OCL5261TU=B#ZHM;0GB^@/Q*(U M,?U>[#F^4L($Q#*$I,82;@V#"H/:/ASS2$#4>$3G#=:P'XXUO?#\ M7HPYOE[$.WGQ2F-'VCRKF7`O**2>$,`4LT3Q,,.I=556(65A3^[P'XX[_4$= M>7>T1PS4HG;""0FS$\(9@U@K)W!0M=;9&42%[WL<0^PTD88'=F0R=0A]5M1* MK-#"4V2P<1IZS"W3]1CMD5($H+[DD3\*>=8$]+N0IC'B>:-&8K5%S*B`%%+$ M6VH0$;5N3"(I:>\M5O!CL:47FF,PY7-57]2[>R;K"I8L*9U8X`S'`"*MH090 M"$7J\==K%,C/^DZCX&ZO?*^/Y*8/<#%O"^7H*^7]Q[KL;QF<^+M)CD\1[H MXVU%F\\GLS+>GEUU$6-3CTI`"'PH$D0:9A54T.$PD7<4"(850KBW/6^/.0]' MJG*K^F*S'J%[?I"^+J+-DYI\1I/$R_-L0ZALV\&[Y M='I;=]-C&DV[;0,)M,!`:SPA/GA-KSCS1%KG!`'$.-!XH&M3D[,G^6^R9[?[ M.EIV^U82):'7G@HBG`_C&?/8:+K5!&&T'.F85L9J%?QP^:43![EZ)7=M[],5P ME&LD\WD(S1^NN:R8L:TL']D>!EU+K2:,&(81(]I;X"'FB"FSB\ZC1Z>^O.`Q M`)2CC"S+MT(6)JVJN[PXKT_&==Y;>E$_H9A)'D(Y0IABGF(!+8LH:N^L=6"' M*+1FO[?:0UH/W5&&HXNR6GS.JLMVEVF7%0^6QP5U!$CO@+0"$.WJ@-T)R"#7 M?8>D+0QHA^7,`&".=,7QQ77,W[-%B\NS*ZHEQ`A&))/((J`,=9[Y:`@,(>VX M[WTE;`NCF&$I,R"H8U"GSIS_#0*KCD:]*IQH;Z@!A"/+@/+60VIB^,ZH9,X` MUW6\:9#\X184(]-R#JH14VBN*^EW*Z7P-\ ME<-[NRFQ#HKC7.-ZX^)T<'`KR+&J6A+8C144G#G*)$-`ZGIMDDD`/'.P[^6_ M+0Q,!IP/#8CH&+SY1UE.O^2SV0J./!9)8!@%#53$.R8"Y87D#CCGH.(4&-Q[ MY74+HXX!^=`3O3'Z_C#T17&>ARCHWKL%AKK;R>PZ7C1LP8LVU1/DM:*6:JJY M]0!S*8R)6GO)N;"P[WBSA2'(@)S9`+(CAZN_E\6D2\3ZM7SB=(BZO7762R$! M!M@:'$=HJ21AU/6=#K^/1`5]&3,$E.,%K8W1:N*U-##,QBCE6`1D(::UY`:9 M,#MS?5-K=\\[L/$P=?"EV([8C='K1WEZFL_R19YU6*-_NU(B0AP5E(/$:RT$ MLL(JYRUD0E%C,>E[>O]]9!;HRX[!\!QST>PDO6N9:VYIA819+;R!#FJ"G*!0 M`11L`?*8^3?`MT,I^H?HWC=6R];"="2V5->A)UY!L)HPR^LDP&+-`'70"6B5 M1]11&O5CR$N(>N>VW,)I[V8X,PBL8]#&/O3&Q^PF*ZY;.)GE%1+$`2;<=YOBBY.;J;*D=**M9<`2A*F1 MEA,@!#11)X."!T6XKV/9PKGP!GBR/J#?)]+M%.$F&#*&M!,^II0C$$&/=-!( M8."%X-#LSO+\)BBR+I[?8=!IM5#R9IU$&LZP0180CR$*]`]S_6@!4D,H(>B[ M)/L^4F/UG0D-!>?8HTXKKBROD#A`',1A3#64"$$@(1A%S1ST%D/O>Q+E?:3! MZCUE'@++,9W*Y_3VF1/LY%O>JIH$$U!8(%E?38#2*:6C30C&A;1>['A.K'5] MS$"PCK9\WY4^;U=*$+4:284]-$C'K%_4\R@AH'P6/6-5N`6+JD,R)+A$!V#-?=O"VVQ$?1M MP00KSCD6Q!/N%762L_`Y\-^R,*7S&O3EQA8NHPS(C;5`'.<`V_/$UTVW,9:4 M3I2!U`:GJ+G6PEK%"0%!)\4@8U@VYS5[/WL]?3MS9:[Q/B".-;H\9)=MO*/S MHF@B@A*<6"6!E-H%3R>EBMH(CESXT#?Y\Q9NY0Q$B341'&6S;SK-8W^DLY,T MGQX6)KW*0RBW:JMO>8U$8T`],01S9KQ`4&@<08KY/(QEH&^4L85!QD#L&`;( M,4CR,5ND86(>5U58`0Z``PK"^)YRV\!#D4*YIHP"/0;9O>R,<\H4V7GLA?=`FK51 M'"?C11#NHIR%WIC?Z[V"%Z\+)\!IZ8AS`&F%B6;<^W$D::JB8SK1);S8`F080VT<.]KF=M,DW[]VSKM9C=$1W4H1_U2Y8F8 M)X%`'")?8F6`A1#SH)&U2O;-'K*%B^=#NY*^&([!BICP)@RJ)U5YDX=`3M_] M,<^FA\7Q51;?\U"D,\SA[?_UT_9'3[7'[,)F4QR>M<75^E_EP.Y\8V\;@$>HJ--$!! M2Z%`&"$60PS*4!A8--VA[#DC$G<+>FJ<\]RACR=YW??A\RQ[>,>3NBRKQ<,K M%U>>Z6ZNGECLXF4:3ISC5`BI+1-!:TFQ,A[I'7@%WG:0YM7!\,'[9I1<09=7 M:5Y%#(_/XK6(H_PFF]XGG/B?;#;U914@6T')5O43(PBBP&F.+:?.J.`-8N2M M++.$0M_WI2%;Z#.WBI.;Z)S5I'QKF?@BOF/NL/!!G'H_[OCLT]WEU459W!T& MB`(V)]?5Y"(-G?.PVKYLHZ-O4XFS&F'H`&5>:^P5TIX#)%"\Y^,Y'"TY_$U6 MG98_`@%'ZJE15EOB6\UU$'(:CQYDQ;QID%Y>(4&$>HEEB+T9A@(J*QSV\4@, M"9-&COL>6=S"DT5;PV,,GOTCS8L(S7'Q*9UE\97>S_)-/B6;7,&[=@TD M7C#`J!'Q/V-6"J2HMP1Z:+3EJ._AR/9[P",>)]DJ)FZD?T8)$8M)/$^3V>S^ MYS-X'@Z*MIB*MV\DH0)`[(5T%BH09I#<$NCKU/"=V+GZ^J)-U`(;3R0!$`7[_):&+4V`5_GZ>:W[+_UG)\W3L]-,**1 M=&L#_WWH=E)E8:XU?;P>[FZOZI=V%]-G&3P[$;!-@PDE88B`5F@2PF1%-?U_ M]JZUN8UD?-?Y]6F,).M%D4-P M9CC2WMW:76D-S`P.#AK=0#\8+]D*+&746>=K0Z,F:%>?A8L#S,&9-NSRO?>; MQO%LW/6`[)F/$'!S\3XI&X3@9:>1/("5-)I:@3C!.)NSL*\'S,^[]=[FERR' MH,^R!U9MQOL>F%5@&CP7+'FI"&H]7&I$1BBM&3&AUK#I;F#_I;;G'J?B/"1] MDBSJ*#X^Z9NY(@%?K%TJWHO)6VT,CE>"\K*D)!O9IGZCU#L-]6GYX/3B>Y,] M<1R<$.5JU5$B(C<%6R6D+U=*M=5ZH+/M:Z0H69@ MG%PSJUG37&X2(KCCD+TK";L_)9=BDCP:T-++B&I'46L0`ZTY$*.JTYY-4-Z- MR<'!)N`L@K!;">%]W;+5""/%`07BA0:JN"E6/RK40"15M33KKNC]181=/>;G M$&^_76ROUR4RNB2%6RR:69G>S8?1B<60&GK+DM(DV".I"E(XA`HX$X;B5M>D")QC+ M/B(5!\/_C`Q,\^7%W,LX.=,R1"`^7&N*@=?H.,A)<1 M^\1=]-4W:-V-V?-;&8-0K6_DSR?2'A;..%JF/>R54 M\%*0&$UMV:1:'X"WPJN>\!Y;;CT0O*TOS0YH.@JQ#D_*2G!)/)K@:'19)2*Q MQGB<5Q-C8,[553/YL]'#SF M,9E):J@5`$SZ$+D0KMP.!B6-#2S$6D^`XX^*SY%KLO8T9$"$S\VNV76]W9:%K@HY/R$$9%DM1+A6(5-HZ2U`G")H))@-Q MM3K9\Y_=9P[DIR`[UJY61EU*@>*/][>LR\L==D68;V:+U>9Z MW7202Z<^NM1"MCQZ(T`8&E*"Z%D*D:C(`5SU^>SK*$!^RCXX(NICYR_HYE]TH&=).^0(T<1JY5T4)'!NRUAQ31-CJL/\)RCIQJ/%:L@I M>$"W,2L7/"SX4X8P4@6#VW@/_-/:$@;/GY"#`\$B<"Z,USB-RB4@3+)@T7Y/ MZ:!4'4@-KJQAX&/)KJV$M,&G"&`U^'8TD'!;5;6)I">T@@>;W_U%#(X#=A1+ MJ9BQA($B7B`BH: M2IBFGCE]-SY/S1MR>#IQ?CL7,3@.T5$%RONZ(@:.,&*-LTL65)N7'R41[' M]W9VC=[XI&"8(Z@_LU*MB(FM0%E41.OO?Z=H'#H48'H M"\YQ!,6FP?>4J^J`I%ZLVA#RVP_?*SWV],N40/320V1*.UQ;23..XS1,$(O; M96T]F`GJ&#W,]3/9TA^R^QDTS<($GO(8/8Y+1A$"D=I1'*&A"F4K.%Y[VSM! MD=,?=T8">PR!]+=FB:@L2A*]RV_SY;P@LIW_:`Z+I`,]QV)&`.DE("/"_'T513W%W+N)*'$(.NU8$GF!>F1X+T`>4X MSHQW7W?#Y#O'NKU>C;N[9!>=XDK2"-H;82-UJ,PSZ4HNU\!=;<+ZX[.VO":B M](3FF(ZOAS78)RVS9]8P:BQ)-$F6F'*I:%7.1V)L,K4.A]V=[T<,W>V5&Z?` M.(KZ42(U?U\M5X_WP\,,V=\QFYNK"$&X")RK""06\GM1$A!!M5+R.ESJJY62 M/C$=1Z#<*4\E`+A<3LV7U_C=]\Y7KOFR*IG[2KO/%W\VF_@GZO0XF_/EQ?IG M"U=QO"S76JO%HAURA_UKL+=FU``#CXYJPZ7F`J%-*,&I)YXRIF2MY\+QGM6O M29F>SH2,1WHVZ=,VR^3(_3-AG/3(*?>&MIVB/)L,-[@LE%QSU!I=SX*96 M,;>3K4S0.^=.Q72D#`.=;/M'[;("P1U#BU12'9*4:)):Q"4(9FW)"%-[<4'> MM"0Z!<,QN!`OUDN4;B5H_*[VZ7Q6[E?FB^L'3O,[V'&@9XZ$2C`B@7*6!A(@ M4DFXLD8(86Q]:-H$;[IZY$N_J%9=%P;#=KN>_W&] M+;Z%GU?OFS_GN$5^;&,S9@TVG%TL-N4VI5G?YBOKQJE1WIN9YD8"XX(J`3IY MB68O8@=%>;5&U=J,=(+W9STPL\_'>-XRSX;90>^[NF54Y!).>%1RS&X*;GDF"ACQ.W* M4TNK_:K?]N%^?XB>)^RRS4OZ%5<%@EYR>FQ_CA1W^?S%M?&7+S\I)R>%Y3R9 M)(0EA"1N<)/2U%&@"NQ!,3JM.$PJ(]?&(H-`NI*,T0O9CD;X&.E;\'(??)[W MQV,>!_#KB<>,(!BES)`0'0U:<(4HW8[+IFIW^`D1Y]0)[12/>1R,KR\>TW$J MG&:LE'0E*AG-I+X;G^*R]M)VRC2IF]_.\9C'(3JJ0+F1H$5]62V+?.TJ6';U MR\9:KIV+AEEBO>&6`_NUSE!Q?CO^K7T+F![@'.6T\?%G'A0R.]MG'TFTS*E@ M$C4:_TT,W(TKT.JHG"D+F-/F]^D98P^HCF2SWF^2/FZ;3;#6 M60%",-`A2F_9+W2L5J,%6HR18/O$&7UNC)Z$Y1C<@$LT+G%F+A8E8=N[Y6T= M\8,\V=LO$]RYHV8N4)3(R2@B_"\Y3"*I55TFN`'URY@^41TGM&N+PVTN[VY; M#M)F=X?LN0Y@*1@(C'HAG+S'BX1J_\0)'J_VRY=>X!Q%S,QFU]^N%^4,X:53 MX<,BI^LSH-U"VS$QSFM3YT_02;I?UIR.Y:B6ME]<;.Z.+[M:V4_[ M9#!"4V.YUQ"#4XKC)/S"*IKA*T._6@O[1"A'L9<>?.)!T_IYXQR,X1"MHX&` MTRE08_S=B'ARM8)DRG9U_:P^M9E.A7-46?*^+HM:HH(DYJPF4E#*9=3W(_)6 MUAZ\3%`_Z5MZU&(X\C'+C;M/J06XU_7OA1Y9HS)%F.H82^NBS_,Q]6ZG;I'CF%'1U/T\X*L M-66))8G@&6V39SIZ0)7?\C8?XFC)NUXA&<\R`^.<&O[W]6WD[.?5"X=6[?+[ MXV+37!9#`VW(E@&?&L1A,]\V_]&L?\QGS8UGUZ=FMKI:MD\Y5%-HZ%=G*Y-3 MJ+@$)6("8Q4#,$%Q!HF%H&L/#Z:LVI_.](G-RFCR^V9W>>BD>+/K_-[\H_VC M_8IAEP?DJ*U!;3IP1@77.CGO'(Y<:%L"D'GMV>B4E<6>)&_?V)Z15>TB.(%4 MC_MG$#1J2J6)UB@EDTRTK";!&:KCI+K,S`2/NH;GU$G0CD&I\]5F3@[U[39[ MK;!:`4F(LZ?)&>2#!!K_5:.#O@?PV^E1XZ<`N(_P\J.BV-RX(*B.$X;N`$1 M4?%D`J=-FA",K5;#NJ<)>)T4G\\`R=L(`94(`#$,F"1&F#X&ZDM MWWU\VH&SE5GN^TCY.$3_>:3\X$"3\<1I<%Q1CWJK\LF0U1!P#KRL5K/K(G-@B?)MVPJ*7T6^[_ZLK[4V/[R^ MYO?!H81I815C1JN0RDV6``V,1J.8PRWTE#6U:6;_$/3U<1 M_J]\!\`#3%X*_MW7/#-)`TF!>.$@2>^82*H=BTW>V.H\7]-;/Q73M^H=O^XJ MU`D\^+5N=KL&=NB5RRUM`"=)I,H&KU5B_&Y4#(V+U\^*?B9U/T-.@'0XHKSH M#OB\48Z2:::33`KW&:X]$/SU]IMCXF\@O*[7F=O!ABH@1Y$2[_&/(AUH\^^?'C7[UJ;EJ:Y8LM[]??'M)D]C5 M---$2SB7AE!P"<$+H/C]C"J%6ZRM/IJ9/!\JIG#5*Y9#<<$WI9KGXAVJTW_^ M>[.K=M6+;3,-0DGM$Q$FV MBM(D2QY]X)3H2-$$M0RT#.WW.F"1I?$*9;ZNR3\!P^'F_./=X6*XV!Z:_$=M M<<@62R'8$D2OK77C]+E^#LN`4,/NG`^`G79;/2HN+JQ=H\*A- MQJU*(98,'Z84>`M1M'L8(T$8PFOU@0EY9PTR_:>`.)P42//-[&+Q7\W%.N'_ M.60O/&F="1H\*,:(M$FZ$`,A*K6CX)JY:&KW@PEY4`TJ"4Z#T/ZIX:_7ZT>,W:\XO-0\ MHWKKJ"0J:&I%X"EH>3,.`]PD4QN^<'R=D]=%C)[P',R@O/F\3\WW]9Z23]<*;W2IJ.';\3A!`41M*NNC?8Y>&3]ZQ'0HCJ3YHEE[ MY.S5:KW_R.%1RQRE0NU8>8@.Y1X0A_I2^_4AR)"J52:]C1/@9V//N0[L+=3UH::$!PD2F2DQ%)E+-&ZU&P% M*=+!4/EA/'1V??.[Y7><\>/\=HYZ3CG[3BYZBMPA8&*)"]%$&R>2UI&JVG"; M":W//@FQ&@_J81?L;1F9NTI'_2S5)P\]M$A?:)XE:SGUT6Y(&>.6C<"12A7G"M2K5Q33B.ETK=:H5O M(+5[/]-]H%K7:;`.N]QNH@]N0]K;?$=7ZZ;/77+/"PXMPPY=,RH4()F1@:+2 MP85.0GC"K-7>:1#DX"XQENOZ[ZMM<]QNV?D9628;@V!1$V6\+G\+@1@`RF\0 MUE37]C%^ZF9%<>DV6QU76K97GU6 M<+?>63@4IXQ3S[R));B+*^:S;OEPS;SY6S^?=%L.BWU7E^4F4<%L91_Q'T+M;=26#8@FBII[V60 MU359)R8/^N;6L\(;9YR48>7&P\)'CR(/6S6H1?YKTY9J?/1+/P+EXM%!L7+,,S+Q+GBE<:J#X4FAAJ7+F;=3*@3=P7-U*!6AKDZ7B((IRW5*:)F) M0"RNFG8TQB8?;&VJ@*DM[F%F>'^%KN.@'2<$LH\*7802;T4`Y03WKB1OT>%N M7)2$-Q`7=>J$=JK0=1R,H]"CUPI=D8$,BI8B,4E!5%H9^@LMY=_`@5M/\]NY M0M=QB(XJ4-[7Y?IE&G@2!M#>\<(EJSC(NQ$9$+5U7"?DSCN4**G%<#\K7M2Q M4.5T3Y,3QC_+CPUL-JO9O)1%^/M\^_433@B^XVNIOMW\:!:K[VUEJ9NF+^M? M_3P_JPBH%!OG);.IN#`SI0L6SG!PA%<77Y\PGRJ(L#H_]$/3\&_-$I6\!7XJ M7'Z;+]L@B"U:)/T1\<`;<@*I>`D")4028J3VTK5X!(H+7-5J25,6;>-1L5_P MA[:.=PVK+^-WU[,/F[O[>N7D(@_T_^?JXF9J;&KFXN@(C#`#`W,S-PM#-S"XSVT:6H@!D_]T\#3()@>*"H"#9V`>WE.E0@UT',"'')X+3(P,3(P,S,Q+GAS9%54"0`#8^6B3V/EHD]U>`L``00E#@``!#D!``#M M6UUOVS84?1^P_\#I9=V#(CMINB5(6N2C*0RX31`G:]\*6J)MHA*IDE1B__M= M4I(M2[(^;*-QYP(!(E'W'I[+0XJ7I'SV;AKXZ(D(23D[M[H''0L1YG*/LO&Y M]3BP+P97O9[U[NWOOYW]8=M?+N_[Z)J[44"80E>"8$4\]$S5!'TFPQOJ@YNT M;6T]E=ZI="@P4N2&B^":C'#DJW,K8M\C[-,1)1[4Z1,-N620>:RP M&!/U"0=$AM@EY]9$J?#4<9Z?GP]\,@TG6`3XP.6!<]CI'G:.CKH6@L"8/`5& MWY;,IT/A'W`Q!LO.D:,?#[$D<_.IF+9`9YRQ*"C']Y1PU"PD#AC98$4$=5,_ M;40K:%$F%6;NG-:T$,;SD;'NGIR<..;IW%1Z988`VW6^?.P/C"06*(20T8@& M(1<*L4+;CK`<&M=(VF.,0QU\U^YT;1U^K&R?NUB9CI/XF"A*'1WB*YF6V`NH M`^!@(:FV72(N&23TV)U#^\FS"(^OY*7;<)IWUJ&S`(ZO)L;GS&BJ2 M<=`U'[>L4Q+W8,R?')='3(E9XW=;F5]ZL]9+;1DU$@(2E#7H9!WG=YL3\@AM MS27UT1>;,R!3=]*:PMS)7&U.@K(G(E5K&AFWY'IS*@Q3M_E47/2*+S?G(:G; MFD7JHR^VP$"%HCV%U,E<59'`C'%ED$Q96AJ&E(UX4@2%>@X_32?R>S)")E\] M36;1ZJS6"04/B5`4DJM,KFX`)H*,SBV=L=MI7O[5Q?X!Y,&I2:&"Y13#S%?@ MXD:^":._()DBZ/?WN26AO7V2!O_#H_+(J&U4X$(9W>6@?#QL&Q2X$']7XPD% M:1L/N$A8]:[7]S3"`U@@"@N^"R$P&YLUM/P,R_'!+`@GG,UZ+F<]!OF*MGZ\ M[U6L;0VC.IPYAY3%HI^]/>P>'G8['62C:RI=G\M($+C)0L9;!2DHTJ@(8,^< M/%:^FD@2[Y:]-=?Y5DN\$Y,JS]Q0;^ZX/)K*_9+25)8JM2ZQK]=6@PDAZ@Y# M(J(F1%%@MW336+2&<%7:@6Z'QT:[`32L$0NN$V!DD-$2&GJU=/O7_DDHJ;P= MW64"::%7T;=Z8,$<7!Q8!@;Q$+5*W;4=D(6P(U6B6P:(&[?Y(%`8U[JQXJG"D*LSMS(4UJ(=9JC)H,X[A4 MICE",PF!O*1XY1/99IDW%R0)>L:X\?GSAO+50-;(^*9&Q@6Z3D?,)&OS`(*; MP"Q"GTB?RVT*NQJZ1N"C=@)GZT&ZHE]"%]48*.Y^FW#?(T+JE$_-MJ=T%7:- MU,>MI,Y6]">*J]IGL:_)4-T.?3HV5)IG/'F_FD7$24F6HR%0!F/OFC[Y[`0R MQO>0WZE9CXTX-+*N('W67(\F8%4B=>;)S?QSF,RESD)C7)0!GC_?-^EN,!7_ M8C\B'PG6O;G=TJ[?L.R(&T-*DL0YYOYHM MJ]/./O M\?[&/7'UO.":+Q8H&]\)SN#2;:E1#4S-VZM3(E.,B!:0:!ESWX2J7/ELX51E M7?R:_/MU\9BE=G7UZ^1E27=X05UB\-5R@C>$15I.E]$#P*SRWS_?4IK&`#"\6G['$)0,"+M0?E M.F@+Q:4A$91[#\;.BT32WYQBJ$U#>R!3=>E#[VD86]9^G>#BS]1/50JS=H`K MM5QY!"WS,C:R?#$%*P(LG-D6(ZLRV;V0FIQVYF-LZ?/R(_%JH@=6C\T7D;>C MW."ZBX0[@9=XG^(A]6')/H]U+=?U0PXX(PJ+63[H83QB(&(RI&J+^M<=F1;$ M;^&P@]U]]:%C,=`FIKL8XHH#NV*`]8:['5[I@595F'4./T^XMP`=;P$WC;?4 MX^<)N'C:T33P2L_=:X#<*4$^RM6/=S$46J1/=YIRZ3YS/H@ZH]T+*[=MFP]H M]>/="Z5BXS,?5C/3W0NQ>M\P'V5CZY=/Q$WODH^2P%)![Y9$FF_2^2Z2'XAK MB@^\3Z84\NL[LW'CDBA>'>IT&Q2%S(PS@Z676RZD9]?4C\R9>MPD/Z">#1K3 MD-M^KRF?[*L7XBU]=F^HE._D%<.LL=J!H5%*\?TT-*LK*;E+=6*C-X8^$`9* M^=`=+[R`,JJC4/2)),;50:^)N',KVG4:[IY(@F&UK@2(^#S74^LU6A_?R MC1;OS,:_^(/;_P!02P$"'@,4````"`#@@*-`.+OT+V)<``#`'`4`$0`8```` M```!````I($`````;'AR>"TR,#$R,#,S,2YX;6Q55`4``V/EHD]U>`L``00E M#@``!#D!``!02P$"'@,4````"`#@@*-`K"<_2I0,``"%HP``%0`8```````! M````I(&M7```;'AR>"TR,#$R,#,S,5]C86PN>&UL550%``-CY:)/=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`X("C0'SL,U/;(0``6FP!`!4`&``````` M`0```*2!D&D``&QX`Q0````(`."`HT#J>)/Q"40``),X`P`5`!@````` M``$```"D@;J+``!L>')X+3(P,3(P,S,Q7VQA8BYX;6Q55`4``V/EHD]U>`L` M`00E#@``!#D!``!02P$"'@,4````"`#@@*-`TT076,(H``"OOP$`%0`8```` M```!````I($2T```;'AR>"TR,#$R,#,S,5]P&UL550%``-CY:)/=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`X("C0)G2W]:;!P``ZD,``!$`&``` M`````0```*2!(_D``&QX'-D550%``-CY:)/=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(```D!`0`````` ` end XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Cash flows from operating activities:    
Consolidated net loss $ (29,868) $ (29,629)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Depreciation 1,125 1,307
Impairment of fixed assets 0 769
Increase in fair value of Symphony Icon, Inc. purchase liability 2,081 1,058
Stock-based compensation 1,718 1,472
Changes in operating assets and liabilities:    
(Increase) decrease in accounts receivable 164 (87)
Increase in prepaid expenses and other current assets (1,395) (565)
Decrease in other assets 24 315
Increase (decrease) in accounts payable and other liabilities (851) 3,849
Decrease in deferred revenue 0 (29)
Net cash used in operating activities (27,002) (21,540)
Cash flows from investing activities:    
Purchases of property and equipment (234) (507)
Proceeds from disposal of property and equipment 0 43
Purchases of investments (151,776) (33,895)
Maturities of investments 22,435 29,041
Net cash used in investing activities (129,575) (5,318)
Cash flows from financing activities:    
Proceeds from issuance of common stock 52 160
Repurchase of common stock (285) (108)
Repayment of debt borrowings (353) (284)
Other financing activities (136) 0
Net cash used in financing activities (722) (232)
Net decrease in cash and cash equivalents (157,299) (27,090)
Cash and cash equivalents at beginning of period 186,309 47,208
Cash and cash equivalents at end of period 29,010 20,118
Supplemental disclosure of cash flow information:    
Cash paid for interest 516 584
Supplemental disclosure of non-cash investing and financing activities:    
Unrealized gain (loss) on investments $ (78) $ 35
XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Balance Sheet Parenthetical (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified
Mar. 31, 2012
Dec. 31, 2011
Restricted investments 430 430
Allowances for accounts receivable 35 35
Accumulated depreciation and amortization, property and equipment 81,654 80,535
Preferred stock, par value per share 0.01 0.01
Preferred stock, shares authorized 5,000 5,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value per share 0.001 0.001
Common stock, shares authorized 900,000 900,000
Treasury stock, shares 380 218
Common Stock [Member]
    
Common stock, shares issued 480,942 480,389
XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaboration and License Agreements
 3 Months Ended
Mar. 31, 2012
Collaboration and License Agreements [Abstract]  
Collaborative Arrangement Disclosure
Collaboration and License Agreements
 
Lexicon has derived substantially all of its revenues from drug discovery and development collaborations, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. Revenues generated from third parties under collaborative arrangements are recorded on a gross basis on the consolidated statements of comprehensive loss as Lexicon is the principal participant for these transactions for the purpose of accounting for these arrangements.
XML 22 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information Document
 3 Months Ended
Mar. 31, 2012
May 01, 2012
Document Information [Line Items]    
Entity Registrant Name LEXICON PHARMACEUTICALS, INC./DE  
Entity Central Index Key 0001062822  
Document Type 10-Q  
Document Period End Date Mar. 31, 2012  
Amendment Flag false  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   480,656,570
XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Revenues:    
Collaborative research $ 152 $ 516
Subscription and license fees 148 80
Total revenues 300 596
Operating expenses:    
Research and development, including stock-based compensation of $1,037 and $839, respectively 23,037 23,921
Increase in fair value of Symphony Icon, Inc. purchase liability 2,081 1,058
General and administrative, including stock-based compensation of $681 and $633, respectively 4,565 4,753
Total operating expenses 29,683 29,732
Loss from operations (29,383) (29,136)
Interest income 56 87
Interest expense (537) (607)
Other income (expense), net (4) 27
Consolidated net loss (29,868) (29,629)
Consolidated net loss per common share, basic and diluted $ (0.06) $ (0.09)
Shares used in computing consolidated net loss per common share, basic and diluted 480,324 337,527
Unrealized gain (loss) on investments (78) 35
Comprehensive loss $ (29,946) $ (29,594)
XML 24 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Cash and Cash Equivalents and Investments
 3 Months Ended
Mar. 31, 2012
Cash and Cash Equivalents and Investments [Abstract]  
Cash and Cash Equivalents Disclosure
Cash and Cash Equivalents and Investments
 
The fair value of cash and cash equivalents and investments held at March 31, 2012 and December 31, 2011 are as follows: 
 
 
As of March 31, 2012
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
 
(in thousands)
Cash and cash equivalents
 
$
29,010

 
$
—

 
$
—

 
$
29,010

Securities maturing within one year:
 
 
 
 
 
 
 
 
Certificates of deposit
 
548

 
—

 
—

 
548

U.S. treasury securities
 
224,155

 
3

 
(60
)
 
224,098

Total short-term investments
 
$
224,703

 
$
3

 
$
(60
)
 
$
224,646

Total cash and cash equivalents and investments
 
$
253,713

 
$
3

 
$
(60
)
 
$
253,656

 
 
 
 
 
 
 
 
 
 
 
As of December 31, 2011
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
 
 
 
 
(in thousands)
 
 
Cash and cash equivalents
 
$
186,309

 
$
—

 
$
—

 
$
186,309

Securities maturing within one year:
 
 
 
 
 
 
 
 
Certificates of deposit
 
548

 
—

 
—

 
548

U.S. treasury securities
 
94,814

 
24

 
(3
)
 
94,835

Total short-term investments
 
$
95,362

 
$
24

 
$
(3
)
 
$
95,383

Total cash and cash equivalents and investments
 
$
281,671

 
$
24

 
$
(3
)
 
$
281,692


There were no realized gains or losses for the three months ended March 31, 2012 and 2011. The cost of securities sold is based on the specific identification method.
XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Recent Accounting Pronouncements
 3 Months Ended
Mar. 31, 2012
Recent Accounting Pronouncements [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
Recent Accounting Pronouncements
In June 2011, the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-05, “Presentation of Comprehensive Income”, which improves the comparability, consistency, and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments in this standard require that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. The standard does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, the standard does not affect the calculation or reporting of earnings per share. This pronouncement should be applied retrospectively for fiscal years beginning after December 15, 2011, with early adoption permitted. Lexicon adopted this pronouncement in 2012 and there was no material impact to its consolidated results of operations and financial condition.

XML 26 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Arrangements with Symphony Icon Inc
 3 Months Ended
Mar. 31, 2012
Arrangements with Symphony Icon Inc [Abstract]  
Arrangements with Symphony Icon Inc
Arrangements with Symphony Icon, Inc.
     
On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the “Programs”). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (“Holdings”), the Company's intellectual property rights related to the Programs. Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.

Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings 7,650,622 shares of its common stock on June 15, 2007 in exchange for $15 million and an exclusive purchase Option (the "Purchase Option") that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and agreed to make up to $80 million in additional base and contingent payments.

The base payments will be in an amount equal to $50 million less 50% of the expenses Lexicon incurs after its exercise of the Purchase Option for the development of LX1032, LX1033 and other pharmaceutical compositions modulating the same target as those drug candidates (the “LG103 Programs”), subject to certain exceptions and up to an aggregate reduction of $15 million. The base payments are payable in Lexicon's discretion at any time before July 30, 2013.

The contingent payments will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize a drug candidate from the LG103 Programs (a “Licensing Transaction”), subject to certain exceptions and up to a maximum of $30 million plus the amount of any reduction in the base payments for Lexicon's development expenses for the LG103 Programs (the “Recapture Eligible Amount”). The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.

The base payments and the contingent payments may be paid in cash, common stock, or a combination of cash and common stock, in Lexicon's discretion, provided that at least 50% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.

Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid $10.0 million in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 14% for the base payments; (2) a discount rate of 18% for the contingent payments; and (3) a probability adjusted contingency. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. During the three months ended March 31, 2012 and 2011, the fair value of the Symphony Icon purchase consideration liability increased by $2.1 million and $1.1 million, respectively.
XML 27 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements
 3 Months Ended
Mar. 31, 2012
Fair Value Measurements [Abstract]  
Fair Value, Measurement Inputs, Disclosure
Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

•
Level 1 - quoted prices in active markets for identical investments

•
Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)

•
Level 3 - significant unobservable inputs (including the Company's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels described above as of March 31, 2012 and December 31, 2011.

 
 
Assets and Liabilities at Fair Value as of March 31, 2012
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
(in thousands)
Assets
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
29,010

 
$
—

 
$
—

 
$
29,010

Short-term investments
 
224,646

 
—

 
—

 
224,646

Total cash and cash equivalents and investments
 
$
253,656

 
$
—

 
$
—

 
$
253,656

Liabilities
 
 
 
 
 
 
 
 
Other long-term liabilities
 
$
—

 
$
—

 
$
57,114

 
$
57,114

Total liabilities
 
$
—

 
$
—

 
$
57,114

 
$
57,114

 
 
Assets and Liabilities at Fair Value as of December 31, 2011
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
(in thousands)
Assets
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
186,309

 
$
—

 
$
—

 
$
186,309

Short-term investments
 
95,383

 
—

 
—

 
95,383

Total cash and cash equivalents and investments
 
$
281,692

 
$
—

 
$
—

 
$
281,692

Liabilities
 
 
 
 
 
 
 
 
Other long-term liabilities
 
$
—

 
$
—

 
$
55,033

 
$
55,033

Total liabilities
 
$
—

 
$
—

 
$
55,033

 
$
55,033


The Company's Level 3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss. The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the three months ended March 31, 2012 and 2011.
 
 
Other Long-term Liabilities
 
 
(in thousands)
Balance at December 31, 2011
 
$
55,033

Change in valuation of purchase consideration payable to former Symphony Icon stockholders
 
2,081

Balance at March 31, 2012
 
$
57,114

 
 
 
Balance at December 31, 2010
 
$
48,267

Change in valuation of purchase consideration payable to former Symphony Icon stockholders
 
1,058

Balance at March 31, 2011
 
$
49,325

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.
XML 28 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Debt Obligations
 3 Months Ended
Mar. 31, 2012
Debt Obligations [Abstract]  
Debt Disclosure
Debt Obligations
 
Mortgage Loan.  In April 2004, Lexicon obtained a $34.0 million mortgage on its facilities in The Woodlands, Texas.  The mortgage loan has a ten-year term with a 20-year amortization and bears interest at a fixed rate of 8.23%.  The mortgage had a principal balance outstanding of $24.5 million as of March 31, 2012. The fair value of Lexicon’s mortgage loan approximates its carrying value.  The fair value of Lexicon’s mortgage loan is estimated using discounted cash flow analysis, based on the Company’s current incremental borrowing rate.
XML 29 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2012
Commitments and Contingencies [Abstract]  
Commitments and Contingencies Disclosure
Commitments and Contingencies
 
Operating Lease Obligations:  A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an agreement which expires in June 2013.  The lease provides for two five-year renewal options at 95% of the fair market rent and includes escalating lease payments.  Rent expense is recognized on a straight-line basis over the original lease term.  Lexicon is the guarantor of the obligations of its subsidiary under this lease.  The maximum potential amount of future payments the Company could be required to make under this agreement is $3.3 million without taking into account the exercise of the renewal options. The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.  The Company had $0.4 million in restricted investments as collateral as of March 31, 2012 and December 31, 2011.  Additionally, Lexicon leases certain equipment under operating leases.
 
Legal Proceedings.  Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.
XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statements of Comprehensive Loss Parenthetical (Parenthetical) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Stock-based compensation expense associated with research and development expense $ 1,037 $ 839
Stock-based compensation expense associated with general and administrative expense $ 681 $ 633
XML 31 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2012
Stock-Based Compensation [Abstract]  
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
 Stock-Based Compensation
 
The Company recorded $1.7 million and $1.5 million of stock-based compensation expense for the three months ended March 31, 2012 and 2011, respectively.  The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions for options granted in the three months ended March 31, 2012 and 2011:
 
 
Expected Volatility
 
Risk-free Interest Rate
 
Expected Term
 
Dividend
Rate
March 31, 2012:
 
 
 
 
 
 
 
 
Employees
 
92
%
 
0.8
%
 
5

 
0%
Officers and non-employee directors
 
80
%
 
1.6
%
 
8

 
0%
March 31, 2011:
 
 
 
 
 
 
 
 
Employees
 
88
%
 
2.2
%
 
5

 
0%
Officers and non-employee directors
 
78
%
 
3.2
%
 
8

 
0%

The following is a summary of option activity under Lexicon’s stock-based compensation for the three months ended March 31, 2012:
 
 
 
Options
 
Weighted Average Exercise Price
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
20,476

 
$
2.84

Granted
 
3,032

 
1.80

Exercised
 
(35
)
 
1.43

Expired
 
(726
)
 
8.57

Forfeited
 
(210
)
 
1.77

Outstanding at March 31, 2012
 
22,537

 
2.53

Exercisable at March 31, 2012
 
14,582

 
$
2.94


During the three months ended March 31, 2012, Lexicon also granted its employees annual restricted stock units. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2012:
 
 
Shares
 
Weighted Average Grant Date
Fair Value
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
2,127

 
$
1.81

Granted
 
2,390

 
1.80

Vested
 
(518
)
 
1.81

Forfeited
 
(227
)
 
1.81

Nonvested at March 31, 2012
 
3,772

 
$
1.80

During 2010, Lexicon granted certain employees restricted stock units with a performance condition. The shares subject to the restricted stock units granted in 2010 vest upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by Lexicon as a basis for a New Drug Application. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. The following is a summary of performance-based restricted stock units activity under Lexicon's stock-based compensation plans for the three months ended March 31, 2012:
 
 
Shares
 
Weighted Average Grant Date
Fair Value
 
 
(in thousands)
 
 
Outstanding at December 31, 2011
 
350

 
$
1.90

Forfeited
 
(5
)
 
1.90

Nonvested at March 31, 2012
 
345

 
$
1.90
XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 37 106 1 false 5 0 false 3 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.lexpharma.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document true false R2.htm 1001000 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) false false R3.htm 1002500 - Statement - Balance Sheet Parenthetical (Parenthetical) Sheet http://www.lexpharma.com/role/BalanceSheetParentheticalParenthetical Balance Sheet Parenthetical (Parenthetical) false false R4.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited Consolidated Statements of Comprehensive Loss (Unaudited) false false R5.htm 1004500 - Statement - Statements of Comprehensive Loss Parenthetical (Parenthetical) Sheet http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalParenthetical Statements of Comprehensive Loss Parenthetical (Parenthetical) false false R6.htm 1005000 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) false false R7.htm 1006000 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) false false R8.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.lexpharma.com/role/BasisOfPresentation Basis of Presentation false false R9.htm 2104100 - Disclosure - Net Loss Per Share Sheet http://www.lexpharma.com/role/NetLossPerShare Net Loss Per Share false false R10.htm 2107100 - Disclosure - Stock-Based Compensation Sheet http://www.lexpharma.com/role/StockBasedCompensation Stock-Based Compensation false false R11.htm 2110100 - Disclosure - Recent Accounting Pronouncements Sheet http://www.lexpharma.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements false false R12.htm 2113100 - Disclosure - Cash and Cash Equivalents and Investments Sheet http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments Cash and Cash Equivalents and Investments false false R13.htm 2116100 - Disclosure - Fair Value Measurements Sheet http://www.lexpharma.com/role/FairValueMeasurements Fair Value Measurements false false R14.htm 2119100 - Disclosure - Debt Obligations Sheet http://www.lexpharma.com/role/DebtObligations Debt Obligations false false R15.htm 2122100 - Disclosure - Arrangements with Symphony Icon Inc Sheet http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc Arrangements with Symphony Icon Inc false false R16.htm 2125100 - Disclosure - Commitments and Contingencies Sheet http://www.lexpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 2131100 - Disclosure - Collaboration and License Agreements Sheet http://www.lexpharma.com/role/CollaborationAndLicenseAgreements Collaboration and License Agreements false false All Reports Book All Reports Process Flow-Through: 1001000 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 1002500 - Statement - Balance Sheet Parenthetical (Parenthetical) Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 1003000 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Process Flow-Through: 1004500 - Statement - Statements of Comprehensive Loss Parenthetical (Parenthetical) Process Flow-Through: 1006000 - Statement - Consolidated Statements of Cash Flows (Unaudited) lxrx-20120331.xml lxrx-20120331.xsd lxrx-20120331_cal.xml lxrx-20120331_def.xml lxrx-20120331_lab.xml lxrx-20120331_pre.xml true true